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Abstract 
A competitive cyclic AMP binding assay was developed and verified to allow reliable 
and reproducible measurement of cyclic AMP binding levels within benign and V0 
malignant human colorectal tissues. Cyclic AMP binding was determined in cytosols 
derived from the centre and periphery of 69 human colorectal cancers and adjacent and 
distant mucosa gathered from a series of patients undergoing elective surgery for 
colorectal cancer. Cyclic AMP binding levels were significantly higher in the periphery 
of tumour than in either adjacent or distant mucosa. Binding levels in tumour centre 
were the same as those in adjacent mucosa but significantly lower than those in distant 
mucosa. Within both the periphery and centre of tumour low levels of cAMP binding 
correlated with advanced disease in terms of stage and grade. Binding levels in all four 
specimens were also highly related within individuals.. 
Cyclic AMP binding protein isotype (R1 and RII) expression was determined in 
cytosols derived from the centre and periphery of 32 human colorectal cancers and 
from related adjacent and distant mucosa by means of [32pl-8-azido-cAMP photo- 
affinity labelling, polyacrylamide gel electrophoresis, autoradiography and laser 
densitometry. A single form of RI was identified with a molecular weight of 48kDa 
(RI-48). There were two forms of RIT with molecular weights of 52 and 54kDa (RII- 
52 and RII-54). Both the centre and periphery of colorectal cancers expressed 
significantly more RI than either adjacent or distant mucosa. Tumours of poor 
histological grade expressed significantly more RI than turnours, that were either well 
or moderately differentiated. High levels of RI were associated with a virtual absence 
of RII-52. R subunits in membrane enriched preparations of colorectal cancers and 
mucosa were also characterised in terms of molecular weight and found to be similar 
to those within cytosol preparations. There was a significant negative correlation 
between total cAMP binding and RI expression in both the centre and periphery of 
tumour but not in either adjacent or distant mucosa 
By means of Western blotting using Y13-259 antibody, ras p2l. levels were 
determined in membrane preparations derived from the periphery of 21 human 
colorectal cancers and related adjacent and distant mucosa. Levels of p2l were lower 
in tumour than in adjacent mucosa but did not relate to stage or grade of disease. There 
was a significant negative correlation between p2l. levels and RI expression in turnour 
but not mucosal preparations. In conclusion, total cAMP binding levels and RI 
expression are related to stage and histological grade of human colorectal cancer; and 
are related to the level of ras p2l expression within turnours but not within benign 
colorectal mucosa 
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activator protein 2 
bovine serum albumen 
catalytic subunit of PK-A 
cyclic adenosine 3': 5'mono-phosphate 
cyclic guanosine 3': 5'mono-phosphate 
cyclic adenosine 3': 5'mono-phosphate binding protein 
cyclic AMP responsive gene 
colorectal. cancer 
cyclic AMP response element binding protein 
dibutryl cAMP 
epidermal growth factor 
familial adenomatous polyposis 
GTPase activating protein 
guanosine monophosphate, 
inhibitory AC G protein 
stimulatory AC G protein 
guanosine triphosphate 
insulin-like growth factor 
PK-A inhibitor protein 
polyacrylamide get electrophoresis 
plasminogen activator 
photoaffinity labelling 
protein kinase A 
type I PK-A 
type 11 PK-A 
protein kinase C 
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PDGF platelet derived growth factor 
PKIP protein kinase A inhibitory protein 
PPK phosphorylase phosphorylase kinase 
RI type I regulatory subunit of PK-A 
RII type 11 regulatory subunit of PK-A 
SEM standard error of the mean 
SD standard deviation 
SDS sodium dodecyl sulphate 
TGF transforming growth factor 
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ChajRter 1: The Clinical Clinical Aspects of Colorectal Cancer 
1.1 The Epidemiology of Colorectal Cancer 
Colorectal cancer (CRQ remains a major cause of morbidity and mortality in Scotland 
with only cancer of the lung and breast being responsible for more deaths in men and a 
women respectively (Table 1.1). 
Table 1.1 Number of Deaths and Death Rate per 100,000 Population 
from Cancers at Different Sites in Scotland 
Number All Lung Female Colon Stomach Prostate Others 









7087 1377 1243 973 424 - 3070 
1 
Deaths All Lung Female Colon Stomach Prostate Others 






















(WHO Mortality Statistics 1988) 
The disease predominantly affects those over 40 years old and the sex incidence varies 
with both age and the site of tumour within the colorecturn, (Table 1.2). There is a 
marked variation in the incidence of colorectal cancer throughout the world (Table 
1.3), between the neighbouring countries of Europe, and even within the United 
Kingdom (Boyle et al 1985, Williams and Lloyd 1990). Because migrants adopt the 
new level of risk associated with their adopted country, either increased (Locke and 
King 1980) or decreased (McMichael and Bonett 1981), this variation has been 
attributed to environmental factors (Correa, Strong and Reif 1977, Correa and Haenzel 
1978, Nomura 1990), and in particular diet (Bresalier and Yim 1985, Bristol et al 
1985, Curren et al 1987, Jacobsen and Thelle 1987, Kune, Kune and Watson 1987). 
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In countries where levels of disease have been historically low, for example Japan, 
there has been a recent marked increase in incidence of colorectal cancer (Lee 1976). 
By contrast, in countries having had a previously high incidence of colorectal cancer, 
there appears to have been a slight fall in total numbers of large bowel cancers and a 0 
relative increase in those arising from the right colon (Beart. el al 1983). 
Table 1.2 Age and Sex Related Deaths from Colonic and Rectal 
Cancer in Scotland 1987 
Colon Cancer 
Age (years) Total 15-24 25-34 35-44 45-54 55-64 65-74 >74 
Number of 
deaths 
Male 491 2 1 14 
_33 
85 ISO 176 
Female 676 - 1 12 35 87 168 373 
Deaths per 
100,000 
Male 1 19.9 1 0.5 1 0.3 1 4.2 1 12 133.1 197 1174 
Female 1 25.6 
_I -_ 
1 0.3 1 3.6 1 12 130 167 1175 
Rectal Cancer 
Age (years) Total 15-24 25-34 35-44 45-54 55-64 65-74 >74 
Number of 
deaths 
Male 313 - 4 9 22 
169 94 115 
Female 297 - - 3 18 
141 79 156 
Deaths per 
100,000 
Mile 12.7 - 1 2.7 8 26.9 50.7 
Female 11.2 - - 0.9 
16.2 31.5 
(WHO Mortality Statistics 1988) 
is 
Table 1.3 Deaths per 100,000 Population from Colorectal Cancer in 




USA Canada Japan Australia USSR 
I 
Mauritius 
Male 19.9 20.7 19.7 16.3 10.8 18.6 5.9 0.2 
Female 25.6 24.5 20.0 16.9 10.1 20.0 7.8 0.2 
Rectal Cancer 
Scotland England CD 
+ Wales 
USA Canada Japan Australia USSR Mauritius 
Male 12.7 12.9 3.7 6.3 8.2 7.5 7.3 2.2 
Female 11.2 9.7 2.9 4.7 5.0 5.5 8.5 3.0 
(WHO Mortality Statistics 1987) 
1.2 The Adenoma-Carcinoma Sequence 
Most, though perhaps not all (Desigan etal 1985, Hamadaetal 1988a, b), colorectal 
cancers appear to arise within the dysplastic epithelium of adenomatous polyps 
(Bockhus et al 1961, Haenzel and Correa 1971, Brahme et al 1974, Day 1984, 
DeCosse 1984, Jass 1989). Epidemiological studies show that there is a strong 
correlation between the incidence of death from colorcctal cancer and the presence of 
Polyps within a population (Bombi 1988). Furthermore, the distribution of such 
Polyps within the colorecturn closely reflects that of carcinoma (Eide 1986a, b). Small 
adenocarcinomas are found, almost exclusively, within adenomas (Lev and Grover 
1981); and the larger an adenoma becomes the more likely it is to hatbour a focus of 
invasive cancer (Muto, Bussey and Morton 1975, Stulc el al 1987). Similarly, the 
earlier a cancer is in its natrual history in terms of stage and grade, the more likely it is 
to contain adenomatous regions (Morson 1966, Eide 1983). 16 
There is also clinical evidence to support the adenoma-carcinoma sequence. For 
example, thorough detection and removal of adenomas from members of a test 
population markedly reduces the subsequent development of cancer in that population 
when compared with matched controls (Gilbertsen and Nelms 1978, Murakami et al 
1990). In addition, adenomas left untreated are associated with the development of 
cancer at the same site (Stryker et al 1987). However, the best demonstration of the 
premalignant nature of the adenomatous polyp comes from the disease Familial 
Adenomatous Polyposis (FAP). FAP is an autosomal dominant syndrome 
characterised by the development of hundreds of adenomas within the large bowel and 
is associated with a virtual certainty of progression to invasive cancer in one or more 
polyps (Bodmer et al 1987). As a consequence of these factors the removal of 
adenomas, both in their familial and sporadic forms, is strongly favoured in clinical 
practice (Lambert, Sobin and Waye 1984). More recently, molecular and genetic 
studies have demonstrated that adenomas and carcinomas are both monoclonal in 
origin (Fearon, Hamilton and Vogelstein 1987) and share similar chromosomal 
abnormalities and ras gene mutations (Vogelsteiý et al 1988, Goh and Jass 1986). 
1.3 Clinical Staging and Prognosis of Colorectal Cancers 
Classically, colorectal cancer has been staged according to the Dukes system (Dukes 
1932), although initially Dukes applied his classification to tumours arising within the 
rectum only. A number of derivative systems have been proposed (Astler and Coller 
1954) and although superficially similar, important but often unrecognized differences 
between them have formed a source of confusion. Therefore, for the purposes of this 
Thesis the original Dukes system is used to assess the stage of the tumours studied; 
that is: 
Dukes A- cancer limited to the bowel wall 
Dukes B- cancer that has penetrated the bowel wall 
Dukes C- any cancer involving lymph nodes regardless of bowel wall status 
Despite its simplicity and long-standing the prognostic power of the Dukes system 
compares favourably with more modem and complex classifications (Morson 1966, 
Monnat et al 1987, Halvorsen and Seim 1988a, b, Shepherd et al 1989). For example, 
in a large prospective multi-centre study carried out in the United Kingdom, factors 
influencing long-term survival were in order of decreasing importance: lymph node 
involvement, tumour mobility, the number of lymph nodes involved, the presence of 
bowel obstruction and depth of primary tumour penetration (Fielding el al 1986). 
Nevertheless, major anomalies do exist within the Dukes system and prognostic 
predictions for individual patients are very much less accurate than they are for large 
groups. 17 
Prognostic difficulties arise partly because of inaccurate staging of disease prior to, 
and even after, surgical treatment (Scott and Grace 1989), and partly due the inability 
of even complex staging systems to reflect the biological characteristics and 
aggressiveness of individual turnours. As a result, less than one quarter of all patients 
can be provided with a reasonably confident prognosis at the time of discharge. 
Furthermore, the majority of these patients comprise either those few with minimal 
disease that will almost invariably do well, or a larger number of patients with 
advanced metastatic disease whose outlook is universally poor. There is therefore an 
urgent need to devise more accurate clinical and biological prognostic markers (Jones 
et al 1989, Moran et al 1989). 
1.4 The Current Treatment of Colorectal Cancer 
Although more than 40% of patients have less than one month's duration of symptoms 
at the time of presentation, up to 70% of colorectal cancers will be advanced by that 
time (Devesa et al 1988) and more than one quarter will present initially as a surgical 
emergency (Serpell et al 1989). As a consequence, screening programs using faecal 
occult blood testin a (Kewenter et al 1988, Miller and Stanley 1988) and colonoscopy 
(Longo, Ballantyne and Modlin 1988) have been extensively evaluated (DeCosse 
1988, Pye et al 1990, Tate et al 1990). Although such programs undoubtedly detect 
cancers at an earlier stage, their ability to improve survival as well as their cost- 
effectiveness remain unproven (Simone 1985, Winawer and Miller 1987, Hardcastle 
and Pye 1989). At the present time approximately half of all patients presenting with 
symptomatic olorectal cancer will undergo potentially curative surgery of which only 
a small proportion can be performed endoscopically or transanally (Berry et al 1990). 
Furthermore, there is still debate over what constitutes 'curative surgery' in terms of 
optimal bowel wall and regional lymph node resection (Jeekel 1986). The remaining 
50% of patients with unresectable disease will receive only palliative treatment which 
may or may not involve surgery. Disappointingly, even those patients undergoing 
what was considered at the time to be a potentially curative resection have a 50% 
chance of developing recurrent loco-regional and/or distant disease. Such recurrent 
disease usually appears within 2 years and is rarely curable (Devesa et al 1988). 
Surgical failure to cure may be due to incomplete resection of the tumour and/or due to 
the presence of occult dissemination at the time of presentation and initial staging 
(Taylor, Mullee and Campbell 1990). 
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The treatment of colorectal cancer also remains limited by the lack of effective adjuvant 
therapy. For example, although radiotherapy can reduce local recurrence and possibly 
improve the survival in rectal carcinoma (Galloway et al 1989), treatment regimens 
have yet to be optimised. Similarly, the results of chemotherapy have been 
disappointing in terms of survival (Mayer et al 1989). In conclusion, failure to 
overcome the difficulties outlined above has prevented clinicians from attaining a 
significant reduction in the overall mortality from colorectal cancer over the past thirty 
years despite improvements in anaesthetic and surgical technique (Canivet et al 1989). 
Currents efforts are therefore directed at staging disease more accurately (Beynon et al 
1989), identifying those at risk of recurrence and subjecting them to worthwhile 
follow-up (Devesa et al 1988), and understanding the fundamental biology of the 
disease so that new modalities of adjuvant control may be developed (Taylor and 
Northover 1990, Cho-Chung 1989). 
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Chapter 2: Cell Signalling, Secondary Messenger Systems and--Protein 
Phosphorylation 
2.1 Secondary Messengers 
It is now well established (Cori and Cori 1945, Pastan, Johnson and Anderson 1975) 
that certain hon-nones exert their effects on cells through the generation of intra-cellular 
adenosine 3', 5'-cyclic monophosphate (cyclic AMP or cAMP), and that reversible 
protein phosphorylation is one of the fundamental biochemical mechanisms regulating 
cellular metabolism (Shenolikar 19SS) (Figure 2.1). Initially, cAMP was found to 
increase in liver cells following exposure to adrenaline and to activate! phosphorylase 
kinase kinase (PKK). Activation of PKK in turn lead to a cascade of enzyme 
phosphorylation and eventually to glycogenolysis. PKK was later renamed cAMP 
dependent protein kinase or protein kinase A (PK-A) when its broader substrate 
specificity was recognised (Walsh, Perkins and Krebs 1968). PK-A is now known to 
mediate all the effects of cAMP and thus the effects of a wide range of hormones, 
drugs, and releasing factors. In recent years, the expansion of interest in growth 
factors and cell-to-cell communication has lead to the discovery of a number of 
different signalling mechanisms (Michell 1989) utilising an wide range of small 
molecules as secondary messengers. Not only is each of these signalling mechanisms 
extremely complex in its own right, it is clear that an intricate process cross-talk carries 
on between them (Wiener and Scarpa 1988) so that they can, together, exert co- 
ordinated control over basic cell processes such as growth and differentiation 
(Serunian and Cantley 1988). 
2.2 Protein Kinases and Protein Phosphorylation 
Reversible protein phosphorylation is a fundamental mechanism by which both pro- 
and eukaryotic cell processes are regulated. A very large number of kinases have now 
been identified primarily through molecular cloning techniques, rather than through 
enzyme purification. This is made possible by the striking homology between their 
catalytic domains (Barker and Dayhoff 1982). Although such homology suggests that 
most, if not all, protein kinases derive from a single ancestral gene outwith their 
catalytic domains they exhibit a wide diversity of structurally unique regulatory 
modules that are important for binding ligand, modulating kinase activity and 
localisation of the holoenzyme. 
In summary, therefore, PK-A is one of a large family of enzymes that play important 
roles in all aspect of cell biology. In the next chapter cAMP and its kinase will be 
described in more detail. 
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Figure 2.1 Secondary Messengers, Protein Kinases and Protein 
Phosphorylation 




* Transmembrane signalling G proteins - Gs, Gi 
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phospholipascs 
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triphosphatc, diacylglycerol 
Ca++ 








Changes in gene expression 
cell proliferation, differentiation 
and mctatx)[ism 
Figure 2.1 shows a general schema by which secondary messengers, protein 
kinases and protein phosphorylation might be involved in the regulation of cell 
processes. Signalling molecules acting in an endocrine, paracrine or autocrine fashion 
bind to specific cell-surface expressed receptors. Complex transmembrane 
mechanisms involving large and small molecular weight guanine nucleotide binding 
proteins (Gilman 1987, Dohlman, Caron and Lefkowitz 1987) such as Gi, Gs, and 
ras (Bar-Sagi 1989), receptor tyrosine kinases and phospholipases result in the 
generation of a range of small molecular weight secondary messengers within the cell 
(Druker, Mamon and Roberts 1989). Secondary messengers bind to and activate a 
range of protein kinases that phosphorylate a wide variety of structural proteins and 
enzymes both within the cystosol and possibly within the nucleus. Protein 
phosphorylation leads to conformational change which in turn leads to changes in 
protein function and so to alterations in cell architecture, metabolism and gene 
expression (Taylor 1989). 
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Chapter 3: The Cyclic AMPAProtein Kinase A System 
3.1 Introduction 
Cyclic AMP (Figure1l) mediates the effects of a wide ran ge of hon-nones, releasing 00 
factors, neurotransmitters and drugs (Table 3.1). A general schema of the cAMP/PK- 0 
A mechanism is as follows (Figure 3.2). 0 
1) ligand binds to its cell surface expressed receptor resulting in a conformational 0 
change that brings about the activation of either a stimulatory or inhibitory guanine- 0 
nucleotide binding protein (Gs or Gi). 0 
2) Gs and Gi respectively stimulate and inhibit the activity of adenyl cyclase (AC) 
which catalyses the conversion of adenosine triphosphate (ATP) to cAMP. 
3) cAMP binds to the regulatory subunits (R) of PK-A leading to dissociation from the 0 
catalytic (C) subunits. The latter are then free to catalyse the phosphorylation of a 
wide range of target proteins, 0 
4) when levels of cAMP fall, R and C subunits reassociate leading to inhibition of the 
kinase activity. 
Individual components of the system will now be discussed in more detail. 
22 
















Figure 3.1 shows the structure of cyclic AMP. Cyclic AMP is formed from the 
purine -adenine, a sugar ribose and a 
high energy cyclic phosphate group. 
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control gene expression 
Protein phosphorylation. 
Figure 3.2 shows the major components of the cyclic AMP secondary messenger 
system. Ligand binds to a specific cell-surface expressed receptor and through a 
complex of membrane events involving conformational change in either Gs or Gi 
results in either the activation or inhibition of membrane associated adenyl cyclase and, 
subsequently, either a rise or fall in cytosolic cAMP concentrations. Cyclic AMP them 
binds to and activates PK-A in the cytosol and possibly the nucleus resulting in its 
separation in to 2C and 2R subunits. C subunits phosphorylate awide range of protein 
substrates within the cell leading to changes in cell architecture, metabolism and gene 
expression. As well as their inhibitory action on C subunits, R subunits may act 
independently by entering the nucleus, binding to DNA, and influencing the 
transcription of cAMP-dependent genes. A range of phosphodiesterases act to degrade 
cAMP and thus to terminate the signal (Lehninger 1975). 0 
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Table 3.1 Ligands acting through the Generation of cAMP as a 




Human chrorionic gonadotropin 






Melanocyte stimulating hormone 
Thyroid stimulating hormone 0 
Inferferon-y 
Nitroprusside and nitro-glycerine 




Nerve and fibroblast growth factor 
Interleukin-I 
Turnour necrosis factor 
Acetyl choline (nicotinc and muscarinic) 
Reference 
Druckner 1997 
Eskin, Garcia and Byme 1989 
Mellon and Vaisse 1989 
Dufai et al 1977 
Dufai et al 1977 
Hemmings et al 1989a, b 
Lasater 1987 
Lomri and Marie 1990 
Ng et al 1983 
Hayashi et al 1989 
Penhoat, Jaillard and Saez 1989 
Sala et al 1979 
Preston et al 1987 
Slominski, Moellman and Kuklinska 
1989 
Gerrard et al 1989 
Jih et al 1986 
Tramontano et al 1986 
Figueiredo et al 1990 
Waldmann, Neiberding and Walter 1987 
Deutsch, Sun and Kroog 1990 
Ortmann. and Perkins 1977 
Plet et al 1986 
Lowe, Nakamura and Gold 1989 
Damon, DAmore and Wagner 1990 
Mochan, Uhl and Newton 1986 
Zhang et al 1988 
Horwitz and Perlman 1984 
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3.2 Protein Kinase A: Regulatory Subunits 
PK-A is unique among the protein kinases in having separate regulatory (R) and 
catalytic (C) sub-units (Figure 3.3). In its inactive form PK-A exists as a tetramer of 
two regulatory sub-units (R) that bind cyclic AMP (also known as cyclic AMP binding, 
proteins or cAMP-BP) and two catalytic units (C) that have serine\threonine kinase 
activity (Edelman, Blumenthal and Krebs 1987). On binding two molecules of cAMP 
each, the cAMP-BP undergo a conformational change (Johnson and Wong 1989) that 
results in the dissociation of PK-A in to two free C subunits and an R-subunit dimer 
(Taylor et al 1988, Taylor 1989). Two main species of cAMP-13P, termed RI and R11, 
are recoanized. RI has a molecular weight of approximately 48 kiloDaltons (kDa) and 
the MW of RII is variable between 50-56kDa (Hoffman et al 1975). The two proteins 
yield different peptide maps on proteolysis (Zoller, Kerlavage and Taylor 1979, Zoller 
and Taylor 1979), can be separated immunologically by use of specific RI and RII 
antibodies (Hoffman, Betchel and Krebs 1977, Lohmann et al 1983, Cho-Chung 
1989) and have different amino acid sequences (Titani et al 1984, Takio et al 1984). 
In addition, although both isoforms can undergo phosphorylation by other kinases 
(Russell and Steinberg 1987), only the Ril protein undergoes autophosphorylation 
(Rosen and Erlichman 1975, Scott and Mumby 1989). The PK-A holoenzyme will 
contain either two RI or two RII, never one of each, and the resulting holoenzyme is 
therefore termed PK-Al or PK-AII. More recently it has been realized that several 
unique and antigenically distinct gene products exist within each class (Nowak et al 
1987) and that their expression may be separately regulated by cAMP itself (Oyen et al 
1988a, b, c, Jahnsen et al 1986b). Thus, to date, RI-cc (Sandberg el al 1990), RI-P 
(Clegg, Cadd and McKnight 1988), RII-a (Scott et al 1987, Oyen et al 1989), and 
RII-P (Jahnsen et al 1985,1986a, Sandberg et al 1988) subunits have been 
identified. At the mRNA level there appears to be even further diversity, due, at least 
in part, to the use of different polyadenylation site signals (Sandberg, Skalhegg and 
Jahnsen 1990). 
Although amino acid sequencing has demonstrated differences between RI and RII, 
their basic structures are similar. The carboxy- terminal two-thirds of both RI and RII 
comprises two tandem cAMP binding domains, termed site A (or 2) and site B (or 1), 
that exhibit extensive homology with each other and with cAMP binding region on the 
Escherichia coli catabolite activator protein (CAP) (Weber el al 1982,1987). Studies 
with a range of substituted cAMP analogs have shown that the two sites are 
functionally distinct and exhibit co-operativity (Ogreid et al 1983,1985,1988, Bubis 
and Taylor 1987). In contrast the amino-terminal third is quite variable, contains most 
of the antigenic sites (Weldon and Taylor 1985) and is responsible for maintaining the 
dimeric nature of the molecule. 
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Limited proteolysis identifies a highly sensitive "hinge" area within the amino-terminal 
and results in a monomeric fragment containing the two cAMP binding sites. Within 
this "hinge" area is a conserved region that is required for C sub-unit interaction. 
Depending on the site of cleavage the R remnant may still be able to form a complex 
with the C sub-unit (Taylor et al 1999, Taylor 1999). The region of the R sub-unit 
that interacts with the C sub-unit contains either a pseudosubstrate s quence (RI) or an 
autophosphorylation site (1111). This region in RI occupies the catalytic site of the C 
sub-unit and can compete with peptide substrates. The same area on R11 can be 
autophosphorylated by an intra-molecular mechanism that does not require 
dissociation of the holoenzyme (Scott and Mumby 1985). Following the binding of 
cAMP R sub-units undergo a conformational change that results in a 10,000-fold 
decrease in their affinity for the C sub-unit. Consequently, the R and C sub-units 
separate allowing substrate to be phosphorylated (Beebe and Corbin 1986). 
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Figure 3.3 The Structure of Protein Kinase A Regulatory Suhunits 
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3.3 Protein Kinase A: Catalytic Subunits 
Active catalytic subunits are 49 kDa monomers that share extensive homology with 
many other kinases (Hanks, Quinn and Hunter 1988) including those with different 
substrate specificities such as pp6O-src from the Rous sarcoma virus (Taylor et al 
1988). Catalytic subunits possess at least five distinct binding sites; namely 
1) a binding site for ATP 
2) two binding sites for Mg++ 
3) a peptide-binding substrate binding site 
4) a recognition site for the R subunit 
5) a catalytic site where phosphotransfer actually occurs (Yoon and Cooke 1987). 
Until recently, C subunits appeared to be homogeneous with identical chemical, 
physical, antigenic and catalytic properties (Flockhart and Corbin 1982). However, 
three genes coding for different forms of the C sub-unit (C-a, C-P and C-y) have now 
been cloned (Uhler el al 1986, Uhler, Chrivia and McKnight 1986, Showers and 
Maurer 1986, Adavani et al 1987). The C-ct and C-P proteins are 901% identical, well 
conserved evolutionarily, and expressed in a tissue specific manner; although there 
appears to be no preferential expression with either RI or R11 (Uhler and McKnight 
1987). Although the isoforms have not yet been demonstrated to be functionally 
distinct it is possible that they possess different substrate specificities (Olsen and Uhler 
1989). Kinzel et al (1987) have also described two C subunits termed Ca and Cb, 
distinguishable by their succeptibility to a specific protease. Although these two forms 
have different isoelectric points, they cannot be separated on SDS polyacrylamide 
electrophoresis as can C-ct and C-P. Thus the relationship of these two sets of 
different proteins is unclear. Furthermore, two forms of a complex between C 
subunits and the PKIP, possibly due to differences in the catalytic sub-units involved, 
have been described (Van Patten et al 1986). 
3.4 Protein Kinase A: Substrates 
The C sub-unit has been shown to phosphorylate, both in vivo and in vitro, a very 
wide range of substrates possessing diverse roles in cellular metabolism, proliferation, 
and communication (Table 3.2). Consequently, there are very few aspects of cell 
biology that could not conceivably be controlled at some point by the cAMP system 
via PK-A. In particular, phosphorylation of transcription factors, cytoskeletal 
elements, and membrane proteins represent clear mechanisms by which cAMP might 
influence cell division, differentiation and communication. 
29 











acetyl Co-A carboxylase 
mannosyl phosphodolichot synthase 




40S ribosomal protein 
PI ribosomal protein 
Cytoskeletal 12roteins 
myosin light chain kinase 
actinomyosin 








Pickett-Gies and Walsh 1995 
Schlender and Reiman 1977 
Andersson et al 1989 
Okuno, Kanamaya and Fujisawa 1989 
Horwitz and Perlmann 1994 
Hashimoto, Schmidt and Schultz 1988 
Reig, Yu and Klein 1990 
Hornsby et al 1987 
Kim et al 1989 
Banjeree. Kousvelari and Baum 1987 
Clarke and Hardie 1990 
Mkrtchian and Anderson 1990 
Pelech, Pritchard and Vance 1981. 
Roberts and Ashby 1978 
Schubart et al 1977 
Lamb et al 1988 
Silver and DiSalvo 1979 
Wang, Walsh and Wang 1987 
Sato et al 1988 
Lazarides 1982 
O'Connor, Gard and Lazarides 1991 
Geisler and Weber 1988 
Wallach, Davies and Pastan 1978 
Zieve 1988 
Escribano and Rozengurt 1988 
Lornri and Marie 1990 
Table 3.2 continued on next page 
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Table 3.2 continued 
Substrate 
Membrane l2roteins 
p88 renal membrane protein 
multi-drug efflux protein 0 
epidermal growth factor receptor 
y-amino-butyric acid receptor 
acetyl-choline receptor 
insulin-regulated glucose transporter 
small molecular weight G proteins 
synapsin 
doparnine and cAMP regulated 
phosphoprotein (DARPP-32) 
cAMP regulated phosphoproteins 
(ARPP- 16,19, and 22) 
gap-junction protein 
Golgi apparatus proteins 
inositol triphosphate receptor 
RAS protein 
Nuclear proteins 
PI nuclear protein 
chromatin 
HI histone 
cAMP regulatory element binding protein 
Table 3.2 continued on next page 
tReference 
Szoka and Ettinger 1978 
Abraham et al 1990 
Ghosh-Dastidar and Fox 1984 
Heuschneider and Schwartz 1989 
Browning et al 1990 
Miles et al 1987 
Smith, Merlie and Lawrence 1987 
James, Hiken and Lawrence 1989 
Lapetina et al 1989 
White et al 1990 
Kawata et al 1989 
Lazarowski et al 1990 
McAtee and Dawson 1990 
Hemmings et al 1989a, b 
Hemmings et al 1989a, b 
Williams et al 1986 
Hemmings et al 1989a, b 
Horiuchi et al 1990 
Voorter and Kistler 1989 
Capasso, Abeijon and Hirschberg 1985 
Suppatone et al 1988 
Sreenath et al 1988 
Lasater 1987 
Taylor 1982 
Laks et al 1981 
Gonzalez and Montminy 1989 
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C3 complement factor 
type I collagen 
atrial natriuretic factor 




Halbrugge et al 1990 
Forsbura et al 1990 
Glass and MacPherson 1986 
Rittenhouse et al 1986 
Feige and Baird 1989 
Tada et al 1979 
Kim, Kim and Rhee 1989 
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3.5 Protein Kinase A: Isoenzymes 
There a number of possible reasons why PK-A should exist as two or more 
functionally distinct isoenzymes. For example such heterogeneity might allow: 
1) activation at different concentrations of cAMP so permitting sequential or 
differential responses to different intensities or qualities of stimulus, 
2) differential sensitivity to other promoting or inhibitory influences, 
3) compartmentalization of enzymes within the cell, 
4) different temporal expression of isoenzymes with distinct functions during 
proliferation and differentiation, or, 
5) R units with separate and independent functions to act within the cell 
There is evidence to support all these hypotheses. Thus, in vitro, PK-AI is generally 
activated at lower concentrations of cAMP than PK-All (Beavo, Betchel and. Krebs 
1974, Builder, Beavo and Krebs 1980); although results vary with the type of assay 
used and on the presence or absence of other factors such as ATP. More evidence for 
differential sensitivity to cAMP comes from the selective effects of cAMP analogs on 
different R subunits (Cho-Chung 1989) where different analogs show preferential 
bindina to bindin- site A and B and to RI and R11. 
Early work suggested that PK-l and PK-11 might be partitioned differently between 
soluble and particulate cellular fractions (Corbin, Keely and Park 1975, Corbin and 
Keely 1977, Corbin et al 1977, Walter et al 1977a, b, Hayes, Brunton and Meyer 
1980). Only a minority of tissues, for example brain (Walter et al 1978) and 
erythrocytes (Dreyfuss, Schwartz and Blout 1978) appear to have significant amounts 
of PK-A activity within their particulate fraction. Within brain tissue microtubule 
associated protein 2 (MAP2), a high molecular weight cytoskeletal protein, is 
associated with up to a third of total PK-AII and is also a substrate (Vallee, 
DiBartolomeis and Theurkauf 1981). Such binding might explain the 
immunocytochemical localization of RII to the mitotic spindle of dividing PtKI kidney 
epithelial cells and to other micro-tubular structures (Wang and Rozengurt 1983, De 
Camilli et al 1986). Phosphorylation of MAP2 appears to inhibit both the rate and the 
extent of micro-tubule assembly (Jamieson et al 1980) and is one mechanism by 
which PK-A might directly control cell division. 
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In, most tissues, however, studies have shown that 50-80% of PK-A activity resides 
within the soluble fraction. Nevertheless, it is likely that further sub-cellular 
compartmentalisation is necessary to avoid sudden bursts of widespread, uncontrolled 
cAMP dependent phosphorylation; and indeed PK-A activity has been localized to the 
Golgi apparatus (Nigg et al 1985a, b), the endoplasmic reticulurn (Mednieks, 
Jun gman and Hand 1987), synaptic junctions (Dudai 1987), microsomes, the nucleus 
(Kuettel et al 1985) and nucleolus (Byus and Fletcher 1982) as well as to the cell 
surface (Kleine and Whitfield 1987). R and C sub-units have also been identified 
within secretory granules and fluids (Hand and Mednieks 1989) suggesting that in 
some circumstances PK-A may be active outwith the cell. 
PK-Al and PK-All also appear to be selectively expressed in cells and tissues during 
different stages in their development and maturation (Smales and Biddulph 1985, Liv 
et al 1976), functional life (Rogers et al 1986, Liu, Chan and Cheng 1986), and cell 
cycle (Costa, Gemer and Russell 1976). Although the experimental work has at times 
been conflicting, a large body of work indicates that whilst PK-All predominates in 
quiescent differentiated cells, RI is associated with rapidly proliferating, transformed 
and possibly malignant cells. For example, RI has been shown to predominate during 
early development (Gentleman et al 1989a, b, Linask and Greene 1989a, b) and 
following trophic responses to short and long-term hormonal stimulation (Byus et al 
1976, Combest Chiasson and Russell 1980, Combest and Russell 1983, Dimino, 
Bieszczad and Rowe 1981, Oyen et al 1987, Hedin et al 1989, Magoffin 1989) 
Conflicting results have been obtained with regard to PK-A isoenzyme activity in 
transformed and malignant cells. For example, although Simian virus (SV40) 
transformation of BALBc/3T3 cells is associated with an increase in RI expression and 
PK-AI activity (Gharrett, Malkinson and Shepherd 1976). cAMP-induced 
differentiation of transformed Swiss/3T3 cells in to mature adipocytes is also 
associated with a relative increase in PK-AI (Liu 1982). Human leukaemic 
lymphocytes and hepatoma cells have lower levels of overall PK-A activity, but 
relatively more RI, than their normal counterparts (Weber et al 1981) and within 
hepatomas increasing levels of both PK-Al and 11 are associated with increasing 
differentiation (Wittmaack, Weber and Hilz 1983, Butcher et al 1972). In summary, 
the available work suggests that there is an association between PK-Al expression 
and immature rapidly dividing cells; whether those cells be in a developing organ, in 
an organ undergoing repair regeneration or trophic response, have been transformed 
by viruses, or are frankly malignant. 
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3.6 Cyclic AMP-dependent Gene Expression 
Cyclic AMP is known to modulate the expression of an increasing number of 
mammalian genes (Table 3.3). The question that remains to be answered is whether 
gene transcription is controlled through phosphorylation of transcription factors by the 
C subunit of PK-A, or, whether R subunits following binding by cAMP might enter 
and act directly and independently within the nucleus. Cyclic AMP responsive genes 
(CARG) genes are generally expressed in tissues that are responsive to hormones 
and/or growth factors. Their rate of transcription is rapidly altered by cAMP and 
because the mRNA so produced usually has a short half-life (Cimbala et al 1985), 
rapid changes in the level of the coded protein can be achieved (Roesler, Vandenbark 
and Hansen 1988). The fact that cAMP continues to exert control over these genes in 
the presence of cycloheximide (Mellon and Vaisse 1989) suggests that cAMP acts 
either through post-transcriptional modification of existing mRNA or protein, or 
through the actions of already synthesised transcriptional factors. Some CARGs are 
known to share a cAMP regulatory element (CRE) (Short et al 1986), and, more 
recently, a second cAMP responsive site has also been identified and termed AP-2 
(Activator Protein 2) (Imagawa, Chiu and Karin 1987). The discovery of these 
sequences has lead to the identification of transcription factors that bind them (Lee, 
Mitchell and Chan 1987, Lee et at 1988). Thus the cAMP response element binding 
protein (CREB) (Andrisani et al 1989, Dwarki, Montminy and Verma 1990) binds to 
the CRE sequence within the somatostatin gene. Interestingly, CREB is 
phosphorylated by PK-A in vitro and in vivo following treatment of the cells with 
forskolin (Montminy and Bilezikjian 1987, Gonzalez and Montminy 1989). Although 
initial experiments failed to show that CREB phosphorylation altered its binding to the 
CRE (Delegeane et al 1987), more recent work with CREB cDNA mutants has shown 
that replacement of the phosphoaccepting Ser-133 with other residues completely 
abolishes transcriptional activity (Gonzalez and Montminy 1989). A second 50-52K 
protein (activating protein 2 AP-2) that binds the AP-2 sequence in a number of 
CARG has also been isolated (Imagawa, Chiu and Karin 1987). Although AP-2 has 
not yet been shown to be a physiological substrate for PK-A it is very probable that 
cAMP regulates gene transcription through reversible phosphorylation of a number of 
transcription factors. 
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Other lines of work also suaaest that an intact C subunit is required for transcriptional 
regulation. For example, the somatostatin gene CRE is not responsive to cAMP in 
PC 12 cells which are deficient in type 11 PK-A (Montminy et al 1987) or in cells that 
are transfected with a plasmid containing the gene for PKIP (Grove et al 1987,1989, 
Day, Waldýr and Maurer 1989). Furthermore, C subunit alone is able to stimulate 
transcription of the urokinase-type plasminogen activator in an in vitro cell free 
system (Nakauawa et al 1988) and transfection of cultured cells with cDNA's 
encoding C subunits confers cAMP regulation to a reporter gene cotransfected under 
the control of a CRE (Maurer 1989). Lastly, micro-injection of C subunit but not R 
subunits up-regulate gene expression in a number of cells (Riabowol et al 1988). 
Despite these findings, other workers have proposed that CARG transcription is 
regulated, at least in part, through the independent actions of R subunits, and in 
particular RII. Such thoughts were initially stimulated by the discovery that the 
promoter- re gul atory regions of some CARG possess homology with the consensus 
catabolite repressor protein binding site within the lac operon of Escherichia coli (de 
Crombrugghe et al 1984). Thus it appeared as though cAMP regulation of gene 
expression in pro- and eukaryotes might be similar (Wynshaw-Boris et al 1984, 
1986). The limited homology between the regulatory (RII) sub-units of PK-A and the 
Escherichia coli repressor protein was taken as further supportive evidence (Weber et 
al 1982). Althouah R subunits have been shown to bind DNA in a sequence specific 
manner (Wu and Wang 1989) there is, as yet, no direct evidence that they are 
transcriptionally active. Similarly it has yet to be shown that the catabolite repressor 
binding protein-like sequences in mammalian genes act as CRE's (Jungmann and 
Kranias 1977, Nagamine and Reich 1985, Jungman and Russell 1977). A number of 
workers have shown that RI (Linask and Greene 1989b) and RII sub-units enter the 
nucleus (Cho-Chung, Tortora and Clair 1988), associate with the nucleolus (Kapoor 
and Cho-Chung 1983) and bind to chromatin (Kucttel et al 1985, Sikorska, Whitfield 
and Walker 1988). By contrast other workers using immunocytochemical techniques 
were able to demonstrate translocation of the C subunit from the perinuclear area and 
Golgi apparatus (Nigg et al 1985 a, b) to the nucleus following cAMP stimulation but 
no such redistribution of R subunits. 
In conclusion, protein phosphorylation by the C subunit of PK-A is required, but not 
necessarily sufficient, for regulation of CARG expression (Buchler et al 1988). Thus, 
in addition, R subunits may be needed to modulate the actions of the C subunit. 
They may do this by fixing C subunits to DNA within the nucleus, so ensuring the 
availability of appropriate substrates, and then rapidly removing active C subunits 
once phosphorylation has occurred (Lohmann et al 1994). A direct transcriptional role 
for R subunits has yet to be demonstrated. 
36 
Table 3.3 Cyclic AMP Responsive Genes 
Gene Reference 
adenovirus EIA Sassone-Corsi 1988 
cc-human chorionic gonadotropin Silver et at 19877 
Mellon et at 1989 
Andersen et at 1988 
somatostatin Montminy et at 1986 
vasoactive intestinal peptide Tsukada et al 1987 
c -fo S Verma and Sassone-Corsi 1987 
Bravo et al 1987 
Tramontano et at 1986 
C_17ývc Ran et at 1986 
Tramontano et al 1986 
tyrosine hydroxylase Lewiý, Harrington and Chikaraishi 1987 
tyrosine arninotransferase Ernest and Feigelson 1978 
Boney et at 1983 
phosphoenolpyruvate carboxypeptidase Short et at 1986 
phosphoenolpyruvate carboxykinase Sasaki el at 1984 
Wynshaw-Boris et at 1984,1986 
lactate dehydrogenase Jungmann el at 1983 
alkaline phosphatase Brown, Stofko and Uhler 1990 
Table 3.3 continued on next page 
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2 I-steroid hydroxylase 
cytochrome p450 
nerve growth factor 0 
renin 
phosphodiesterase 
major histocompatibility complex 
Reference 
Dean et al 1990 
Imagawa et al 1987 
Maurer 1989 
Hadcock et al 1989 
Collins et al 1988 
Nakagawa et al 1988 
Nagamine and Reich 1985 0 
Brown and Papaconstantinou 1979 
Blosser and Appel 1980 
Weinmaster and Lemke 1990 
Gerard et al 1989 
van Heuverswyn et al 1985 
Druckner et al 1987 
Philippe and Misotten 1990 
Druckner and Brubaker 1989 
John et al 1989 
Rice et al 1990 
Mellon and Vaisee 1989 
Kagawa and Waterman 1990 
Lund et al 1990 
Ahlgren et al 1990 
Mochetti et al 1989 
Nakamura et al 1989 
Swinnen, Joseph and Conti 1999 
Figueiredo el al 1990 
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Chapter 4: Cyclic AMP. PK-A and Control of Cell Growth 
4.1 Introduction 
Cyclic AMP and PK-A mediate the effects of a large number of hormones having 0V 
diverse effects on the growth and differentiation of a wide variety of cells (Pastan, 0 
Johnson and Anderson 1975). It is not surprising, therefore, that a large amount of en 0 
work has been directed at defining the mechanisms involved. In this section two 
conflicting observations will be addressed; namely 
1) that cAMP, its derivatives or agents that increase cAMP can cause growth inhibition 
of certain transformed cell lines in vitro; suggesting that cAMP has a predominantly 
negative role to play in cell proliferation, and, 
2) that in many normal cell types there is clear evidence that cAMP acts as a stimulator 
of proliferation. 
4.2 Cyclic AMP as an Inhibitor of Cell Growth and a Promoter of Cell 
Differentiation 
Early studies demonstrated that cAMP, in the form of dibutryl-cAMP (DB-cAMP), 
and other cAMP elevating agents were capable of inhibiting the proliferation of a 
number of different benign (Leitman, Fiscus and Murad 1986) and malignant (Pastan, 
Johnson and Anderson 1975) cell types. To achieve such effects DB-cAMP had to be 
used at unphysiological millimolar concentrations and the important- growth 
modulating and toxic effects of certain DB-cAMP metabolites uch as adenosine were 
not appreciated. Nevertheless, a large amount of work was conducted during the 
1970's demonstrating that-, 
1) cAMP exerts a primarily negative effect on cell growth (Nose and Katsuta 1975, 
van Wijk, Wicks and Clay 1972), and, 
2) cAMP levels are reduced in a number of dividing (Millis, Forrest and Pious 1972), 
transformed (Otten, Johnson and Pastan 197 1, Carchman, Johnson and Pastan 1974) 
and malignant (Goldberg, Burke and Morris 1974) cell types, and, 
3) virally transformed cells possessed an attenuated AC response (Beckner, Hattori 
and Shih 1985, Levitski et al 1986). 
It appeared therefore that proliferation, transformation and possibly carcinogenesis 0 
might be associated with either an under-, or at least, inappropriately stimulated 
cAMP system. 
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However, results were often conflicting. For example, Morris hepatoma cells 
transplanted in to mice were shown to have lower levels of cAMP and to exhibit a 
markedly reduced response to glucagon when compared to adjacent normal liver 
(Butcher et at 1972, Hickie, Walker and Croll 1974). Further studies demonstrated no 
difference in basal adenyl cyclase (AC) activity but that phosphodiesterase activity was 
increased in hepatoma cells suggesting that low basal cAMP levels might be due to 
increased degradation (Hickie, Walker and Datta 1975). By contrast Brown et at 
(1970) had previously measured AC in a number of different clones of Morris 
hepatoma cells and found that while the fastest growing tumours had the highest AC 
activity, slow-growing tumours had AC activity that approached that of normal liver. 
Chayoth, Epstein and Field (1972) also found elevated cAMP levels in malignant 
hepatic nodules when compared to normal adjacent liver. Rhoads, Morris and West 
(1972) found that phosphodieste rase levels were decreased in hepatoma cells 
compared with recipient livers. Granner (1972) found that cAMP binding was 
markedly reduced in hepatoma when compared with normal liver whereas Thomas et 
at (1973) found that cAMP levels were higher in hepatomas than in normal liver. 
More recently, experiments with a new range of analogs has confirmed that cAMP is 
able to inhibit the growth and promote the differentiation of a wide ranae of 
transformed and malignant cells both in vitro and in animal experiments. Depending 
on the nature of the substitution present, the analog will bind preferentially to one or 
other of the two binding sites present on each PK-A regulatory subunit. C-2 and C-8 
substituted analogs will selectively bind site I (site B) and C-6 analog's will bind site 2 
(site A) (Doskeland 1978, Rannels and Corbin 1980). Furthermore, C-8 -thio or - 
halogen analogs will preferentially bind the site I of RII rather than Rl, and pairs of 
analogs selective for site I and 2 act synergistically (Robinson-Steiner and Corbin 
1983, Ogreid et at 1985). The most potent of the analogs, 8-chloro-cAMP (8-Cl- 
cAMP), has been shown to inhibit the growth of a broad range of human cancer cells 
lines at micromolar concentrations, including hormone-dependent and independent 
breast cancers, colon cancers, fibrosarcoma, glioma, lung carcinoma . Ewings 
sarcoma, a thyroid cancer cell line and leukaemias (Tortora et at 1988, Ally et at 
1988,1989, Cho-Chung 1989, Cho-Chung et at 1989. Endo et at 1990, Tortora, 
Clair and Cho-Chung 1990). Many of these cell lines are resistant to the effects of D13- 
cAMP even at high concentrations. Furthermore, the effects of 8-Cl-cAMP are not 
enhanced by the addition of phosphod i este rase inhibitors suggesting that the early 
theory that DB-cAMP acts through competing for phosphodiesterase, so increasing 
endogenous cAMP levels, is incorrect. In fact, within hepatocytes, adipocytes and 
cardiac muscle cells cAMP analogs actually reduce cellular cAMP levels (Gettys et at 
1987). 
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Interestingly, 8-Cl-cAMP has virtually no effect on normal cells such as NIH3T3 cells 
(Cho-Chung et al 1989, Cho-Chung 1989), rat kidney cells, mammary cells and 
normal blood lymphocytes (Tortora et al 1989a, b) suggesting that cAMP acts in a 
fundamentally different way in benign and malignant cells. Cell-cycle analysis of cells 
treated with 8-Cl-cAMP shows that inhibition is not associated with changes in the 
fractions of cells present in GI, S or G2/M phases (Tagliaferri et al 1988a, b). In 
addition to their growth inhibiting effect, cAMP analogs also appear to promote cell 
differentiation. For example, following 8-Cl-cAMP treatment the H-ras murine 
sarcoma cell line 13-313-4 (Tortora et al 1989b) and Ki-ras transformed rat kidney cells 
revert to their normal phenotype. Similarly, treatment of a number of human leukaemia 
cells lines results in the increased expression of differentiation markers, decreased 
expression of markers characteristic of immature progenitor cells, and morphological 
change (Tortora et al 1988a, b, Levine, Lamaziere and Broxmeyer 1985, Tagliaferri 
1985,1988a, b, Vinci, Tabilio and Beauchamps 1984). The production of increased 
cAMP levels with phosphodiesterase inhibitors and PGE also promotes the 
differentiation of human and mouse neuroblastorna cells with the induction of neurites, 
enzymes associated with neurotransmission and increased sensitivity of adenyl cyclase 
to catecholamines (Prasad 1975, Prasad and Kumar 1975). The treatment of human 
melanoma cell lines with cAMP analogs also resulted in differentiation with the 
production of cellular outgrowths and an increase in premelanosomes, as well as 
markedly reducing their growth rate (Giuffre et al 1988). Analog treatment has also V 
been associated with suppression of proto-oncogene expression. Thus cAMP analogs 
markedly reduce the expression of c-myc protein in HL-60, MOLT-4 and K-562 
leukaemia cells (Cho-Chung et al 1989, Cho-Chung 1989, Tortora fet al 
1988,1989a, b, McCachren et al 1986) and reduce ras p2l expression in MCF-7 and 
MDA-MB-231 breast (Katsaros et al 1987, Tagliaferri et al 1988a) and colon cancer 
cell lines (Ally et al 1988). Analog treatment also antagonizes the promoting effects of 
TGF-a on transformed cells (Tortora et al 1989b). Cyclic AMP analogs have also 
been shown to exert effects on tumours in vivo. For example, the growth and 
metastatic potential of several breast, lung and colonic cancer cells lines is greatly 
diminished when transplanted in to nude mice treated with cAMP analogs (Cho-Chung 
et al 1989). Treatment was also able to prolong the mean life span of innoculated mice 
without apparent toxicity (Avery et al 1988). The effects of cAMP analogs on cell 
proliferation and differentiation are associated with changes in PK-Al and 11 
isoenzyme expression (Handschin and Eppenberger 1979, Lohm ' ann et al 
1983, 
Katsaros el al 1987, Tortora el al 1988, Ally et al 1988, Tortora el al 1990). 
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To summarise, therefore, four different regulatory units of PK-A have now been 
identified at the gene/mRNA level; namely 
1) RI-a - formerly known as RI and found in most tissues, 48 kiloDaltons (kDa). 
2) RI-P - found in brain tissue, 48kDa. 
3) Rll-(x - found in most tissues, 54-56kDa. 
4) RII-P - found in brain, neuroendocrine tissues and ovary, 51/52kDa. 
I shall now discuss how cAMP analog treatment of cell lines effects the expression of 0 
these different R subunits. Untreated transformed cells contain predominantly RI-Ct or 
RI-P. Following treatment with 8-Cl-cAMP there is an increase in Rll-(x or RII-P and 0 
a decrease in RI forms resulting in a 20-fold decrease in RI/RlI ratio. 8-Cl-cAMP has 0 
a high affinity for site I of RII-a and RII-P (4.6 times that of cAMP itself) but low 
affinity for the site 2 on these receptors (5% that of cAMP). Thus 8-Cl-cAMP has a 
90-fold greater affinity for site I than does cAMP. However, it has higher affinity for 0 
site 2 of RI-cc than for site 1; 2.7 versus 2.0-fold that of cAMP respectively (Ally et al 
1988). Comparison of different analogs has shown that their growth inhibiting ability 
is correlated with their ability to bind RII proteins'preferentially when compared to RL 
rather than their ability to induce kinase activity. In agreement with this is the finding 
that the pattern of protein phosphorylation is similar before and after growth inhibition 
by 8-Cl-cAMP. 
In a human colorectal cancer cell line (LS-174T) three major R proteins have been 
identified, a 48 kDa RI (RI-ot), a 52 kDa RII (RII-P) and a 56 kDa R11 (RII-a). 
Treatment with S-Cl-cAMP causes a decrease in RI and an increase in both R11 forms 
within the cytosol. Additionally RII-a moved rapidly (within 10 minutes) in to the 
nucleus. There was also transcriptional activation of the RIT-P gene and inactivation of 
the RI gene. The nuclear translocation of R11-P is interesting in that it contains four 
positively charged amino acids (Jabnsen et al 1986b) and by drawing parallels with 
the simian virus 40 large T antigen it is possible that controlled exposure of this 
sequence might act as signal for regulating the transport of RII in to the nucleus 
(Kalderon et al 1984). Interestingly, despite the 90% homolog between RI and RII ely 
this sequence does not appear in Rl. Furthermore, the formation of a DNA-protein 
complex with a labelled CRE-containing oligonuclcotide in nuclear extracts from colon 
(LS 174-T), gastric (TMK-1) and phaeochromocytorna (PC12) cancer cells was greatly 
increased following analog treatment. The ability of analogs to promote this complex 
was closely related to their ability to cause translocation of RII to the nucleus 
(Yokozaki, Clair and Mednieks 1989, Mednieks, Yokozaki and Tortora 1988). 
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4.3 Cyclic AMP as a Promoter of Cell Proliferation 
The work discussed above has tended to lead to the general acceptance of cAMP as a 
purely negative regulator of cell division. However, it is well recognised that in many 
cells cAMP is clearly involved in mitogenic signalling and actually promotes 
proliferation in response to hormonal stimulation (MacManus and Whitfield 1969, 
Boynton and Whitfield 1980,1983, Boynton et al 1981). Moreover, unlike non- 
cAMP-dependent systems, cAMP appears to act as a stimulus to growth with 
differentiation (Dumont et al 1989). For example, P-adrenergic agonists stimulate 
proliferation of rat parotid cells in vivo and in culture (Tsang, Dixon and Whitfield 
1980) and thyroid stimulating hormone (TSH) not only increases thyroxine production 
but also promotes DNA synthesis and growth, even goitre, within the thyroid gland 
(Jin et al 1986, Roger, Servais and Dumont 1983,1987). 
The factors controlling passage through the cell cycle are extremely complex and 
imperfectly understood. However, in quiescent (GO) mammalian cells, there is a tag of 
10-20 hours between early events following the interaction of growth factors with 
their receptors and the commencement of DNA synthesis. It is during this crucial pre- 
replicative phase (G 1) that cell cycle progression is controlled. Beyond a certain point, 
however, the cell appears committed to divide regardless of what external stimuli it 
might receive (Olashaw and Pledger 1988). Cyclic AMP appears to exert different 
effects on the progression through division depending on which particular cell and 
system is being studied, as well as on when in the cycle the nucleoside is added 
(Willingham, Johnson and Pastan 1972). This may be because cAMP has to interact 
with or modulate the effects of a number of different growth factors using different 
signalling pathways. 0 r. 1 
An example of this interaction is the well-studied effect of mitogenic factors on 
BALBc/3T3 fibroblasts. Progression to division in these cells results from the 
synergistic action of at least three growth factors. Thus a short exposure to platelet 
derived growth factor (PDGF) makes the cells "competent" so that they may then 
undergo division in response to stimulation by epidermal growth factor (EGF) and 
somatomedin C (O'Keefe and Pledger 1983). Raising cAMP levels in this system 
potentiates acquisition of the competent state but sustained elevation impedes 
progression to division - possibly by down-regulating the expression of the EGF- 
receptor (Leof et al 1982). In other 3T3 lines cAMP appears to initiate the pre- 
replicative phase (Rozengurt and Mendoza 1985), whilst in bronchial epithelial cells 
cAMP becomes important only once GI has been initiated by other factors (Willey et 
al 1985). T51 B liver cells and thymic lymphoblasts arrested near the end of GI by 
Ca++ deprivation, can be made to divide by cAMP or agents that will raise 
endogenous cAMP, and division in dog thyrocytes is dependent on continous 
stimulation by cAMP throughout GI (Roger et al 1987). 
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Partial hepatectomy results in the release of a wide range of hormones and growth 
factors that bring about liver regeneration. Such regeneration provides a convenient in 
vivo model for studies in to the control of cell proliferation and in particular the effects 
of cAMP (Michalopoulos 1990). The transient surge of cAMP (MacManus et al 1972, 
1974), Rif (Boynton and Whitfield 1980) and PK-A activity (Byus, Hedge and 
Russell 1977, Boynton et al 1981, Ekanger et al 1989) that is associated with DNA 
synthesis during the pre-replicative phase of liver regeneration has been attributed to 
hormone stimulation of AC activity and appears necessary for subsequent DNA 
synthesis and replication. In support of this is the observed rise in P-adrenergic a 
receptor expression following resection and that the rise in cAMP can be blocked by 
P-adrenergic antagonists (Soriano, Pujo and Bachs 1988). However, despite the initial 
surge there is gradual decrease in AC activity with time (Mahler and Wilcer 1988), and 
a marked decrease in the C sub-unit mRNA has been observed following partial 
hepatectomy (Roth et al 1990), demonstrating that the involvement of cAMP is both 
biphasic and complex. 
Although the effects of cAMP are usually considered to be intra-cellular events, a 
number of mammalian cells including rat liver cells have been shown to express 
surface RI and to a lesser extent RII (Kleine and Whitfield 1987) and to secrete both 
PK-A and cAMP (Hand and Mednieks 1989). External cAMP might trigger the 
release of free C subunit and result in the phosphorylation of proteins both in the 
medium and on the cell surface. It has been postulated that activation of such surface 
PK-A by secreted or exogenous cAMP is involved in the initiation of DNA synthesis 
within regenerating liver. Cyclic AMP and purified PK-A catalytic subunits can 
stimulate replication in rat T51B liver cells arrested in GI by Ca++ deprivation 
(Boynton el al 1981) and the effect of cAMP can be blocked by adding the the specific 
protein inhibitor of PK-A (PKIP). Thus it is possible that secreted cyclic AMP might 
act in a paracrine/autocrine way to regulate important events in mammalian cells as has 
been well demonstrated in prokaryotes (Klein and Whitfield 1987). 
There is also evidence that cAMP might promote proliferation through effects on 
cytoskeletal proteins (Geisler and Weber 1988). As these proteins bind both the 
plasma and nuclear membranes (Georgatos and Blobel 1987) they have been 
implicated in the transmission of signals from the cell surface to the nucleus. One such 
protein, vimentin, is phosphorylated by PK-A in vitro reducing its ability to form 
filaments. Quiescent cells have low basal levels of vimentin phosphorylation which is 
markedly increased in response to cAMP. In intact cells, therefore, it may be that 
cAMP leads to disassembly of these filaments so removing a possible constraint to 
proliferation (Chan, Goate and Puck 1989). Interestingly, certain growth factors such 
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as PDGF that increase vimentin synthesis also increase cAMP levels (Rozengurt et al 
1983) making it possible that growth factors might alter cytoskeletal function at two 
different levels - transcription and phosphorylation. 
Not only do cAMP analogs exerts influence over oncogene expression in transformed 
and malignant cells but an interesting relationship exists between cAMP and proto- 
oncogene expression in normal cells. For example cAMP induces ras protein (Dere, 
Hirayu and Rappoport 1986), and c-nývc (Reuse et al 1986, Reuse, Maenhaut and 
Dumont 1990) within thyrocytes, and c-fos expression in Swiss/3T3 cells (Tsuda el al 
1986), BALBc/3T3 cells (Ran et al 1986) and FRTL thyroid cell lines (Tramontano et 
al 1986). TSH also stimulates ornithine decarboxylase (ODC) activity, polyamine 
synthesis and ras mRNA in FRTL cells (Dere, Hirayu and Rappoport 1986). The 
expression of such proto-oncogenes correlates well with the ability of cAMP to 
potentiate competence and it is possible that many will contain cAMP response 
elements. 
Although cAMP appears able to mimic or interact with other growth factors to induce 
cell progression to division, the cAMP system acts in ways quite distinct from the 
other well-defined mitogenic signalling systems i. e. the receptor tyrosine kinases such 
as EGF and the phosphoinositol (PI) pathway leading to PK-C activation. Thus, in 
dog thyrocytes, TSH (cAMP) does not activate the phosphatidylinositol (PI) pathway, r. 51 
nor does it increase tyrosine phosphorylation. Similarly, acetyl-choline activation of 
the PI system actually decreases cAMP. EGF has no effect on the cAMP, nor 
activates PI degradation. Furthermore, TSH produces a completely different pattern of 
protein phosphorylation to both EGF and PK-C activators (Dumont et al 1989). In 
addition, whereas EGF and PK-C activate the Na+/K+ antiporter, cAMP doo-s not 
(Rozenourt and Mendoza 1985). The pattern of protein synthesis induced by cAMP 
and the other pathways is also distinct (Lamy et al 1986). Even at the nuclear level, 
although all three pathways are associated with the induction of proto-oncogenes, 
whereas c-fos expression due to EGF is transient and c-myc more prolonged the 
reverse is true following TSH induction (Reuse et al 1986, Reuse, Maenhaut and 
Dumont 1990). Such independent control of proto-expression is not unexpected since 
the c-fos contains distinct cAMP, EGF and TPA inducible elements (Verma and 
Sassone-Corsi 1987). However the most fundamental difference between cAMP and 
the other systems is that it induces not only the proliferation but also the differentiation 
of cells, and that the latter effect is antagonized by cAMP-independent mitogenic 
signals. In this respect it is interesting that over-activity of the cAMP system has been 
associated with adenomatous cellular change but not to date with frank malignancy. 
For example, increase adenyl cyclase activity due to mutations within the Gi protein 
have been 
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found within pituitary adenomas (Vallar, Spada and Giannatasio 1987) but not as yet 
in the common solid turnours. Similarly, although the thyroid-stimulating a 
immunoglobulins that stimulate AC activity in Graves disease lead to goitre there is no eý 
premaliocnant potential (Duh et at 1989). It may be that overactivity of the cAMP 
system can lead to benign hyperproliferation and neoplastic adenomatous rowth, or is 4: 1 9 
involved in the very earliest steps of carcinogenesis, whilst the classical oncogenes 
involved in other signalling mechanisms are responsible for de-differentiation and the 
malignant process. 
In summary, therefore, cAMP can be demonstrated to have a positive influence on the 
proliferation of normal cells and although this appears to be reversed in transformed 
and malignant cells, the promotion of differentiation is common to both. The reasons 
for these differences are unclear at the present time. 
0 
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Chapter 5: Oncogenes and Colorectal Cancer 
5.1 Introduction 
Many of the 40 or so distinct oncogenes so far described are known to derive from 
normal cellular genes (proto-oncogenes) coding for products important in the control 
of proliferation and differentiation. Such protooncogenes may become "activated", so 
acquiring oncogenic potential, through either quantitative or qualitative changes in their a01! ) 0 
expression. For example, over-expression of the normal product through gene 
amplification, rearrangement or insertion of a retroviral promoter may lead to 
transformation, whilst chemical or radiation-induced mutation may result in an altered 
product that is oncogenic even at a normal or reduced level of expression (Nishimura rn 
and Sekiya 1987). 
Ras genes were first identified as the acutely transforming principle of the rat sarcoma 
retroviruses (Kirsten and Mayer 1967) generated by the transduction of the normal rat 
cellular rav gFnes. Gene transfer assays have identified mutated ras genes as dominant 
oncogenes in a variety of human turnours includ ing colorectal cancers (Krontiris and 
Cooper 1981, Perucho et al 1981, Pulciani et al 1982, Santos et al 1982,1984, 
Shimizu et al 1983, Capon et al 1983a, b). 
5.2 Structure of ras Genes and Proteins 
Three highly conserved ras genes (Ha-ras, Ki-ras and N-ras), most likely arising 0 01 
from a common ancestor, have been identified in the mammalian genome. These genes 
code highly related 21kDa proteins, known as collectively as ras p2l. Ras p2l bind 
guanine nucleotides, possess intrinsic GTPase activity and show sequence homelogy 
with the a subunits of certain G proteins suggesting that they may be involved in 
signal transduction. Although ras p. roteins are associated with the plasma membrane 
(Willingham el at 1980, Willumsen et at 1984a, 1985), the primary translational 
product is formed within the cytosol (Shih et at 1982) and attachment to the plasma 
membrane requires the acylation of Cys-186 by palmitic acid (Sefton et at 1982). 
Mutants lacking Cys-186 remain in the cytosol and do not have transforming 
properties (Willumsen et at 1984b). Processed ras proteins attached to the plasma 
membrane exhibit a faster miaration rate in SDS-PAGE than their unmodified 
cytosolic counterparts and although this may be due to fatty acid acylation it is possible 
other post-translational modification(s) occurs prior to membrane attachment. 
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Deduced amino acid sequences of p2l proteins have identified four domains. 
1) a hiohly conserved amino-terminal third 0 
2) a second domain of 80 amino acids that shows 85% homolog between different .y 
mammalian species 
3) a highly variable region encompassing the rest of the molecule exceptfor 
4) the last four amino acids where the sequence Cys(186)-X-X-R-COOH (where X is 
any aliphatic amino acid) is found in all p2l proteins (Barbacid 1987) 
Although deletion of the hypervariable region appears to have no effect on the 
biochemical properties of ras proteins, its conservation suggests that it is important 
and it has been proposed as an effector molecule interaction site with variability 
confering specificity on the individual ras proteins (Willumsen el al 1985, Lacal, 
Anderson and Aaronson 1986). 
Ras p2l proteins exist in equilibrium between a GTP bound (active) and a GDP 
bound (inactive) form. Most cellular ras protein would appear to be in the inactive 
form but following an as yet unidentified stimulus it undergoes a conformational 
change allowing the exchange of GDP for GTP. In this active state the ras protein 00 ell 
presumably reacts with its putative effector molecule, the protein's intrinsic GTPase 
activity ensuring a rapid return to the inactive state and termination of the signal. 
5.3 Mechanisms of Ras "Activation" 
Ras proteins most commonly acquire transforming properties through undergoing 
point mutation at key residues within the molecule. It is also possible that ras acquires 
oncogenic potential by being over-expressed in its "wild-type" form, 0 
Studies of normal and mutant proteins expressed in Escherichia coli (Sweet, et al 
1984, McGrath et al 1984, Gibbs et al 1984), purified, and then micro-injected in to 
test cells has shown that activation arises from mutations that favour the predominance 
of the GTP bound form. Mutation could achieve this by inhibiting GTPase activity, 
favouring exchange of GTP for GDP, or by producing a conformational change that 
would allow activation without GTP. Most recently, a GTPase activating protein 
(GAP) has been identified which interacts with ras p2l so increasing its GTPase 
activity. Mutated ras would appear unable to react with this protein so explaining its 
existence in a GTP bound active form (Cales et al 1988, Parsons 1990). Naturally 
occurring ras oncogenes most commonly contain mutations at codons 12,13,53 and 
61 although in vitro mutagenesis studies have identified "activating" mutations at other 
codons. 
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5.4 Ras p2l Proteins as Members of a Multi-gene Family 
Ras genes appear to be members of a large gene family coding for small proteins with 
limited sequence homology to p2l. Thus, in addition to the classical heterotrimeric G 
proteins, an increasingly large number of small (20-25kDa) molecular weight G- 
proteins (SMG) are being identified within mammalian tissues. Besides the ras family 
this group includes the rho, ral, rab, yptl and arf genes (Taparowsky et al 1983, 0 t5l 
Touchot, Chardin and Tavitian 1987, Lowe et al 1987, Sewell and Kahn 1988). The 
proteins coded for by these genes all share consensus sequences for GTP binding and a 
GTPase domains. Many have been purified to homogeneity, and some sequenced and 0 
cloned. Despite this, their function remains largely unknown although like ras they 
are proposed to play a role in signal transduction. 
5.5 Ras p2l, Growth Factors, Cellular Proliferation and Differentiation 
The functional similarity of ras p2l to G proteins, together with the ability of activated 
forms to stimulate cell division in the absence of serum, suggests that they act down- 
stream from growth factors and perhaps transmit their signals from the cell surface. 
Indeed, the introduction of activated ras proteins in to cells closely mimics the action 
of growth factors such as Epidermal Growth Factor (EGF) and Platelet Derived 
Growth Factor (PDGF) in a number of a ways. For example, ras proteins activate the 
Na+/K+ antiporter (Moolenaar et al 1983), increase intra-cellular pH (Hagag et al 
1987), promote expression of c-fos in the nucleus (Greenberg and Ziff 1984. Stacey 
et al 1987), and increase membrane ruffling (Bar-Sagi and Feramisco 1986) and 
pinocytosis (Bar-Sagi, Fernandez and Feramisco 1987). Similarly , the introduction of 
antibodies to ras prevents entry of cells in to S phase. Time course expcrimentsshow 
ras proteins to be necessary about up to about 8 hours after serum induction 
(Mulcahy, Smith and Stacey 1985), a point coinciding withthe beginning of S phase; 
but not once S phase has been entered. 
As well as their role in proliferation there is also considerable evidence to link ras 
proteins with differentiation - which is perhaps surprising given their more usual 
association with malignancy. However, despite differentiation and proliferation often 
being thought of as antagonistic processes, "growth" factors can also be 
"differentiation" factors. For example, Nerve Growth Factor (NGF), which promotes 
the differentiation of adrenal cell line PC-12, is mimicked by activated but not normal 
ras proteins (Bar-Sagi and Feramisco 1985) and can be blocked by anti-ras antibody 
(Hagag, Halegoua and Viola 1986). 
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Furthermore, in non-malignant cells there appears to be no clear association between 0 
proliferation and p2l expression (Goyette et al 1984), with some of the highest p2l. 0 
levels being found in differentiated tissues such as brain, heart and endocrine glands 0 
as well as in cancers (Tanaka et al 1986, Furth, Aldrich and Cordon-Cardo 1987). 
5.6 The Mechanism of Action of Ras Proteins 
If, as seems likely, ras proteins receive and transmit messages from surface receptors, 
how do they perform their function and what are their cellular targets ? In this context 
there is considerable evidence to link ras proteins, either directly or indirectly, to a 
number of different signalling pathways. 
For example, it has been proposed that ras might the be the putative G protein (Gp) 
(Cockcroft 1987, Wakelam et at 1986) linking phospholipase C (PL-C) to cell surface 
receptors. PL-C mediates the hydrolysis of membrane polyphospho-inosi tides (PPI 
,) to diacylglycerol (DAG) and inositol triphosphate (ITP) that activate PK-C and 
mobilize calcium respectively. Certainly, phorbol-ester induced down-reguation of 
PK-C activity markedly inhibits the ability of activated ras proteins to transform 
Swiss 3T3 cells (Lacal et at 1987a) and ras activation is associated with increased 
membrane turnover and DAG formation in transformed and normal cells (Priess et at 
1986, Wakelam et at 1986, Lacal et at 1987b). Moreover, the observation that PK-C 
can phosphorylate ras proteins (Jeng et at 1987) and that Ha-ras has the ability to 
inhibit c-fos induction by phorbol esters constitutes further indirect evidence of 
interaction. Ras p2l protein may also transmit the signals generated by the binding of 
polypeptide growth factors to receptor tyrosine kinases (RTK). Thus ras proteins can 
inhibit autophosphorylation of the insulin receptor (O'Brien el at 1987) and PDGF-R 
(Parries et at 1987). EGF can increase the GDP binding of ras proteins and there is 
increase in TGF-, cx production in some ras transfornýed cells (Kamata and Feramisco 
1984). The relationship between rav and the cyclic AMP system is discussed below. 
5.7 Ras p2l Protein and the Cyclic AMP Secondary Messenger System 
The yeast Saccharomyces cerevisiae possesses two genes (RASI and RAS2), coding 
for 4OkDa and 41kDa RAS proteins that are homologous to mammalian ras proteins 
and that activate adenylate cyclase (AQ (Papageorge et al 1984). Although 
mammalian ras proteins can activate AC in RAS deficient yeast cell membranes there 
is still debate as to whether ras proteins have any direct effect on AC in mammalian 
cells. A relation between Ki-ras protein and AC activity is suggested by bursts of Ki- 
ras transcription co-inciding with the increase in AC activity that occurrs in both 
regenerating liver cells and BALBc/3T3 cells as they near the GIN transition 0 
so 
(Campisi et al 1984). Although it has been shown that Ha-ras p2l protein neither 
inhibits nor stimulates AC activity (Beckner, Hattori and Shih 1985, Broek et al 
1985), Ki-ras p2l which is structurally different and expressed at different times in 
the cell cycle (Goyette et al 1984) has been postulated to have an indirect effect on AC 
- possibly by indirectly inhibiting Gi. Thus, activation of Ki-ras transcription in 
quiescent NRK cells leads to an early increase in AC activity, GI transit, and 
replication (Franks, Durkin and Whitfield 1989). The fact that foskolin, a powerful 
stimulator of AC catalytic sub-unit, does not mask or overide the effect of ras gene 
activation makes it unlikely that p2l directly stimulates AC. Furthermore, the fact that 
p2l. retained its effects at Mg2+ concentrations that are optimal for Gi but sub-optimal 
for Gs suggests that p2l is acting not by stimulating Gs but by inhibiting Gi. The 
slowness of AC activation following activation of p2l also suggests that the 
mechanism is indirect. Ras gene activation has been shown to increase phop4atidyl- 
inositol degradation and the observation that diacylglycerol (DAG) activates PK-C 
suggests a possible mechanism as PK-C is known to activate AC in platelets (Katada 
et al 1995) and pituitary cells (Summers and Cronin 1986) by inactivating Gi. 
Xenopus laevis oocytes contain AC which, as in mammals, is regulated by the GTP 
binding proteins Gs and Gi (Mulner et al 1985, Olate et al 1984). Both insulin, acting, 
through the tyrosine kinase activity of its receptor (Morgan et al 1986), and 
progesterone acting through inhibition of AC (Mulner et al 1985), can induce 
maturation. Micro-injection of activated ras also induces maturation but without any 
change in cAMP levels (Birchmeier, Broek and Wigler 1985). This, together with the 
fact that anti-ras antibody can block the effects of insulin but not progesterone (Kom 
et al 1987, Deshpande and Kung 1987) has been taken as evidence for ras proteins 
mediating the effects of insulin and not progesterone. However, there is a considerable 
body of evidence to support an indirect but functionally important interaction between 
ras and cAMP. For example, phosphorylation of yeast RAS protein by PK-A inhibits 
the ability of RAS to activate AC (Resnick and Racker 1988) and NIH3T3 cells 
transfected with mutated c-Ha-ras gene isolated from EJ human bladder carcinoma 
cell line show markedly reduced basal, PGE2 and isoprotenerol induced cAMP 
accumulation when compared with non-transfected cells (Gorman, Benjamin and 
Tarpley 1987) 
As discussed above ras p2l belongs to a large family of small molecular weight G- 
proteins that share marked structural, and possibly functional, similarities. Messenger 
RNA coding for a p2l-like SMG termed SMG-25A (Matsui et al 1988) is detectable 
in rat phaeochromocytorna cell line PC12 and increases after these cells are induced to 
differentiate in response to NGFordibutyryi-cAMP(Sanoetal 1989). Another SMG 
51 
termed SMG-21 of molecular weight 22kDa and found in human platelets (Kawata et 
al 1989) is phosphorylated by PK-A but not by PK-C (Hoshijima et al 1988). The 
c-Ki-ras p2l is also phosphorylated by PK-A and PK-C (Ballester, Furth and Rosen 
1987) and c-Ha-ras p2l by PK-C (Jeng et al 1987). Phosphorylation does not affect 
the protein's GTP binding or GTPase activity but it is possible that it does affect the 
protein's ability to interact with other targets or activating proteins. 
5.8 Anti-ras Antibody: Y13-259 
One of the commonest reagents used to characterise and manipulate ras proteins is the 
rat monoclonal antibody designated Y13-259. This antibody is able to bind all 
mammalian and inve. rtebrate ras products and can block both ras transformation and 
the mitogenic response of certain cells in culture to serum. The epitope recognized by 
this antibody has been localized to residues 70-89 and as binding of Y13-259 has no 
effect on the known biochemical properties of ras proteins and it is presumed Y13-259 
inhibits the association of ras with a putative effector protein (Barbacid 1987). 
5.9 Ras Genes and p2l Expression in Human Cancers 
Ras oncogenes are the most frequently identified oncogene family in human cancers 
(Nishimura and Sekiya 1987) and ras oncogenes have also been found to be 
reproducibly activated in a variety of carcinogen-induced animal turnours (Barbacid 
1987). It is generally accepted that most carcinogens are mutagens and although the 
majority of these mutations will be silent, one will eventually occur at a critical sites 
such as those discussed above. Ras aenes may then act in concert with other genetic 
events or with specific developmental programs to cause malignancy (Vogelstein et al 
1988). It is possible that ras oncogenes become activated early in life but perhaps only 
later, in the presence of a suitable hormonal milieu promoting proliferation, do their 
malignant properties become manifest. Although ras oncogenes become activated in 
somatic rather than germ-line cells (Bos et al 1985, Santos et al 1984, Fujita et al 
1988) and normal cells in patients with high cancer risk syndromes do not appear to 
contain ras oncooenes, the existence of rare alleles has been associated with certain 
cancers (Krontiris et al 1985, Heighway et al 1986). As yet it is not known how the 
presence of such rare alleles might predispose to cancer development but it is possible 
that certain alleics are more succeptible to mutational events. 
Although ras oncoarenes have been identified in a variety of human cancers including 
bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, melanoma, 
neuroblastoma as well as in a number of haernopoietic malignancies and in sarcomas 
the actual incidence of ras mutation within a particular cancer can be difficult to 
determine (Barbacid 1987). The earliest studies were carried out by means of 
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transfection assays which will most likely produce an under-estimate due to DNA 
degradation and contamination with non-malignant cells. The generation of oligo- 
nucleotides to sequences around the critical 12th and 61st codons have allowed more 
accurate detection. However, ras genes can be theoretically activated by up to 100 
different base substitutions, of which 30 have been detected in natural ly-occurring 
turnours, so that the numbers of probes required for full evaluation could be very 
large. Another approach has been the generation of monoclonal antibodies that would 
differentiate normal and activated ras proteins. As well as activation of ras genes, 
over-expression of p2l has been identified in a variety of turnours, presumably due to 
gene amplification. Thus expression of ras genes is sometimes higher in tumours than P 
in the normal tissues from which the tumour arises. For example, breast (Hand et al 
1984,1987), bladder and prostate cancer (Viola et al 1985) but not colon (Kerr et al 
1985, Williams et al 1985, Ghosh, Moore and Harris 1986) would seem to over- 
express p2l. However, with such immuno-histochemical studies there is always the 
important question of the antibody specificity. For example, RAP5 may recognize 
cytoplasmic components distinct from p2l and there may be significant amounts of 
non-specific staining particularly of formalin-f ixed paraffin embedded tissue sections. Cý 
5.10 Conclusions 
in summary, ras p2l is one of a family of SMG that appear to be involved in signal 
transduction within one or more different pathways. With respect to the present 
study, p2l has been shown to interact, albeit indirectly, with components of the cAMP 
system. In particular the growth modulating effects of cAMP appear to be associated 
with changes in ras expression in a range of benign, transformed and malignant cells. 
The relationship between cAMP and p2l will be covered more fully in the Discussion. 
S3 
Chapter 6: The Aetiology and Pathogenesis of-Colorectal -Cancer 
6.1 Introduction 
Although our knowledge of the processes leading to invasive colorectal cancer remains 00 
incomplete, a number of important genetic and environmental factors have been aý' 
identified and several steps in the sequence of carcino(yenesis defined. A possible 
sequence of events is as follows: 
1) genetic factors make colorectal epithelium suceptible to luminal carcinogens derived 0 
from food, bile salts or bacterial metabolism. 
2) environmental factors dictate whether or not such carcinogens are present and able 
to act. 
3) carcinogens cause mutations within DNA leading to activation of certain oncogenes 0 
and inactivation of tumour suppressor genes. 
4) as cells become more deranged so they become refractory to the normal signals a 
brought to bear through endocrine, neurocrine, paracrine and autocrine mechanisms. 0 
5) later, metastasis suppressor genes may be lost allowing the development of 
disseminated disease, 
Some of these steps will now be discussed in more detail with particular reference to 
the possible involvement of the cAMP signal transduction pathway. 
6.2 Genetic Factors 
Although Familial Adenomatous Polyposis (FAP) accounts for only a small 
proportion of all colorectal cancers, Hereditary Non-polyposis Colonic Cancer 
(HNPCC or Lynch Syndrome) (Lynch et al 1985,1988) and other less well defined 
(Yenetic susceptibilities (Li 1988) may be important in a much larger number of cases 
(Cannon-Albright et al 1988, Moolgavkar 1989, Tutton 1989). Thus, relatives of 
patients with colorectat cancer are at increased risk of developing both colorectal 
adenomas and cancers (Ponz de Leon et al 1987) and pedigree analysis has identified 
an autosomal dominant pattern of inherited suceptibility in one kindred (Burt et al 
1985). The recent discovery that a gene on chromosome 5 (FAP locus) (Leppert, 
Dodds and Scambler 1987, Bodmer et al 1987) is lost in FAP as well as in a variable 
proportion of sporadic cancers (Solomon et al 1987, Wildrick and Boman 1988, 
Okamoto et al 1988) has further confirmed the importance of genetic factors in the 
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pathogenesis of colorectal cancer (Shaw and Costa 1989). Cytogenetic analysis and 
Restriction Fraction Length Polymorphism (RFLP) studies have identified 
abnormalities of several other chromosomes in colorectal cancers; for example, 
chromosomes 2 (Gardner, Rogers and Woodward 1982), 7,8 and 13 (Reichman, 
Martin and Levin 1985) and 17 and 18 (Fearon, Hamilton and Vogclstein 1987, 
Monpezat et al 1988). Identification of the products for which the FAP gene and these 
other less well defined loci code will represent a major advance in our understanding 
colorectal carcinogenesis. CP 
6.3 Environmental Factors 
The geographical variation in the incidence of colorectal adenomas and cancers 
provides strong evidence for the importance of environmental factors in the aetiology 
of colorectal cancer (Jensen 1984, Nomura 1990, Trock, Lanza and Greenwald 
1990). There is a complex and sometimes inconsistent (Kolonel 1987) relationship 
between left-sided colorectal cancer and a so-called "Western" diet hioh in animal fats 
and low in fibre (Philips and Snowdon 1985). By contrast, in developing countries 
where there is a low incidence of colorectal cancer overall, right-sided disease 
predominates and is of uncertain aetiology. Rectal cancer would appear to have 
separate risk factors (Correa and Haenzel 1978) such as excess alcohol consumption 
(Wu et al 1987). 
6.4 Mechanisms Controlling the Proliferation of Normal and Malignant 
Colorectal Mucosa 
Clinically, it would appear that colorectal adenomas and cancers often arise within a 
bowel whose epithelium has undergone widespread field change and become unstable. 
Thus patients undergoing resection for colorectal cancer have an increased chance of 
having synchronous adenomas and cancers as well as an increased risk of developinc 
metachronous lesions in the future (Bulow, Svensen and Mellerngard 1990). The 
pathological basis of this increased risk appears to be the development of a 
"hype rprol iferati ve" epithelium that may be especially succeptible to luminal 
carcinogens (Lipkin 1974,1985, Lipkin, Sherlock and Bell 1963, Lipkin et al 1983, 
Deschner, Lewis and Lipkin 1963). Normally, DNA synthesis and cell division are 
restricted to the basal three-quarters of colonic crypts,, the so-called proliferative zone 
WZ), and cell renewal exactly matches the loss of senescent cells into the lumen. 
Chcmically-induced colorcctal cancer in experimental animals is associated with an 
early increase in DNA synthesis (Matthews and Cooke 1986) and an expansion of the 
PZ. Furthermore, the susceptibility of inbred mouse strains to chemical carcinogens 
can be predicted on the basis of the proliferative characteristics of their colorectal 
epithelium (Glickman, Suissa and Fleiszer 1987, Deschner et al 1984). Substances 
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that either increase (Deschner 1987) or decrease (Lipkin, Sherlock and DeCosse 1980, 
Reddy, Maruyama and Kelloff 1987, Lipkin and Newmark 1985) proliferation 
similarly affect the ability of carcinogens to produce turnours. Studies in humans have 
also identified a correlation between colorectal epithelial proliferation and risk of 
cancer development (Deschner and Lipkin 1975, Deschner 1983, Deschner et al 
1983, Lipkin et al 1983,1984,1985, Lipkin, Enker and Winawer 1987, Lipkin 
1988), and have shown that the rate of proliferation within individuals can be 
manipulated by means of diet (Lipkin et al 1989). Furthermore, patients with 
adenomas and cancers possess "hyperproliferative" epithelium throughout their colons 
(Maskens and Deschner 1977, Terpstra et al 1987). The complex mechanisms 
controlling proliferation within colorectal epithelium are poorly understood but are 
likely to comprise neurocrine (Tutton and Barkla 1980a), endocrine (Hoff, Chang and 
Mak 1981, Tutton and Barkla 1982a, b), paracrine and possibly autocrine mechýnlsms 
(Pommier 1988). 
6.5 Neurocrine Mechanisms 
Although early workers had identified trophic nerve fibres and postulated that they 
might be responsible for the control of cell division within tissues (Bizzozero 1894), 
the role of neurocrine mechanisms in the regulation of cell proliferation has been 
relatively ignored. However, catecholamines through activation of cAMP and other 
pathways (Lefkowitz and Caron 1988) do influence the division of a wide range of 
cell types both within and outwith the gastro-intestinal tract. For example, a- 
adrenergic activation stimulates the proliferation of lymphocytes and jejunal crypt 
cells, whilst P-adrenergic activation stimulates proliferation in the parotid gland and in 
haemopoietic stem cells. By contrast, P-stimulation inhibits proliferation in jejunal 
and duodenal crypts, buccal epithelium, lens tissue and epidermis. Serotonin (5-HT), 
again possibly acting through cAMP (Dudai 1988), stimulates proliferation of 
hepatocytes, basal epithelial cells, fibroblasts and jejunal crypt cells. Histamine. via its 
adenyl cyclase linked H2 receptors, stimulates proliferation in jejunal crypt cells and 
haemopoietic stem cells. 
Tutton and Barkla (1980b) measured the mitotic rate of cells in rat colonic crypts and 
in dimethyl-hydrazine (DMH)-induced colonic carcinomas and found that 
sympathectomy reduced cell proliferation in normal colonic crypts but had no effect 
upon turnours. Metaraminol, which releases nor-adrenalin from nerve endings, 
accelerated colonic cell proliferation but again had no effect on tumours. a-adrenergic 
blockade also inhibited crypt cell proliferation. P-adrenergic stimulation and blockade 
respectively inhibited and stimulated colonic cancer growth but had no effect on 
normal colonic crypts. Thus it appears that normal colonic epithelium is under 
autonomic control and in colon adrenergic fibres have been demonstrated in close 
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proximity to the bases of the crypts of Lieberkuhn. The demonstration that a- 
adrenergic manipulation does not effect cell proliferation within colonic turnours 
suggests that an important control mechanism may have been altered or lost during 
carcinogenesis. By contrast, however, whereas normal epithelium appeared refractory 
to P-adrenergic manipulation, colonic turnours were inhibited by P-stimulation known 
to be mediated though the cAMP signalling mechanism. Theophylline, a 
phosphodiesterase inhibitor that increases cAMP levels, inhibits thymidine uptake 
within normal colonic epithelium but has no significant effect on colorectal adenomas 
or cancers. This suggests that cAMP mediated control has been lost at an early stage 00 
in the malignant process and has perhaps allowed the development of pre-malignant 
adenomas (Margolis, Philpers and Alpers 1976). Furthermore, within adenomas and 
cancers cAMP/cGMP ratios were significantly reduced suggesting under-activation of 
the cAMP system (DeRubertis, Chayoth and Field 1976). Similar results were found 
in DMH-induced colonic tumours in rats (DeRubertis and Craven 1980) when 
compared to normal mucosa. Cyclic AMP levels within normal mucosa are also lower 
in proliferating cells obtained from deep within crypts than in more superficial non- 
proliferating cells (Craven and DeRubertis 1980). Alpers and Philpott (1975) 
demonstrated that theophylline increased cAMP levels and decreased thymidine 
uptake in rabbit normal colonic epithelium as did dibutryl-cAMP. Furthermore, 
treatment of rats with the carcinogen dimethy1hydrazine (DMH) produces an increase 
in colonic DNA synthesis associated with a decrease in cAMP and Protein Kinase A 
activity but a relative increase in Type I isoenzyme (DeRubcrtis and Craven 1980). 
Furthermore, vaso-active intestinal peptide (VIP) and PGE2, both substances that 
increase cAMP, were able to inhibit the effects of DMH. Cyclic AMP has been also 
been postulated as a marker for pre-malignant change in the large bowel (Latner. 
Turner and Tregoning 1979). These observations suggest that cAMP, possibly acting 
in a neurocrine manner, has an inhibitory influence on normal colorectal mucosa and 
that this control may be lost or altered in pre-malignant and malignant colonic 
epithelium. 
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6.6 Endocrine Mechanisms 
A number of hormones have been implicated in the initiation and progression of 
colorectal cancer (Townsend et al 1988). 
Sex Steroids: The epidemiological association of colorectal cancer with breast and C) 
gynaecological cancer has lead to suggestions that exposure to sex hormones is :Ia!. V 
important in the aetiology of colorectal cancer (Davidson, Yoshizawa and Kolonel 
1985, Furner et at 1989, Davis et at 1989). Althouah it has been suggested that these 00 
effects might be mediated indirectly through changes in bile acid pool size and 0b 
composition, oestrogen receptors (ER) have been detected in a significant proportion 00 
of colorectal cancers (Magnusson et at 1999, Alford et at 1979). 
Vitamin D: The observation that the incidence of colorectal cancer correlates well with 
exposure to sunlight lead to the suggestion that Vitamin D might protect against the 
development of CRC (Garland and Garland 1980, Garland et al 1985,1989). Vitamin 
D supplementation reduced the incidence of colorectal cancer in a large cohort of 
American men and in rats challenged with a potent carcinogen (Pence and Buddingh 
1988). Human colon cancer cell lines have Vitamin D receptors (Frampton, Suva and 
Eisman 1982) and Vitamin D metabolites suppress their in vitro growth and promote 
differentiation (Waroovich and Lointer 1987, DeLuca and Ostrem 1987). Vitamin D 
also causes regression of human turnour xenografts in vivo (Eisman, Barkla and 
Tutton 1987). In a recent study of more than 25,000 people conducted over 8 years 
those with higher levels of serum Vitamin D were much less likely to develop 
colorectal cancer (Garland et al 1989). Vitamin D levels may be a marker for calcium 
or milk intake as both are associated with reduced CRC incidence (Slattery, Sorenson 
and Ford 1998, Kune, Kune and Watson 1987) and possibly act by reducing colonic 
mucosal proliferation (Lipkin and Newmark 1985, Rosen 1987). However, rapid 
fluctuations of serum Vitamin D with exposure sunlight (Lawson, Paul and Black 
1979) suggests that this may be an important factor. Although Vitamin D is thought to 
act by binding to a cytosolic receptor it also appears to interact with the cAMP system. 
For example, Vitamin D decreases the parathyroid hormone (PTH) stimulation of 
adenylate cyclase, cAMP and PK-A activation in rat osteosarcoma cells (Titus et al 
1989). 
Vitamin A: Vitamin A (retinoic acid, RA) and its synthetic derivatives are potent 
inhibitors of chemical carcinogenesis in laboratory animals, inhibit in vitro cell line 
growth, and promote differentiation of cells both in vivo and in vitro (Roge1j, Loewy 
and Niles 1985). They have therefore have been considered as possible anti-turnour 
agents. At least some of these effects are mediated through cAMP and PK-A (Sani, 0 
Banjeree and Peckham 1980, Ludwig, Loewy and Niles 1980, Niles, Ludwic, and 0 
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Makarski 1984) as they can be mimicked either by cAMP or agents that increase intra- 
cellular cAMP levels (Lotan et al 1978, Abou-Issa and Duruibe 1986). for example. 
RA-induced differentiation of mouse embyonal carcinoma (EQ (Piet et al 1986) and 
melanoma cells (Ludwig, Loewy and Niles 1980) is also associated with an increase 
in PK-A activity in both membrane and cytosolic fractions. Furthermore, there was an 
increase in cyclic AMP binding proteins, and in particular III. These changes occur 
immediately prior to growth inhibition, and melanoma cells deficient in PK-A were 
resistant to the effects of RA. By contrast RA-induced differentiation of F9 
teratocarcinoma cells (Piet, Evain and Anderson 1982) and growth, inhibition of 
transformed mouse IOTI/2 (Hohmann and Greene 1990) was associated with an 
increase in PK-A and total cAMP-BP but a relative reduction in RI isoform. 
Although it is generally accepted that steroid hormones bind to specific cytosolic 
and/or nuclear DNA-binding receptors and do not act directly through cAMP, recent 
work on breast cancer has shown that cAMP binding protein expression is related to 
oestrogen receptor status (ER) and and also to prognosis (Miller et al 1985,1990, 
Miller 1987). How steroid receptors and the cAMP system interact remains unclear but 
steroid hormones have been shown to regulate the autophophorylation of RII (Liu. 
Fiske and Chen 1980) and also the expression of certain cAMP associated membrane 
receptors such as the P-adrenergic receptor (Collins, Caron and Lefkowitz 1988), In 
addition, phosphorylation of certain steroid receptors, possibly by PK-A in a manner 
similar to CREB, may affect their interaction with ligand or with DNA (Brown and 
DeLuca 1990). 
Gastrin a polypeptide hormone produced predominantly in gastric mucosa, stimulates 
gastric secretion and the growth of cells within the stomach, small intestine and colon 
(Johnson 1977). Gastrin receptors have been detected in animal (Singh et al 
1985b, 1986) and human colonic epithelium and in human colorectal cancers (Rae- 
Venter, Townsend and Thompson 1981, Rae-Venter et al 1981). Although the 
physiological significance of these receptors is unclear, pentagastrin enhances the 
growth of colorectal carcinoma in mice and decreases their survival (Winsett el al 
1986) whereas as proglumide, a gastrin receptor antagonist, inhibits growth and 
increases survival (Beauchamp et al 1985). Gastrin-enhancement of DMH-induced 
rodent colorectal carcinogenesis is also inhibited by secretin (Elwyn, Jones and 
Romsdahl 1985) and the long-acting somatostatin analog 201-995 (Singh et al 1986). 
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Chronic endogenous hypergastrinaernia due to antral exclusion also promotes 
carcinogen-induced colon cancer in mice (McGregor et al 1982). Human colon 
cancers grown in nude mice and in tissue culture are stimulated by gastrin (Murukami 
and Masui 1980, Sirinek, Levine and Moyer 1985, Kusyk, McNeil and Johnson 
1986). Although the mechanisms through which gastrin exerts its cellular effects are 
unclear, Sumiyoshi et al (1984) demonstrated that pentagastrin stimulates an increase 
in cAMP, Protein Kinase A activity and growth in a human xenotransplantable gastric 
cancer cell line. Furthermore, gastrin was shown to enhance selectively PK-Al 
expression in rat gastric mucosa and chemically initiated gastric carcinomas (Yasui and 
Tahara 1985). A recent study has demonstrated gastrin receptors on 56% of colon 
cancers examined and in patients with gastrin receptors, the levels of expression in 
tumour correlated with those in related normal mucosa. Furthermore, cancers that 
were allocated to Dukes stage A and B had higher levels of receptors than more 
advanced cancers (Upp et al 1989). Moreover, Watson et al (1989) showed that 16 
of 31 human colorectal cancers grown in vitro exhibited a trophic response to 
physiological levels of gastrin which was markedly higher than that of related normal 
mucosa. Interestingly. the gastrin-responsive tumours were predominantly of 
advanced stage and poor grade. 
Vasoactive Intestinal Peptide (VIP) VIP exerts control over many aspects of 
gastrointestinal function and at least some of its effects are mediated through cAMP 
(Laburthe el al 1978, Laburthe and Dupont 1982, Pratt and Takahashi 1989). The 
finding that VIP enhances mucosal proliferation and chemical carcinogenesis (lishi ef 
al 1987) in the rat colon has lead to suggestions that VIP promotes the development of 
colorectal cancer by generating a hyperproliferative epithelium. Recently, specific and 
physiologically active VIP receptors have been identified on human colorectal cancers 
(Luis et al 1987, Galons et al 1990). However Johnson (1977) was unable to 
demonstrate an effect of VIP on the proliferation of normal colonic mucosa and VIP 
had no effect on a human colon cancer cell line grown in nude mice or serum-free 
medium (Murakami and Masui 1980). 
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Polyamines: Polyamines are ubiquitous low molecular weight polycations probably 
involved in the synthesis of DNA and RNA. They are produced by and essential for 
the growth of all prokaryotic and eukaryotic cells so far studied (Tambor and Tambor 
1984). Tissues levels are primarily regulated by ornithine debarboxylase (ODC) 
which catalyses the rate limiting conversion of ornithine to putrescine. Increased ODC 
activity and polyamine levels are found in rapidly dividing cells and some cancers 
including those of brain, skin and intestinal origin. A close relationship exists between 
the cAMP levels, PK-A and ODC activity in dividing tissues (Byus, Hedge and 
Russell 1977) and both dibutryl cAMP and a number of hormones known to act 
through cAMP stimulate ODC activity (Janne, Posso and Raina 1978). Furthermore, 
ODC is now known to be a cAMP regulated gene (Guroff et al 1988) and DB2-cAMP 
induced differentiation of the HL60 human leukaemia cell line is associated with 
reduction in ODC mRNA and activity (Rius and Aller 1989). There is good evidence 
therefore that the cAMP system exerts important controls over polyamine metabolism 
within normal and possibly malignant cells. Animal studies have demonstrated 
increased polyamine synthesis during colorectal carcinogenesis and the growth of 
some colorectal cancers may be polyamine-dependent (Ball et al 1976, Upp et al 
1988). Furthermore, difluoromethyl-ornithine (DFMO), an irreversible inhibitor of 
ODC drastically reduces the ability of DMH to cause colorectal cancers in mice 
(Kinasnorth, King and Diekema 1983). The trophic effects of gastrin on intestinal 
growth are also blocked by DFMO (Seidel et al 1985). DFMO has also been shown to 
inhibit the growth of mouse colon cancers in vitro and in vivo (Marx et al 1983), of 
two human colon cancers in nude mice (Upp, Townsend and Thompson 1987), and 
of human colorectal cancer cell lines (Kingsnorth, Russell and LaMuraglia 1983). 
Elevated levels of polyamines have been found in human colorectal cancers and 
adenomas when compared to related normal mucosa. Levels were also higher in 
colonic mucosa from patients with cancer than in the mucosa of those patients 
undergoing resection for non-malignant disease suggesting a generalized proliferative 
abnormality in the colonic mucosa of patients with colorectal cancer (Upp et al 1988, 
LaMuraglia, Lacaine and Malt 1986). Polyamine levels are also elevated in the benign 
mucosa of patients with FAP and in their f irst-degree relatives (Luk and Baylin 1984). 
Increased polyamine levels, possibly under the control of cAMP, appear to be a 
marker for increased mucosal proliferation, and may be involved in the initiation 
and/or promotion of colorectal cancer. 
Taken together, the above results suggest that human colorectal mucosa and cancers 
may be under the control of gastro-intestinal hormones and in particular gastrin and 
VIP. Furthermore, it is possible that at least some of these effects are mediated 
through the cAMP secondary messenger system. 
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6.7 Paracrine and Autocrine Mechanisms 
Colorectal carcinoma cells secrete and express surface receptors for several 
polypeptide growth factors including insulin-like growth factor I (IGF-1), 0 V. ý 
transforming growth factor (TGF) (i and P, and EGF suggesting that these and other Cý 000 
related molecules function in an autocrine or paracrine fashion to modulate tumour cell 
growth (Coffey, Shipley and Moses 1996, Coffey et al 1987, Murthy, Anzano and 
Greig 1989, Culouscou, Remacle-Bonnet and Garrouste 1987, Culouscou et al 
1990). Although these growth factors act through well-defined receptor tyrosine 
kinase (RTK) molecules and not directly through cAMP, there exists a complex 
process of cross-talk between the two systems (Yarden and Ullrich 1988, Weinmaster 
and Lemke 1990). 
E12idermal Growth Factor (EGR EGF is a small polypeptide that stimulates the 
growth of a wide range of normal and malignant cells, including colorectal cancer cells :0t:. 
in vivo, and promotes differentiation of some epithelial tissues in vitro. The EGF 
receptor (EGF-R) possesses tyrosine kinase activity and is expressed in several types 
of human cancer cells including those derived from colon. Bradley et al (1986) found 
that well-to-moderately differentiated human colorectal cancer cell lines express 
increased amounts of (EGF-R) when compared to poorly differentiated cell lines and 
normal colonic mucosa. By contrast, Yasui et al (1988) were unable to demonstrate 
any significant difference in EGF binding between human colorectal cancers and 
related normal mucosa and Magnusson et al (1989) were unable to demonstrate a 
correlation between binding and pathological stage or grade of disease, It has been 
postulated that over-expression of EGF-R might contribute towards the transformed 
state and indeed the expression of EGF-R appears to be necessary for the growth of 
normal colorectal mucosa (Al-Nafusi and Wright 1982) and colorectal cancer cells in 
culture (Steplewski and Koprowski 1987). 
Transforming Growth Factors-(TGF) TGF are a heterogeneous group of small 
polypeptides able to reversibly transform normal cells in culture. A subgroup, TGF- 
cc, bind to the EGF-R and are present in conditioned media and extracts obtained from 
a variety of transformed cells, TGF-a may act in an autocrine manner possibly 
rendering such cells independent of normal physiological controls. Human colon 
cancer cell lines produce transforming growth factors and express TGF receptors 
(Roberts et al 1988) suggesting that they may be important in colorectal 
carcinogenesis. Interestingly cAMP analogs are able to reduce TGF-ct expression and r) 0 
reverse its transforming effects in a number of cel lines (Tortora et al 1989b). 
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Insulin-like Growth Factors OGF-l and IGF are polypeptides that are closely 
related to the structure of insulin, are produced by a number of foetal and adult tissues 
and are capable of stimulating cell proliferation. Adult colonic mucosa contains low C) 
levels of rnRNA for TGF-I and -11 whereas a proportion of colorectal cancers 
have 
been shown to contain elevated levels of message (Tricoli et al 1986). 
Plasminogen Activators (PA): PA are serine proteases found in plasma, body fluids 
and organs and are involved in fibrinolysis, tissue degradation and repair, 
inflammation, and malignant transformation (Verspaget et al 1989). Treatment of 
cells with tumour promoters or tumour viruses enhances the secretion of PA (Wiggler 
and Weinstein 1976) and a number of solid turnours, including colon (Friedman, 
Gillin and Lipkin 1984) demonstrate increased PA expression (DeBruin et al 1987a, b, 
Kogha et al 1985). Measurement of PA in normal colonic mucosa and cancer has 
allowed complete discrimination between the normal and malignant state with 
adenomatous polyps expressing PA at an intermediate level. Thus the adenoma- 
carcinoma sequence appears to be associated with an early increase in PA expression. 
It has been postulated that PA might act to degrade the basement membrane and 
pericellular matrix and indeed experimental antibodies to PA have been shown to 
inhibit metastases (Verspaget et al 1986, Ossowski and Reich 1983). Secretion of PA 
also reduces the number of gap junctions between cells so reducing their 
intercommunication (Ossowski 1988). Interestingly PA also have homology with 
EGF (Dano et al 1985) and a role for PA in autocrine growth stimulation has been 
postulated. Plasminogen activator gene has been identified as a cAMP responsive gene 
(Nakagawa et al 1998) and thus it is likely that cAMP will exert important controls 
over the type and level of PA released by cells. 
6.7 Conclusions 
In summary, colorectal cancer arises from the complex interaction of environmental 
and inherited factors leading through loss or mutation of genetic material to a cell that 
no longer responds to the neurocrine, endocrine, paracrine and possibly autocrine 
mechanisms that would normally regulate its proliferation and differentiation. It is 
clear from the work reviewed in this section that abnormalities of the cAMP signalling 
pathway might be involved at many different points in such loss of control. 
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Chapter 7: The Aims of the Thesis 
The historical review has aimed to show how the cyclic AMP system has become 
implicated as an important factor in the process of malignant transformation and in 
particular how it might be involved in the aetiology of human colorectal cancer. 
Although the isoforms of PK-A have been extensively studied with respect to cell lines 
and animal tumours, very little work has been performed on human tumours and, to 
date, no such studies have been carried out on resected colorectal. cancers. The aim of 
this Thesis was therefore to examine whether there are abnormalities in cAMP/PK-A 
system of human colorectal tumours when compared with related histologically benign 
mucosa. It was also intended to examine any potential relationship between 
cAMP/PK-A system and the expression of the oncoprotein most commonly associated 
with colorectal cancer, namely, ras p2l protein. 
In order to achieve the above aims three separate assays were developed and used. 
Firstly, a competitive binding assay using [3H]-cAMP was validated and used to 
determine the total level of cAMP binding to, and hence the total level of R subunit 
within, both benign and malignant colorectal tissues. Secondly, a [32pj-8-azido- 
cAMP photoaffinity labelling technique (PAL) combined with polyacrylamide gel 
electrophoresis (PAGE) and immunoprecipitation with specific anti-R antibodies was 
developed to enable specific labelling and quantification of RI and RII isoforms. 
Thirdly, the above techniques were combined with Y 13-259 Western blotting for ras 
p2l to examine the relationship between p2l. and PK-A expression. 
6.4 
Materials and Methods 
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Chapter 8: Materials 
8.1 Chemical Reagents 
Chemical reagents were obtained from the following sources. 00 
Unlabelled Cyclic Nucleotides 
Adenosine 3', 5' - cyclic monophosphate sodium salt; and guanosine 3', 5' - cyclic 
monophosphate sodium salt were purchased from Sigma Chemicals, Poole, Dorset, 
UK. 
Radiochemicals 
PHI-adenosine 3', 5'- cyclic monophosphate, ammonium salt, specific activity. 42-59 
[tCi/mmol; and [14C] methylated protein mixture, specific activity 5[tCi/mmol, were 
purchased from Amersham International PLC, Amersham, Bucks, UK. 
[32P]-8-azido adenosine 3', 5'- cyclic monophosphate, specific activity 44-49 tiCi/jig 
and [12511-Protein A. specific activity 56-62 [tCi/[tg, were purchased from ICN 
Radiochemicals, Irvine, California, USA. 
Buffer. Electrophoresis and Cell Culture- Reagents 
All reagents were of "Analar" or "Electrophoretic Purity" grade, 
Tris (2-amino-2-[hydroxy methyl I-propane- 1,3-diol, EDTA (diamino- ethanetetra- 
acetic acid disodium salt), M902.61-120, CaC12.2H20, KCI, HCI, NaHCO3, NaCl, 
Sodium lauryl sulphate (SDS), ammonium persulphate, and glycerol were purchased 
from Fisons, UK. 
Sucrose, KH2PO4, K2HP04, Nonindet (NP40), were purchased from BDH 
Ltd., UK. 
MES ([N-morpholinol ethanesulphonic acid), mercaptoethanol, deoxycholic acid 
sodium salt, BSA (bovine serum albumin, fraction V), theophylline (1,3 - 
dimethylxanthine) were purchased from Sigma Chemicals, UK. 
Aprotinin (Trasylol) was purchased from Bayer UK Ltd., UK. 
Tris, Glycine, TEMED (N, N, N', N' - tetramethyl-ethylenediamine) and 
Acrylamide/BIS were purchased from Biorad Laboratories Ltd., UK. 
Dulbecco's Minimal Essential Medium, New Born Calf Serum and Heat Inactivated 
Foetal Calf Serum were purchased from Gibco, UK. 
Ham F12 was purchased from Flow Laboratories, UK. 
Penicilin and Streptomycin were purchased from Glaxo Laboratories Ltd., UK. 
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Solvents 
All solvents were of "Analar" grade. 0 
Ethanol, methanol, phosphoric acid, and glacial acetic acid, were purchased from 
BDH Ltd., UK. 
Other Reagents 
Coomassie Brilliant Blue G-250 was purchased from Sigma Chemicals, UK. 
Bromophenol Blue was purchased from G. T. Gurr Ltd., UK. 
Kodak XR developer and fixer from Kodak, UK 
NE-260 liquid scintillator was purchased from Nuclear Enterprises, UK. 
Antibody Y13-259 anti-ras antibody was a gift of Mr. R. Morris, University 
Department of Patholoff, Edinburgh 
8.2 Non-chemical Materials 
Non-chemical materials were obtained from the following sources. 
MF-Millipore HAWP (mixed esters of cellulose) filters, 0.45um pore size and 25mm 
diameter, were purchased from Millipore, UK. 
Kodak X-omat-RP film was purchased from Kodak, UK. 
Nitrocellulose membranes were purchased from Bio-rad Laboratories Ltd, UK. 
Whatman No. I filter paper 18.5 and 30 cms diameter was purchased from Whatman 
International, UK. 
Model 220 Dual Vertical Slab Get Electrophoresis Cell was purchased from Bio-rad 
Laboratories Ltd., UK. 
Electrophoresis Power Supply 5WI400, Gel Slab Drier, and Destainer Power Supply 
was purchased from Pharmacia, UK. 
8.3 Buffers 
All buffers were made up in distilled water at room temperature and stored and used as 
described in Chapter 9: Methods. 
Buffer A 
20mM Tris, 0.25M sucrose, 2mM magnesium chloride, ImM calcium chloride, 
10mM potassium chloride, 16mM HCI, with and without Aprotinin 100 KIU/ml, pH 
7.5. 
Buffer B 
55mM potassium phosphate, to which II mM thcophylline was added immediately 
before use, pH 6.5. 
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Buffer C 
Buffer B with lOmM magnesium chloride added immediately before use, pH 6.5. 
MES/M,. YC12-Buffer 
0.27M MES and 53mM magnesium chloride, pH 7.5. 
Buffer 10 
O. IM sodium chloride, 5mM magnesium chloride, 1% Nonindet NP-40,0.5% 
sodium deoxycholate, 20mM tris, pH 7.5. 
Sample Buffer 
3% sodium lauryl sulphate (SDS), 15% mercaptoethanol, 30mM Tris, 30% glycerol, 
1% bromophenol blue saturated solution. 
Electrophoresis Buffer 
25mM Tris, 0.2M glycine, 3.5mM SDS 
Transfer Buffer 
25mM Tris, 0.15M sodium chloride, 2[tM EDTA, 0.1% Nonindet NP-40 
Lvsis Buffer 
25mM Tris-Hcl, pH 8.0,5OmM sodium chloride, 0.5% Nonindet NP-40, with the 
addition of PMSF 
Note: the half-life of PMSF in aqueous solution is about 30 minutes. A solution of 
PMSF was therefore made up in absolute alcohol (5mg in 250ul. ) and added on the 
c4v of the experiment as aI 000-fold dilution immediately prior to use. 
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Chapter 9: Methods 
9.1 Procurement and Storage of Colorectal Tissues 
Approval for the the study was obtained from all Consultants and Senior Lecturers in 
Surgery within the Royal Infirmary of Edinburgh and Chalmers Hospital. Patients 
admitted under their care provided the main source of human colorectal tissues. 
Procurement and processing of tissues was carried out with the kind assistance and 
co-operation of Dr. A. Wyllie, Reader, University Department of Pathology. 
Operative specimens were removed fresh from theatre and taken immediately on ice to 
the University Department of Pathology. Appropriate samples were then removed 
from the specimen and placed immediately into liquid nitrogen. All specimens were 
kept in liquid nitrogen or in a -70C freezer until assayed. 0 
9.2 Preparation of Cytosol and Membrane Fractions 
All procedures were perfomed on a bed of ice or in a cold room at 04C. Tissues were 
removed from liquid nitrogen or freezer and allowed to thaw slowly on ice. A 
representative portion was then removed and placed in 15% formal saline for 
histological purposes. An adjacent piece of tissue weighing approximately 200mg. 
was then finely cut with scissors and placed in a cold homogenizing tube. Buffer A 
(w/v 1: 10) was then added and the sample homogenized (Silverson, UK) at maximum 
speed for two bursts of 15 seconds. The homogenate was centrifuged at 4C at 
105,000g for I hour in an OTD-50 Ultracentrifuge (Sorvall ARC-1, Du Pont 
Instruments, Herts., UK). The supernatant was harvested with a Pasteur pipette and 
used as "cYtosol". The pellet was removed carefully from the base of the centifuge 
tube and resuspended in 2ml. Buffer 10 in a Teflon glass homogenizer. The resultant 
suspension was centifuged at 4C at 750g for 20 minutes and the supernatant used as 
the "membrane" preparation. 
9.3 Preparation of ras p2l Protein 
Standard ras p2l protein was obtained from a mouse derived fibroblast cell line 
NlH/3T3, clone 13-313-4, transfected with Harvey murine sarcoma virus (Ha-MuSV) 
DNA. This cell line was a gift from Dr. Y. S. Cho-Chung, NIH, Washington DC, 
USA and was routinely maintained with the technical assistance of Mr. W. N. Scott. 
The cell line was maintained in monolayer culture at 37C in Dulbecco's minimal 
essential medium (DMEM) containing 10% heat inactivated foetal bovine serum and 
44mM sodium hydrogen carbonate in an atmosphere of 95%/5% air/C02. The 
medium was also supplemented with Penicillin (100 IU/ml) and Streptomycin 
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(100ug/ml). Confluent flasks of 13-3B-4 cells expressing high levels of p2l were 
harvested by adding EDTA (0.02%, 15-20mi. ). Following agitation the monolayers 
detached and the suspension was centrifuged in universal containers at 10OOrpm for 
10 minutes at 4C. The supernatant was discarded and the cell pellet was washed with 
5ml. of phosphate buffered saline. The cells were re-centrifuged as before and re- 
suspended in Iml. of Lysis Buffer. The cells were refluxed, vigorously without 
frothing through a 21F and then 23F gauge needles. This suspension was centrifuged 
at 10,000rpm for 30 minutes at 4C. The supernatant was then divided in to aliquots 
and stored at -70C until use as standard in Western blots for p2l. 
9.4 Cyclic AMP Binding Assay 
Cyclic AMP binding was measured by means of a competitive assay using [3H]- 
cAMP and radioinert cyclic AMP. Cytosols derived from colorectal tumours and 
mucosa (50[d) were incubated with [3H]-cAMP (100[d of 25nM to give a final 
concentration of lOnM) and Buffer B containing radioinert cAMP (100[d to give final 
concentrations of 0,10,20,40,80, and 10,000ýM cAMP) to give a final volume of 
250ýtl in 12x75mm soda glass test-tubes. Each assay was performed in duplicate. 
Following thorough mixing each reaction mixture was left to incubate overnight at 4C. 
Cyclic AMP binding assays were also performed on membrane preparations derived 
from colorectal turnours and mucosa. During characterisation of the assay incubation 
times and temperatures were changed as described in the Results Section. In other 
experiments, to assess the specificity of binding, competitive assays with [3H]-cAMP 
were performed using other ligands than radio-inert cAMP. 
To separate bound from free cAMP, buffer B without cAMP (2ml) was added to each 
test-tube. After mixing, the contents of each tube was filtered (pore size 0.45[tm) at 
5mmHg negative pressure. The filter was washed twice with Buffer C at 5rnmHg (20 
ml. ). Filters were placed in polythene scintillation vials and thoroughly dried on a 
heating block at 37C. Micellar fluor (5ml. NE-260) was added and the vials allowed 
to incubate for 2 hours at 37C or overnight at room temperature. Radioactivity bound 
to the filter was measured in a Tricarb liquid scintillation counter (Packard). The 
counting efficiency of [3H]-cAMP on filters was found to be 3 1%. 
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To check for inter-assay variation, assays were perforned. using partially purified Type 
11 PK-A (Sigma) which had been diluted with Buffer A, aliqotted, and kept at -70C. 
In each control experiment 50[d was incubated in duplicate with 13H]-cAMP (1001AI, 
25nM to give final concentration IOnM) in the absence and presence of 10, OOOnM 
radioinert cAMP (100pl). To check the amount of [3H]-cAMP being used in each 
assay, 100[d of the IOnM 3H-cAMP was added to each of two filters and then dried 
and then counted as described above. 
9.5 Cyclic AMP Binding Assay Using [32pj-8-azido-cAMP 
Cyclic AMP binding assays were also carried out using [32p]-g-azido-cAMP as radio- 
active ligand so that binding of this cAMP analog could be compared with that of 
cAMP itself. Assays were carried out as described above except that they were 
conducted in the absence of daylight to reduce the formation of covalent ' 
bonds 
between the azido group and the receptor sites. In addition the amount of [32P]-8- 
azido-cAMP added was determined by the date of manufacture, the recorded specific 
activity at that time and the effect of decay (half-life 14.3 days). The [32p]-8-azido- 
cAMP bound was measured by scintillation counting and calibration showed the 
efficiency to be 90%. 
9.6 Measurement of Cytosol and Membrane Protein Concentration 
Cytosol and membrane protein concentration were determined by the 
spectrophotometric method of Bradford (1976). The method depends upon the 
brown to blue colour change, resulting in an increase in the absorption of light at the 
595nm wavelength, accompanying the binding of Coomassie Brilliant Blue to protein. 
Coomassie Blue G-250 (100mg) was dissolved in 95% ethanol in water (v/v to 50MI. ) 
by stirring for 20 minutes. Phosphoric acid (85% v/v with distilled water to 100ml. ) 
was added and the mixture stirred for a further 20 minutes. The solution was made up 
to I litre with distilled water and then filtered once through a double thickness of 
Whatman No. 1 filter paper. Bovine serum albumen was dissolved in 0.15M sodium 
chloride to give a stock solution of I mg/ml. From this stock standards were prepared 
to the following concentrations and stored in Iml aliquots at -20C until use: 10,20, 
30,40,50,60,70,80, and 100mg/ml. These standards were used to calibrate the 
spec trophoto meter. Other standards of 40,80 mg/ml, and 250,350, and 500mg/ml 
diluted to lie within the standard curve, were prepared from Sigma Protein Standards 
and used as internal standards between assays. 
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The cytosol preparations were diluted x4 and x8 and the membrane preparation x7 and 
x12 so that their protein concentration would lie between 20 and 100 mg/ml. The 
Coomassie Blue reagent (5ml) was very gently mixed (to prevent air bubbles) with 
each diluted test sample and allowed to sit on the bench for 10-20 minutes. The light 
absorbance was then measured at 595nm in a Beckman Spectrophotometer. The 
absorbance was compared with that of a standard curve obtained from the protein 
standards. Correction was then made for the dilution factor. The internal standards 
were also measured and the assay was repeated if there was more than a 10% 
inaccuracy. 
9.7 Analysis of Results 
Cyclic AMP binding results were derived by Scatchard analysis (Scatchard 1949). 
Briefly, the amount of bound and free [31-11-cAMP was derived mathematically from 
the total amount of cAMP present in each assay and the amount of radioactivity bound. 
Calculations were performed by means of a computer speadsheet (Eight-in-One 
Professional, Logotron, UK). Plots of bound/free (y-axis) vs. bound cAMP (x-axis) 
allowed binding (Bmax, nmol cAMP per 50[d wet weight cytosol) to be derived from 
the intersection of the plotted line with the x-axis. Determination of cytosol and 
membrane protein concentration enabled the results to be finally expressed as fmol. 
cAMP bound per mg. of cytosol or membrane protein. The slope of the line represents 
the association constant of the binding whilst its reciprocal represents the dissociation 
constant of binding (Kd) (units 10-8M). 
9.8 Photoaffinity Labelling (PAL) of cAMP Binding Proteins 
The method for photoaffinity labelling to characterise cAMP binding proteins was 
adapted from that of Pomerantz et al (1975). Cytosols of known protein content were 
diluted with Buffer A to a concentration of lmg/ml. Diluted cytosol (501tt, 50[too 
protein) was incubated with 0.4uM [32pl-8-azido-cyclic AMP (diluted in MES/MgCl2 
buffer, 15[d) and with MES/MgCl2 containing 1000-fold excess (0.4mM) radioinert 
cAMP or no cAMP (I 5ýtl, to give final volume 801d). MF-S/MgC12 with and without 
cAMP was made up fresh for each assay. Reaction mixtures were thoroughly mixed, 
and incubated at 4C for I hour in 96-well pyrex immunoplates in the dark. The 
mixture was then irradiated with UV light at 254nm for 5 minutes by placing them on 
a bed of ice beneath a Mineralight UVS- II lamp at a distance of 8 cms with the 
immunoplate lid removed. Sample buffer (401d) was added to each well, thoroughly 
mixed, and then the whole 120ul transferred to a 12x75mm soda glass test-tube. The 
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tubes were seated with parafilm and placed in a pre-heated water-bath at 80C for 5 
minutes. 40[tl (16[tg protein) aliquots of the mixture was then added to the SDS- 
PAGE apparatus. [14C]-methylated protein mixture (201tl) was mixed with sample 
buffer (100[d), and denatured as described above. Aliquots (50[d) were added to each 
gel as a molecular weight standard. The gels were run at room temperature at 
35mA/gel. The gel was dried down or transblotted and autoradiographs produced and 
analysed. 
9.9 Immunoprecipitation of cAMP Binding Proteins 
Immunoprecipitation of specific cAMP binding proteins with specific monoclonal 
antibodies was kindly performed by Dr. Cho-Chung and her colleagues (NIH, 
Washington, USA) on specimens provided by and also assayed in the Department of 
Surgery, Royal Infirmary, Edinburgh. Turnours were homogenized in a Teflon/glass 
homogenizer (10 strokes, motor driven pestle) with Iml buffer Ten (0-IM NaCl, 
5mM MgC12,1% Non-idet P-40,0.5% Na deoxycholate, 2 KlU/mI bovine aprotinin, 
20 mM Tris-HCI, pH 7.4) containing proteolysis inhibitors (0.1 mM pepstatin, 0.1 
mM antipapain, 0.1 mM chymostatin, 0.2 mM leupeptin, 0.5 mg/mI soybean trypsin 
inhibitor) and centrifuged for 10 minutes. The resulting supernatants were used as 
turnour extracts. Photoactivated incorporation of [32pj-8-azido-cAMP was performed 
at 23C for 45 minutes using 20pg of turnour protein in a total volume of 501AI of 
buffer Ten. After UV irradiation for 30 seconds, 5[d of I OnM cold cAMP was added 
to the reaction mixture and immuno-precipitation performed using anti-RI and anti-Ril 
antiserurn and protein A sepharose. The pellets of anti gen-antibody complex, after two 
washes with PBS (700 IAl each was with changing tubes), were solubilized and 
subjected to SDS-PAGE, transferred to nitrocellulose and exposed to X-ray film as 
described above. 
9.10 SDS-Polyacrylamide Gel Electrophoresis (PAGE) 
SDS-PAGE was based on the-method of Laemmli (1970). The apparatus used was a 
Bio-rad Model 220 Dual Vertical Slab Gel Electrophoresis Cell powered by Pharmacia 
Electrophoresis Power Supply 5001400. The glass plates were thoroughly cleaned 
with water and acetone and the apparatus assembled and then levelled. Separating gel 
solution containing 12% acrylamide/BIS, 4.5% Tris (pH 8.8), and 0.05% SDS was 
mixed. Immediately prior to pouring the polymerizing agents, ammonium persulphate 
(0.06%) and TEMED (0.08%) were added. The separating/stacking el interface was 
smoothed by carefully layering distilled water of the surface of the separating el until 
it had set. This water was then removed by means of a syringe and 23F gauge needle. 
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Stacking gel solution contained 4% acrylamide/B[S, 1.5% Tris (pH 6.8), 0.1% SDS, 
0.05% ammonium persulphate, and 0.1% TEMED and was mixed in a similar way. A 
Teflon well-forming comb was placed in to the apparatus and the stacking get was 
added with a Pasteur pippette, being careful to avoid air-bubbles. The whole assembly 
was allowed to set, the comb was removed and the wells rinsed with distilled water. 
The cell was then lowered in to the running tank and electrophoresis buffer added to 
both upper and lower reservoirs ensuring that no short circuit was present. The 
appropriate samples were then added to the wells and separated. Running times varied 
between assays and samples. For the purposes of separating photoaffinity labelled 
cAMP binding proteins the get was run for 3-4 hours to obtain separation of proteins 
very close in molecular weight (MW = 52,50 and 48kDa). By contrast, in Western 
blotting experiments for the detection of ras p2l (MW = 21 kDa) running times were 
only 1-2 hours. 
9.11 Drying Down of Gels 
The separating gel was placed in Fix I solution (20% acetic acid, 30% methanol) for 
45 minutes, Fix 11 solution (10% acetic acid, 40% ethanol) for 45 minutes with gentle 
shaking, and then Fix III solution (acetic acid 7%) for a futher 45 minutes. The get 
was then wrapped in cellophane and dried in a Pharmacia Get Slab Drier conneqted to 
a Pharmacia Destainer Power Supply and a vacuum pump. 
9.12 Transblotting of Gels 
The separating gel was removed from the glass plates and soaked in Transfer Buffer 
for 15 minutes. Electrophoretic transfer was performed using a Bio-rad Transb1ot Cell 
on to nitrocellulose sheets (Bio-rad). Transfer was conducted at 4C, at 60V with no 
current limit for 2 hours or overnight. The nitrocellulose was then processed 
appropriately depending on the assay being performed. 
9.13 Preparation and Development of Autoradiographs 
The following procedures were performed in a dark room. Transblotted nitrocellulose 
sheets, placed with filter paper in 15x3Ocm polythene freezer bags, or dried gels were 
placed in metal X-ray boxes in contact with a sheet of Kodak X-Omat-RP X-ray film. 
The closed box was then placed in a -70C freezer for between 24hours and 5 days 
depending on the isotope used and the estimated extent of radio-active decay. 
Following exposure the film was placed in Kodak X-ray developer and then fixer 
diluted 1: 5 with distilled water. The film was then thoroughly rinsed with water and 
allow to dry. 
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9.14 Laser Densitometry 
Autoradiographs from both PAL and p2l assays were analysed with the kind 
assistance of Dr. Daryl Green, Senior Scientist, MRC Computer Sciences Dept, 
MRC, Western General Hospital, Edinburgh. The laser densitometer scans the 
autoradiograph and generates a plot of distance (x-axis) against optical absorbance 
(arbitrary units 0-500). Each protein band present on the gel appears as a separate 
peak. Background absorbance is deducted and the area under the peak determined by 
integration. For the purposes of PAL assays the areas for each specific cAMP-BP 
were summed and then the relative percentage comprised by each isoforms derived by 
simple arithmetic. Non-specific bands were ignored. For the purposes of Western 
blotting a similar process was followed but the results were also corrected on the basis 
of the p2l. and tumour standards run concurrently on each get. The results of the PAL 
assays are expressed as percentage whereas those of the Western blotting assays are 
expressed as arbitrary units based upon the corrected optical density of the p2l band 
under study. 
9.15 Western Blotting for ras p2l. Protein 
The [14C]-methylated protein standards were used in a manner identical to that 
described for the PAL SDS-PAGE separation. Membrane preparations of known 
protein concentration were diluted with Buffer 10 to produce solutions of 1.5mg 
protein/ml and added (1001ii = 150pg protein) to sample buffer (50PI) in glass test- 
tubes. The tubes were sealed with Parafilm and the mixtures denatured in a pre-heated 
water-bath at 80C for 5 minutes. The samples (100[tt = 100jig protein) were then 
transferred to the get. To provide a reference p2l, a cell lysate prepared from NIH- 
3T3 clone, 13-3B-4, transfected with Ha-MuSV DNA was added (20pl) to sample 
buffer (80pl), denatured and added ' 
to the gel (100ttl). As a second control membrane 
preparation from a tumour expressing p2l was run in each experiment. The samples 
were run at 35mA/get until the sample buffer (coloured blue) was almost at the bottom 
of the gel. The gel was then removed from the apparatus and either dried or 
transblotted and autoradiographs produced and analysed. 
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9.16 Pathology and Histology 
Operative specimens underwent routine diagnostic histopathology in the University 
Department of Pathology from which information on tumour stage and grade was 
derived. In addition, when cytosol and membrane fraction preparation was 
undertaken, adjacent pieces of tissue were placed in 15% (v/v) formal saline. 
Histolog on these fragments was kindly performed in the Department of Clinical Ily 
Surgery by Mr. Walter Hawkins and Mrs. Dorothy Gray. Haernatoxylin and eosin 
slides were then examined under the light microscope to confirm the nature of the 
tissue. Patients undergoing surgery for colonic disease were identified by means of the 




Chapter 10: Characterisation of the Cyclic AMP Binding Assay 
10.1 Effect ofTime andTemperature of-incubation on-theffinding. of 120-cAMPto 
Cytosols Derived from Human ColorectaY Cancers and Mucosa 
Figures 10.1 to 10.4 show the effect of time and temperature of incubation on the 0 
level of cyclic AMP binding to cytosols derived from a human colorectal cancer and 
related normal mucosa. Specific binding is expressed as the number of counts of 0 
13HI-cAMP bound to tumour cytosol in the absence of cold competitor less the 
number of counts bound in the presence of excess (10, OOOnM) radio-inert cAMP 
(non-specific binding). These initial studies showed that, at both room temperature 
(RT) and 4C, binding rose rapidly over the first three hours of incubation in both 
tumour and mucosal cytosols. Although, initially, binding at RT rose faster (Figure 
10.2 and 10.4), binding at both RT and 4C reached its maximum 3 hours. However, 
whereas binding levels then fell following prolonged incubation at RT, at 4C, binding 
was maintained or increased with incubation of up to 24 hours. By contrast, non- 
specific binding was higher following incubation at RT than at 4C. Similar results 
were obtained in experiments on both malignant and benign tissues. Temperature and 
time course experiments using full Scatchard analysis at each time and temperature 
condition, perfomed on six pairs of benign and malignant colorectal tissues and two 
breast cancers confirmed that , in each case, binding following incubation at 
4C 
overnight was higher than following incubation at room temperature (RT) for three 
hours (Table 10.1). Furthermore, there was a significant correlation between binding 
to colorectal tumours and mucosa following incubation at 4C overnight and RT for 3 
hours (Figure 10.5). For these reasons it was elected to routinely perform the cyclic 
AMP binding assay overnight in the cold room. 
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Figure 10.1 The Effect of Time (0-24 hours) and Temperature (RT and 
4C) of Incubation on Binding of [3111-cAMP to a Cytosol Derived 
from a Human Colorectal Cancer 
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Figure 10.1 shows the specific and non-specific binding of [3H]-cAMP to a cytosol 
derived from a human colorectal cancer following incubation at RT and 4C for 
different times up to 24 hours. Specific binding is expressed as counts per minute 
(cpm) of [3H]-cAMP bound per 501LI of cytosol in the absence of 10,000nm radio- 
inert cAMP less the cpm per 50til of cytosol in the presence of 10, OOOnM radio-incrt 
cAMP. Binding (cpm) per 501tl of cytosol in the presence of 10,000nM radio-inert 
cAMP represents non-specific binding, Specific binding following incubation at RT 
was lower than at 4C whereas non-specific binding was higher at RT, Specific 
binding following incubation at 4C was maintained up to 24 hours whereas at RT 
binding declined after 3 hours. Non-specific binding increased slightly with increased 
time of incubation at both temperatures. 
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FigurelO. 2 The Effect of Time (0-3 hours) and Temperature (RT and 
4C) of Incubation on Binding of [3H]-cAMP to a Cytosol Derived 
from a Human Colorectal Cancer 
Bound 13111-cAMP (cpm) 
0 30 60 90 
II ----I 
120 130 180 
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Figure 10.2 shows the specific and non-specific binding of [3HI-cAMP to a cytosol 
derived from a human colorectal cancer following incubation at RT and 4C for 
different times up to 3 hours. Specific binding is expressed as counts per minute 
(cpm) of [3H]-cAMP bound per 50til of cytosol in the absence of 10,000nm radio- 
inert cAMP less the cpm per 50til of cytosol in the presence of 10, OOOnM radio-inert 
cAMP. Binding (cpm) per 501d of cytosol in the presence of 10,000nM radio-inert 
cAMP represents non-specific binding. Although specific binding following 0 
incubation at RT initially rose more quickly than at 4C, by 1-2 hours, binding at 4C 
was higher. By contrast, non-spccific binding was higher at RT. 
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FigurelO. 3 The Effect of Time (0-24 hours) and Temperature (RT and 
4C) of Incubation on Binding of [3H]. cAMP to a Cytosol Derived 
from Human Colorectal Mucosa 
Bound 13111-cAMP (epm) 
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Figure 10.3 shows the specific and non-specific binding of [3H]-cAMP to a cytosol 
derived from histologically benign mucosa related to a human colorcctal cancer 
following incubation at RT and 4C for different times up to 24 hours. Specific binding 
is expressed as counts per minute (cpm) of [3H]-cAMP bound per 50[d of cytosol in 
the absence of 10,000nm radio-incrt cAMP less the cpm per 50[d of cytosol in the 
presence of 10, OOOnM radio-inert cAMP. Binding (cpm) per 50pl of cytosol in the 
presence of 10, OOOnM radio-inert cAMP represents non-specific binding. Specific 
binding following incubation at RT was lower than at 4C whereas non-specific 
binding was higher at RT. Specific binding following incubation at 4C was maintained 
up to 24 hours whereas at RT binding declined after 3 hours. Non-specific binding C) increased slightly with increased time of incubation at both temperatures. 
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FigurelO. 4 The Effect of Time (0-3 hours) and Temperature (RT and 
4C) of Incubation on Binding of [3H]-cAMP to a Cytosol Derived 
from Human Colorectal Mucosa 
Bound 13RI-cAMP (cpm) 
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Figure 10.4 shows the specific and non-specific binding of [3H]-cAMP to a cytosol 
derived from histologically benign mucosa related to a human colorectal cancer 
following incubation at RT and 4C for different times up to 3 hours. Specific binding 
is expressed as counts per minute (cpm) of [3H]-cAMP bound per 50[ti of cytosol in 
the absence of 10,000nm radio-inert cAMP less the cpm per 501tI of cytosol in the 
presence of 10, OOOnM radio-inert cAMP. Binding (cpm) per 50[tt of cytosol in the 
presence of 10, OOOnM radio-inert cAMP represents non-specific binding. Although 
specific binding following incubation at RT initially rose more quickly than at 4C, by 
1-2 hours, binding at 4C was higher. By contrast non-specific binding was higher at 
RT. 
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Table 10.1 The Effect of Time (0-24 hours) and Temperature (RT and 
4C) of Incubation on Binding of [3H]. cAMP to Cytosols Derived from 
Six Human Colorectal Cancer and Mucosa Pairs and from Two Human 
Breast Cancers 
Tissue under Binding (fmol/mg protein) Binding (fmot/maprotein) IM 
examination following incubation at 4C following incubation at RT 
overnight for 3 hours 
Patient I 
Colorectal cancer 4444 3419 
Colorectal mucosa 3196 2643 
Patient 2 
Colorectal cancer 1896 1643 
Colorectal mucosa 1288 994 
Patient 3 
Colorectal cancer 3855 3043 
Colorectal mucosa 3316 2996 
Patient 4 
Colorectal cancer 3592 2337 
Colorectal mucosa 1748 1699 
Patient 5 
Colorectal cancer 2886 2362 
Colorectal mucosa 2149 1841 
Padent 6 
Colorectal cancer 2510 1573 
Colorectal mucosa 1477 1181 
Table 10.1 continued 
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TablelO. 1 (continued) The Effect of Time (0-24 bours) and 
Temperature (RT and 4C) of Incubation on Binding of [3HIcAMP to 
Cytosols Derived from Six Human Colorectal Cancer and Mucosa Pairs 
and from Two Human Breast Cancers 
Tissue under Binding (fmoUmg protein) Binding (fmol/mgprotein) 
examination following incubation at 4C following incubation at RT 
overnight for 3 hours 
Patient 7 
Breast cancer 4141 3965 
Patient 8 
Breast cancer 5824 4377 
Table 10.1 shows binding expressed as fmol. cAMP bound per mg. cytosol protein 
in six human colorectal cancer and related mucosa pairs and in two human breast 
cancers following incubation at either RT for 3 hours or at 4C overnight. In each case 
binding is higher following incubation overnight at 4C. 
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Figure 10.5 Correlation between [3H]-cAMP Binding to Cytosols 
Derived from Human Colorectal Cancer and Mucosa Following 
Incubation at RT for 3 hours and 4C Overnight 
Bound 13HI-cAMP after incubation at 
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Figure 10.5 shows the significant correlation between binding obtained in individual 
tissues following incubation at either RT for 3 hours or overnight at 4C. The figure 
depicts the data points for the 6 human colorectal cancer pairs and two human breast 
cancers shown in Table 10.1 
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10.2 The Effect of Cytosol Protein Concentration on the Binding of [aHl-cAMP to 
Cytosols Derived from Human Colorectal Cancer and Related Mucosa 
There was a statistically significant linear correlation between cAMP binding to 
cytosols derived from a human colorectal cancer and related mucosa and the protein 
concentration of those cytosols over a wide range of protein concentrations (Figure 
10.6 and Figure 10.7). For the purposes of the later cAMP assays the standard curve 
for measuring protein concentrations lay between 40 and 100 mg/ml. Tumour and 
mucosal cytosols were therefore diluted to lie within this range prior to performing a 
cyclic AMP binding assay. 
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Figure 10.6 Correlation between Cyclic AMP Binding and Protein 
Concentration in a Cytosol Derived from a Human Colorectal Cancer 







R sqtuired = 0.990 
0 IIIIItII 
50 100 150 200 250 300 350 
Cytosol protein concentration (mg/ml) 
FigurelO. 6 shows the correlation between specific [3H]-cAMP binding and protein 
concentration in a tumour cytosol diluted with Buffer A over a wide protein 
concentration of 60mg/ml to 317mg/ml . Specific cAMP is expressed as counts per 
minute (Cpm) of [3H]-cAMP bound per SOpI of diluted cytosol in the absence of 
10, OOOnM radio-inert cAMP less the cpm bound per 50pl diluted cytosol in the 
presence of 10,000nm radio-inert cAMP (non-specific binding). 
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Figure 10.7 Correlation between Cyclic AMP Binding and Protein 
Concentration in a Cytosol Derived from Histologically Benign Mucosa 
Related to a Human Colorectal Cancer 
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FigurelO. 7 shows the correlation between specific [3H]-cAMP binding and protein 
concentration in a tumour cytosol diluted with Buffer A over a wide protein 
concentration of 21mg/ml to 190mg/ml . Specific cAMP was expressed as counts per 
minute (cpm) of [3111-cAMP bound per 50[d of diluted cytosol in the absence of 
10, OOOnM radio-inert cAMP less the cpm bound per 50VI of diluted cytosol in the 
presence of 10,000nm radio-inert cAMP (non-specific binding). 
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10.3 The Specificity of fifil-cAMP Binding to Cyclic AMP Binding Proteins in 
Cvtosols Derived from Colorectal Cancers and Related Mucosa 
At physiological concentrations, ligands other than cAMP itself are unable to produce 
significant displacement of [3H]-cAMP from cAMP binding proteins in cytosol 
derived from a human colorectal cancer (Table 10.2 add Figure 10.8). For example, 
whereas radio-inert cAMP at a concentration of 8OnM produces almost complete 
displacement of [3H]-cAMP binding it requires cGMP at a million-fold higher 
concentration to produce the same displacement. AMP at concentrations between 10 
and 80ýtM did not produce any displacement of binding. Even at concentrations as 
high aslOmM only approximately 10% of binding was displaced. By contrast, BSA at 
concentrations greater than 40g/l enhanced [3H]-cAMP binding to a small extent. 
However, [3H]-cAMP did not bind BSA in the absence of cytosol (Table 10.3). 
Similar results were obtained in related histologically benign mucosa (Tables 10.4 and 
Figure 10.9). 
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Tablel. 0.2 TheSpecificity of [3H]-cAMP Binding to cAMP Binding 
Proteins as Shown by the Ability ofRadio-inert cAMP and Other 
Ligands to Produce Displacement of [3H]. cAMP from a Cytosol 









0 2302 0 2421 0 2351 0 2372 
lOnM 1819 lomm 2312 10[tm 2341 log/l 2456 
20nM 1719 2OmM 1743 20[tM 2292 20g/l 2472 
4OnM 1325 4OmM 1543 4ORM 2419 40g/l 2632 
8OnM 822 8OmM 1123 80[tM 2333 80g/l 2823 
10[tm 162 tomm 2195 loog/l 2734 
Table 10.2 shows the ability of different ligands to dsplace [3H]-cAMP from 
cAMP-BP present in a cytosol derived from a human colorectal cancer where cGMP 
is cyclic guanosine 3'. -5'-monophosphate, AMP is adenosine monophosphate, and 0 
BSA is bovine serum albumen (fraction V). Binding is expressed as counts per minute 
(cpm) of 13HI-cAMP bound per 501il of cytosol. 
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Table 10.3 Binding of BSA to [3H]-cAMP in the Absence of Cytosol 
Concentration of radio- Binding of (3RI-c AMP Binding of [3HI-cAMP 
inert cAMP (cpm) to 400 BSA (cpm) to 100g/l. BSA 
solution solution 
0 186 213 
10nm 241 253 
20nm 227 169 
4OnM 312 185 
8OnM 237 206 
IOMM 1177 1215 
Table 10.3 shows the inability of BSA at either 40g/I or 100g/I to bind j3HI-cAMP 
in the absence of cytosol despite its apparent ability to enhance binding of 13HI-cAMP 
to cAMP-BP present in both turnour and mucosal. cytosol prepatations 
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Tablel. 0.4 TheSpecificity of [3H]. cAMP Binding to cAMP Binding 
Proteins as Shown by the Ability ofRadio-inert cAMP and Other 
Ligands to Produce Displacement of [3H]. cAMP from a Cytosol. 












0 1947 0 2009 0 1864 
lOnM 1432 IOMM 1983 IORM 1874 log/l 1954 
2OnM 1276 2OmM 1723 20[tM 1842 20gll 1935 
4OnM 996 4OmM 1333 40[tM 1951 40g/l 2187 
SOnM 712 80mm 916 80[tm 1734 80g/l 2377 
10[tm 213 IOMM 1637 loog/l 2459 
Table 10.4 shows the ability of different ligands to displace [3HI-cAMP from 
cAMP-BP present in a cytosol derived from histologically benign mucosa related to a 
human colorectal cancer where cGMP is cyclic guanosine 3': 5'-monophosphate, 
AMP is adenosine monophosphate, and BSA is bovine serum albumen (fraction V). 
Binding is expressed as counts per minute (cpm) of [3HI-cAMP bound per 50[tt of 
cytosol. 
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Figure 10.8 The Specificity of [3HI. cAMP Binding to cAMP Binding 
Proteins as Shown by the Ability of Radio-inert cAMP and Other 
Ligands to Produce Displacement of [3HI-cAMP from a Cytosol 
Derived from a Human Colorectal Cancer 
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Figure 10.8 shows the ability of different ligands to displace [3H]-cAMP from 
cAMP-BP present in a cytosol derived a human colorectal cancer where cGMP is 
cyclic guanosine 3': S'-monophosphate, AMP is adenosine monophosphate, and BSA 
is bovine serum albumen (fraction V). Binding is expressed as counts per minute 
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Figure 10.9 TheSpecificity of [3H]-cAMP Binding to cAMP Binding 
Proteins as Shown by the Ability of Radio-inert cAMP and Other 
Ligands to Produce Displacement of [3H]. cAMP from a Cytosol 
Derived from Histologically Benign Mucosa Related to a Human 
Colorectal Cancer 
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Figure 10.9 shows the ability of different ligands to displace [3H]-cAMP from 
cAMP-BP present in a cytosol derived from histologically benign mucosa related to a 
human colorectal cancer where cGMP is cyclic guanosine 31: 5'-monophosphate, 
AMP is adenosine monophosphate, and BSA is bovine serum albumen (fraction V). 
Binding is expressed as counts per minute (cpm) of [3HI-cAMP bound per 501d of 
cytosol. 
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10.4 The Effect of Storage on the Ability of Whole Tissues and-Cytosols to Bind 
1231il-cAMP 
Although benign and malignant colorectal tissues were processed and assayed as soon 
as possible after procurement it was thought important to assess the stability of 13H]- 
cAMP binding both within whole tissues and and in derived cytosols following 
storage for different periods of time. 
Freezing, storage for 24 hours at -70C, and slow thawing of whole tissues and 
cytosols did not reduce [31-11-cAMP binding in either turnour or mucosal specimens 
(TablelO. 5). In addition, storage of cytosols at -70C for longer periods of time 
showed binding to be stable up to one week and, indeed, after even a month of 
storage there was only a small reduction in the total binding (Table 10.6). Similar 
results were obtained following prolonged storage of mucosal cytosol al -70C. 
Moreover, in terms of the dissociation constant of binding there appeared to be little 
change in the characteristics of binding after prolonged storage (Figure 10.10) 
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Table 10.5 Binding of [3H]. cAMP to Fresh and Stored Whole Tissues 
and Cytosols Derived from Three Human Colorectal Cancers and 
Related Histologically Benign Mucosa 
Specimen type Binding of [31-11- 0 




Binding of [31-11- 
cAMP (cpm) in 
freshly prepared 
cytosol following 
storage at -70C for 24 hours and slow 
thawing 
Binding of [3HI- 




that has been stored 
at -70C for 24 hours and then 
thawed slowly 
Tumour centre 2739 2727 2812 
Tumour periphery 5396 5432 5595 
Adjacent mucosa, 3754 3429 3281 
Distant mucosa 3612 3276 3377 
Tumour centre 4412 4558 4776 
Tumour periphery 4511 4582 4119 
Adjacent mucosa, 2916 3217 3228 
Distant mucosa 2834 3125 2983 
Tumour centre 1866 1632 1743 
Tumour periphery 2190 2007 2075 
Adjacent mucosa 1864 1439 1777 
Distant mucosa 1900 1745 1896 
Legend to Table 10.5 on next page 
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Table IO. S shows the binding of [3H]-cAMP to cytosols derived from the centre 
and periphery of three colorcctal cancers and from their related adjacent and distant 
mucosa. Binding is expressed as [3H]-cAMP bound (cpm) per 50[11 of cytosol in the 
absence of radio-inert cAMP less the cpm of [3H]-cAMP bound in the presence of 
10, OOOnM radio-incrt cAMP (non-specific binding). Figures represent the average of 
assays performed in duplicate. There was no difference in binding between whole 
tissues processed fresh; cytosols prepared from fresh tissues, stored at -70C for 24 
hours, and then thawed slowly-, and cytosols, prepared from whole tissues that had 
been stored for 24 hours at -70C and then allowed to thaw slowly. 
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Figurel. 0.10 Scatchard Plot Representing the Binding of [3H]. cAMP 
to a Cytosol Freshly Prepared from a Human Colorectal Cancer and 
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Figure 10.10 continued on next page. 
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Figure 10.10 continued. 
Bound/free [3111-cAMP 
Cytosol stored for 
one month at . 70 C 
Kd = 1.16 
Bmax = 1.69 
0.8 1.0 1.2 1.4 1.6 1.8 
Bound PHI-cAMP (nmol) 
Figure 10.10 shows Scatchard plots representing binding to a cytosol derived from 
a human colorectal cancer when. it was first prepared (upper plot) and following 
storage at -70C for one week (middle plot) and one month (lower plot). 
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Tablel. 0.6 The Effect of Storing Cytosols Derived from the Centre and 
Periphery of Human Colorectal Cancers and from Their Related 
Adjacent and Distant Mucosa on Their Ability to Bind [3H]. cAMP 
Specimen type Binding of 13HJ- 




Binding of [3HJ- 
cAMP (cpm) to 
cytosols stored 
at -70C for one 
week and then 
slowly thawed 
Binding of [31-11- 
cAMP (cpm) in 
cytosols stored 
at -70C for one 
month and then 
slowly thawed 
Tumour centre 2739 2554 2176 
Tumour periphery 5396 5123 4782 
Adjacent mucosa, 3754 3888 2678 
Distant mucosa. 3612 3456 3074 
Tumour centre 4412 4833 3902 
Tumour periphery 4511 4500 4210 
Adjacent mucosa 2916 2999 1876 
Distant mucosa 2834 2927 2043 
Tumour centre 1866 1803 1234 
Turnour periphery 2190 2265 1888 
Adjacent mucosa 1864 1774 1384 
Distant mucosa 1900 1841 1178 
Legend to Table 10.6 on next page 
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Table 10.6 shows the binding of [3HI-cAMP to cytosols derived from the centre 
and periphery of three colorcctal cancers and from their related adjacent and distant 
mucosa. Binding is expressed as 13HI-cAMP bound (cpm) per 50ýd of cytosol in the 
absence of radio-inert cAMP less the cpm of [3H]-cAMP bound in the presence of 
10, OOOnM radio-inert cAMP (non-specific binding). Figures represent the average of 
assays performed in duplicate. There was no difference between the level of [3HI- 
cAMP bindina to freshly prepared cytosols and to cytosols that had been stored at 
minus 70C for one week. There was some loss of binding to cytosols following 
storage at -70C for one month 0 
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10.5 Intm-tumour and Intra-mucosal Variation in Cyclic AMP Binding 
Cyclic AMP binding assays on 3 separate but contiguous samples of tumour and 3 
separate but contiguous samples of both adjacent and distant mucosa showed that 
there was a degree of intra-tumour and intra-mucosal variation in 13HI-cAMP 
bindina, even when results were corrected for differences in cytosol protein 
concentration (Table 10.7). In all three specimens, however, binding was higher in 
tumour than in mucosa. Within tumour, the difference between the lowest and highest 
binding was 522 fmol/mg. cytosol protein representing 8.2% of the mean value. 
Similarly, figures for adjacent and distant mucosa were 2.4% and 3.3% respectively. 
The dissociation constants (Kd) of binding also showed a degree of variability but in 
all three specimens Kd was lower in tumour than mucosa. 
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TablelO. 7 Variation in the Ability of Cytosols Derived from Separate 
but Contiguous Areas of Colorectal Cancer and Related Adjacent and 
Distant Mucosa to Bind [3H]-cAMP 
Sample I Sample 2 Sample 3 
Tumour 
Dissociation 1.32 1.21 1.34 
constant 
(10-8M) 
Bmax 2.06 2.00 1.82 




Dissociation 1.55 1.81 1.97 
constant 
(10-8M) 
Bmax 2.04 2.45 2.51 




Dissociation 1.71 1.88 1.61 
constant 
Bmax 1.88 1.89 1.69 




It became apparent from macroscopic and microscopic examination of tumour samples 
that there might be a degree of contamination of tumour periphery with normal 
mucosal elements. In addition, the centre of the tumour was often necrotic. ulcerated 
and contained a considerable amount of non-malignant cellular debris. It was therefore 
decided to compare cyclic AMP binding within the centre and periphery of the same 
tumour. Such comparison revealed that bindingwas almost always lower in the centre 
than in the periphery even when correction had been made for cytosol protein content. 
It was therefore decided to routinely assay both the centre and the periphery of each 
tumour. Similarly, it was felt mucosa immediately adjacent to the tumour might be 
contaminated with malignant cells and indeed cAMP binding in mucosa adjacent to 
tumour was lower than that in distant mucosa. It was therefore decided to routinely 




Chapter 11: Results of the Cyclic AMP Binding Assays on Colorectal 
Cancer and Mucosa 
11.1 Patients and Ttimours 
Total specific cAMP binding was measured in cytosols derived from the centre and 
and periphery of 69 colorectal cancers and from their related adjacent and distant 
histologically benign mucosa. Details of the patients and tumours are shown in Table 
11.1 and binding results are shown in full in Table 11.2. 
The average age of the patients was 69.6 +/- SE 1.2 years. Thirty-three patients were 
female (average age 73.4 +/- SE 1.6 years) and were significantly older than the 36 
male patients (average age 66.5 +/- 1.6 years, p=0.003 by unpaired West). There 
was no significant correlation between patient age and the level of cAMP binding in 
either tumour or mucosal samples (Table 11.3). Cyclic AMP binding was not 
significantly affected by the site of origin of the turnour within the colorectum. (Table 
11.4). 
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Table 11.1 Distribution of Tumours by Sex of Patient, Site of Origin, 
Dukes Stage and Histological Grade 
Caecum Ascending Descending tD. Sigmoid Rectum Total 
colon Colon colon number 
Total number 20 4 7 19 19 69 
Male patients 8 3 4 8 13 36 
Female patients 12 1 3 11 6 33 
Dukes A - 1 2 2 5 
turnours 
Dukes B 13 3 2 11 12 40 
turnours 
Dukes C 9 1 4 6 5 24 
tumours 
Well 1 2 1 4 
differentiated 
tumours 
Moderately 10 2 4 16 9 41 
differentiated 
tumours 




Table 11.2 Cyclic AMP Binding in the Centre and Periphery of 69 
Colorectal Cancers and Related Adjacent and Distant Mucosa 
Dukes 
stage 








B WE AC F 73 2615 2886 1562 1727 
B MO AC M 64 1462 2753 1779 1263 
B MO AC M 55 1638 3321 2794 1642 
C WE CA M 63 1324 1500 720 1187 
C MO CA M 78 100 1232 285 1195 
B MO CA F 81 920 1012 1350 1291 
C PO CA M 67 2023 2545 1867 3321 
B PO CA M 83 2147 3837 3037 3641 
C MO CA F 86 2500 1949 1350 2191 
B MO CA F 75 3499 3776 2339 2279 
B MO CA F 79 1000 2569 3359 1928 
B PO CA M 75 1695 1101 2000 2411 
B PO CA F 84 1300 2150 1941 2030 
C PO CA F 75 1105 2115 1035 1771 
B MO CA M 66 557 782 1364 1935 
B MO CA F 79 1070 1121 1666 1965 
B PO CA M 64 214ý 2283 1479 1783 
B PO CA F 66 641 843 1013 1124 
C MO CA M 78 1650 2162 1867 1526 
C MO CA F 83 698 2345 1630 2347 
B MO CA F 69 2095 3539 1967 2108 
C PO CA F 94 1324 1773 1678 1641 
C PO CA M 68 1880 2313 1429 1646 
B WE CA F 62 1066 2600 1642 2000 
B MO CA M 67 2570 5210 3080 4016 
A MO DC F 60 965 2014 388 933 
C PO DC F 80 1454 2728 1696 2156 
C PO DC F 80 2941 3132 1778 2505 
B MO DC M 58 2476 5324 3096 3999 
[C MO I DC I M1 47 1 985 1 1380 1 989 1 1309 
Table 11.2 continued on next page 
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c PO DC M 70 1130 1864 1268 1770 
c PO RE F 58 2088 3068 1761 2027 
B MO RE M 50 1920 2641 1227 2190 
B MO RE F 55 622 4961 3286 3894 
B WE RE M 71 2853 3576 2316 2476 
B MO RE M 64 2234 2985 2112 1319 
B MO RE M 61 2390 3536 2286 3002 
A PO RE M 73 1708 2154 2499 3012 
B MO RE M 75 2977 4018 3210 3515 
B MO RE F 73 633 1787 2020 1250 
B MO RE M 69 2579 3771 2313 3149 
B PO RE M 63 1923 2000 1909 1707 
c MO RE M 84 2134 2916 4095 3955 
B MO RE M 85 1253 1454 556 892 
c PO RE M 63 843 1476 1317 1667 
B PO RE F 81 996 1397 1000 1237 
B PO RE M 68 1111 1448 1306 1312 
c PO RE F 64 1600 1676 1608 1490 
A PO RE M 76 3264 5616 3549 4444 
c PO RE F 82 931 1415 1121 1000 
c MO St M 58 602 1700 967 1666 
c MO Sl F 68 2137 3655 3152 3372 
B MO sl M 65 525 2229 1124 949 
B PO Sl F 67 2318 3365 2115 2538 
B MO sl F 65 1329 3269 2139 2904 
B MO sl M 70 2787 3646 1630 3069 
B MO Sl F 72 3418 5000 1808 2034 
B MO sl F 69 2476 2616 1654 2288 
B MO Sl M 60 1430 1369 556 892 
A MO Sl F 76 575 656 781 1198 
B MO Sl M 69 1598 2189 1333 1667 
IA I MO I SI IM 180 11421 11664 11174 1 1388 
Table 11.2 continued on next page... 
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B MO sl F 79 1802 1562 2050 1973 
B MO Sl F 76 2505 5028 3220 2983 
c MO sl M 47 2144 3349 2383 2887 
B PO Sl F 59 1570 2147 1062 1770 
c MO Sl M 70 5312 6358 4514 4211 
c MO Sl M 50 1741 1971 1454 1505 
1CI PO ISI I F1 73 1 1782 1 _2255 11036 11118 
Table 11.2 shows the binding of [3H]-cAMP (fmol/mg/ cytosol protein) to cytosols 
derived from the centre and periphery of 69 consecutive human colorectal. cancers and 
from related adjacent and distant histologically benign mucosa. The following 
abbreviations are used: WE = well differentiated, MO = moderately differentiated, PO 
= poorly differentiated, M male, F= female, CA = caecum, AC = ascending colon, 
TC = transverse colon, DC descending colon, SI = sigmoid colon, R= rectum 0 
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Table 11.3 Relationship Between the Level of cAMP Binding to the 
Centre and Periphery of Colorectal Cancers and Related Adjacent and 
Distant Mucosa and the Age of Patient from which the Tissues Derive 
Specimen type Correlation coefficient Probability value 
Tumour centre +0.05 0.67 
Tumour periphery -0.09 0.44 
Adjacent mucosa +0.05 0.71 
Distant mucosa. +0.01 0.93 
Table 11.3 shows that there was no significant relationship between the level of 
cAMP binding within turnour and mucosa cytosols and the age of the patient from 
which the tissue oriainated 0 
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Table 11.4 Cyclic AMP Binding in Tumours Derived from Different 
Regions of the Colorectum 
Site of Caecum Ascendina 0 
Descending 0 
Sigmoid Rectum 
tumour colon colon colon 
Tumour 1470(178) 1760(292) 1802(324) 1972(253) 1795(186) 
centre 
Tumour 2102(205) 2615(390) 3076(592) 2731(290) 2843(331) 
periphery 
Table 11.4 shows that there was no significant difference between the average (and 
standard error) of cAMP binding (fmol/mg cytosol protein) to cytosols derived from 
the centre and periphery of colorectal cancers arising from different sites within the 
colorectum. 
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11.2 Cyclic AMP Binding in Tumours and Mucosa 
Cyclic AMP binding levels in the centre and periphery of 69 colorectal cancers as well 
as in their related adjacent and distant histologically benign mucosa re shown in Table 
11.5 and Figure 11.1. Cyclic AMP binding levels were significantly lower in tumour 
centre than in tumour periphery (p < 0.00001) or distant mucosa (p < 0.0003) but not 
significantly different from levels within adjacent mucosa. Binding to tumour 
periphery was significantly higher than in either adjacent or distant mucosa (p < 
0.0001 and p<0.0003 respectively). Binding in adjacent mucosa was also 
significantly lower than in distant mucosa (p < 0.005). All statisctical comparisons are 
made using the paired West. In only 10 tumours was binding lower than in related 
mucosal samples and such turnours were significantly more likely to arise within the 
caecum than at other sites within the colorectum (p = 0.05 by Chi-squared test). In 
summary, therefore, the periphery but not the centre of colorectal cancers expressed 
significantly more cAMP-BP than either adjacent or distant mucosa from the same 
patient. 
Binding in the four tissue types was also highly inter-related as shown in Table 11.6 
and Figures 11.2 to 11.7 
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Figure 11.1 Cyclic AMP Binding in the Centre and Periphery of 69 
Colorectal Cancers and in Related Ajacent and Distant Mucosa 

































Tummw Adjacent Distant 
periphery mucosa mucosa 
Figure 11.1 shows the distribution of cAMP binding (fmol/mg protein) to cytosols 
derived from the centre and periphery of 69 human colorectal cancers and from related 
adjacent and distant histologically benign mucosa. Horizontal bars indicate the mean 
value. 
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Table 11.5 Cyclic AMP Binding Levels within the Centre and Periphery 












Mean 1748 2608 1842 2125 
Standard error 107 151 105 111 
Standard 
deviation 
890 1254 874 918 
Minimum too 656 295 892 
Maximum 5312 6358 4514 4229 
Table 11.5 shows the mean, standard error, standard deviation, and range of cAMP 
binding (fmol/mg protein) to cytosols derived from the centre and periphery of 69 
human colorectal cancers and related adjacent and distant mucosa. 
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Table 11.6 Correlation Coefficients Relating cAMP Binding in the 
Centre and Periphery of Colorectal Cancers and in Related Adjacent and 
Distant Mucosa 
Tumour Turnour Adjacent Distant 
centre periphery mucosa mucosa 
Tumour - 0.75 0.60 0.61 
centre 
Turnour 0.75 - 0.77 0.78 
periphery 
Adjacent 0.60 0.77 - 0.83 
mucosa 
Distant 0.61 0.78 0.83 
mucosa 
Table 11.6 shows the correlation coefficients relating cAMP binding to cytosols 
derived from tumour (centre and periphery) as well as mucosa arising in the same 
individual. 
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Figure 11.2 Correlation Between Cyclic AMP Binding in the Centre and 
Periphery of Colorectal Cancers 
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Figure 11.2 shows the relationship between cAMP binding (fmol/mg protein) to 
cytosols derived from the centre and periphery of 69 colorectal cancers. 
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Figure 11.3 Correlation Between Cyclic AMP Binding in the Centre of 
Colorectal Cancers and Distant Mucosa 
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Figure 11.3 shows the relationship between cAMP binding (fmol/mg protein) to 
cytosols derived from the centre of 69 colorectal cancers and related distant mucosa. 





Figure 11.4 Correlation Between Cyclic AMP Binding in the Centre of 
69 Colorectal Cancers and in Related Adjacent Mucosa 
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Figure 11.4 shows the relationship between cAMP binding (fmol/mg protein) to 
cytosols derived from the of 69 colorectal cancers and related adjacent mucosa. 
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Figure 11.5 Correlation Between Cyclic AMP Binding in the Periphery 
of Colorectal Cancers and Adjacent Mucosa 
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Figuie 11.5 shows the relationship between cAMP binding (fmol/mg protein) to 
cytosols derived from the periphery of 69 colorectal cancers and related adjacent 
mucosa. 
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Figure 11.6 Correlation Between Cyclic AMP Binding in the Periphery 
of Colorectal Cancers and Distant Mucosa 
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Figure 11.6 shows the relationship between cAMP binding (fmol/mg protein) to 
cytosols derived from the periphery of 69 colorectal cancers and related distant 
mucosa. 
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Figure 11.7 Correlation Between Cyclic AMP Binding in Mucosa 
Adjacent To and Distant From Colorectal Cancers 
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Figure 11.7 shows the relationship between cAMP binding (fmol/mg protein) to 
cytosols derived from adjacent and distant mucosa related to 69 colorectal cancers. 
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11.3 Cyclic AMP Binding in Turnours, of Different Dukes Stage and in Related 
Mucosa 
Cyclic AMP binding levels in the centre and periphery of tumours of different Dukes 0 
stage, as well as in related adjacent and distant mucosa, are shown in Table 11.7. 0 
There was no significant difference between binding in the centre and periphery of In 
Dukes A and Dukes B tumours. However, binding in the centre and periphery of 
Dukes B tumours was significantly higher than that found in Dukes C turnours (p < 
0.05 and p<0.01 by unpaired t-test respectively). Binding in mucosa adjacent and 0 
distant to Dukes B turnours was also higher than that related to Dukes C tumours (p 
0.024 and p=0.08 respectively by unpaired West) 
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Table 11.7 Cyclic AMP Binding in Cytosols Derived from the Centre 
and Periphery of Colorectal Cancers of Different Dukes Stage and from 
Their Related Adjacent and Distant Mucosa 
Dukes A Turnours 
(n = 5) 
Dukes B Turnours 
(n = 40) 
Dukes C Turnours 
(n = 24) 
Tumour centre 1593(377) 1966047) 1431(127) 
Turnour periphery 2421(841) 2925(218) 2120(129) 
Adjacent mucosa 1678(587) 2037(133) 1551(158) 
Distant mucosa 2195(669) 2239(148) 1921(151) 
Table 11.7 shows the mean (and standard error) of cAMP binding to cytosols 
derived fromthe centre and periphery of 69 colorectal cancer of different Dukes stage; 
and from related adjacent and distant mucosa 
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11.4 Cyclic AMP Binding Levels in Tumours of Different Histological Grade and in 
Related Mucosa 
Tumours of poor histological grade tended to have lower levels of cAMP binding. 
Thus, cAMP binding in centre of well differentiated and moderately differentiated 
turnours was statistically higher than that found in the centre of poorly differentiated (p 
< 0.003 by two-sample west). There was a similar trend in the tumour periphery but 
this did not attain statistical significance (p = 0.07 by two-sample West). There was no 
significant difference in cAMP binding in either adjacent or distant mucosa related to 
turnours of different grade (Table 11.8) 
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Table 11.8 Cyclic AMP Binding Levels in the Centre and Periphery of 
Colorectal Cancers of Different Histological Grade and in Related 
Adjacent and Distant Mucosa 
Well Moderately Poorly 
differentiated differentiated differentiated 
tumours turnours turnours 
(n = 4) (n = 41) (n = 24) 
Turnour 1964(450) 1776(159) 1663(131) 
centre 
Turnour 2640(432) 2798(217) 2279(207) 
periphery 
Adjacent 15W (327) 1959(156) 1688(131) 
mucosa 
Distant 1848(269) 2197(154) 2047(174) 
mucosa 
Table 11.8 shows the mean (and standard error) of cAMP to cytosols derived from 
the centre and periphery of 69 colorectal cancer of different histological grade; and 
from adjacent and distant mucosa. 
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11.5 Dissociation Constants (Kd) of Cyclic AMP Binding to Tumotir and Mucosa 
The dissociation constant (Kd) of binding to cytosols derived from tumour centres 
was significantly lower than the Kd of binding to the other tissue types (p < 0.04 by 0 
paired t-test). There was no significant difference between the Kd of cAMP binding to b0 
turnours of different grade or stage (Table 11.9). 
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Table 11.9 Dissociation Constants (Kd) of Cyclic AMP Binding to 
Colorectal Cancers of Different Stage and Grade 
Turnour Tumour Adjacent Distant 
centre periphery mucosa mucosa 
All tissues 1.97(0.09) 2.23(0.12) 2.17(0.13) 2.30(0.13) 
Dukes A 1.96(0.33) 2.01 (0.40) 1.96(0.18) 2.36(0.36) 
Dukes B 1.98(0.36) 2.26(0.13) 1.92(0.14) 2.14(0.15) 
Dukes C 1.96(0.17) 2.23(0.18) 2.62(0.27) 2.54(0.26) 
Well 
differentiated 
2.29(0.11) 2.33 (0.23) 2.09(0.21) 2.37(0,43) 
Moderately 
differentiated 
1.90(0.12) 2.33(0.18) 2.09(0.16) 2.37(0.18) 
Poorly 
differentiated 
2.02(0.19) 1.98(0,15) 2.34(0.25 2.18(0.20) 
Table 11.9 shows the mean (and standard error) of the Kd of cAMP binding to 
cytosols derived from the centre and periphery of 69 colorectal cancers of different 
Dukes stage and histological grade; and from related adjacent and distant mucosa 
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11.6 Comparison of 121il-cAMP and IaZAPI-8-azido-cAMP Binding to Tumour and 
Mucosa 
Both L3H]-cAMP and (32P]-S-azido-cAMP (in the absence of light) bound to cytosols 
derived from colorectal cancers and related mucosa with similar characteristics in terms 
of total binding, Bmax and Kd (Table 11.10 and Figures 11.8 to 11.10). 0 
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Table 11.10 Comparison of [3HI-cAMP and [32p]-8-azido-cAMP 
Binding to Cytossols Derived from a Colorectal Cancer and front 
Related Adjacent and Distant Mucosa 
[32p]-g-azido- OHI-cAMP as 
cAMP as ligand. lioand 4: 1
Turnour cAMP binding 3879 4343 
(fmol/mg protein) 0 
[proteinj 56 56 
(M, O', /Ml) 
Bmax 2.166 2.40 
Dissociation 1.9 2.1 
constant (10-8M) 
Adjacent mucosa cAMP binding 2087 2196 
(fmol/ma protein) 
[protein] 68 68 
(Mgt") 
Bmax 1.40 1.52 
Dissociation 1.56 1.76 
constant (10-8M) 
Distant mucosa cAMP binding 2513 2544 
(fmol/mg protein) 
[protein] 63 63 
(Mg/ml) 
Bmax 1.58 1.61 
Dissociation 1.52 1.67 
constant (10-8M) I I 
Table 11.10 shows the characteristics of 13H]-cAMP and [32pi-8-azido-cAMP to 
cytosols derived from a colorectal cancer and from related adjacent and distamt mucosa 
in terms of total binding (fmol cAMP bound/mg protein), Bmax (nmol cAMP bound 
per 50[ig wet weight of cytosol) and dissociation constant (10-8M) 
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Figure 11.8 Comparison of [3H]-cAMP and [32pl-8-azido-cAMP 
Binding to Tumour Cytosol 
Bound/free 
132P 1-8-azido-c AMP 
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Figure 11.8 shows two Scatchard plots representing binding of [32PI-8-azido- 
cAMP (upper graph) and [3HI-cAMP (lower graph) to a cytosols derived from a 
colorectal cancer, 
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Figure 11.9 Comparison of [3H]-cAMP and [32p]-8-azido-cAMP 
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Figure 11.9 shows two Scatchard plots representing binding of [32p]-8-azido- 
cAMP (upper graph) and [3HI-cAMP (lower graph) to a cytosols derived from 
mucosa adjacent to a colorectal cancer. 
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Figure 11.10 Comparison of [3H]-cAMP and [32pl-8-azido-cAMP 
Binding to Cytosols Derived from Distant Mucosa 
Bound/free 
132 P 1-8-azido. c AM P 
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Figure 11.10 shows two Scatchard plots representing binding of [32p]-8-azido- 
cAMP (upper graph) and [3HI-cAMP (lower graph) to a cytosols derived from 
mucosa distant to a colorectal cancer. 
132 
11.7 ComRarison of Cyclic AMP Bindingto Membrane Preparations and Cytosols 0 
Turnour and-Mucosa 
Cyclic AMP binding in the membrane fractions derived from adjacent mucosa was 
significantly higher than binding in turnour periphery (p = 0.034 by paired t-test). 
Binding in adjacent mucosa was also higher than that found in distant mucosa but this 
did not attain statistical significance (p = 0.13 by paired West). Binding in tumour 
periphery and distant mucosa were very similar (Table 11.9). 
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Table 11.11 Comparison of Total cAMP Binding Levels in the 
Membrane Fractions of Eight Tumours and Related Adjacent and 
Distant Mucosa 
Turnour Adjacent Distant 
periphery mucosa mucosa 
2072 2243 2245 
2329 2198 2282 
2168 2671 2300 
2293 2343 2405 
2499 2624 2187 
2320 2655 2701 
2727 3003 2404 
2432 2535 2460 
Mean 2355 2534 2373 
Standard error 71_ 94 57 
Table 11.9 shows the mean and standard error of 13HI-cAMP to membrane 
fractions derived from the centre and periphery of eight colorectal cancers and from 
related adjacent and distant mucosa. 
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Chapter 12: Results of Photoaffinity Labelling 
12.1 Molecular Weights of Cyclic AMP Binding Proteins 
Photoaffinity labelling (PAL) followed by polyacrylamide, gel electrophoresis (PAGE) 
identified several species of cyclic AMP binding protein in cytosols derived from both 
normal and malignant tissues (Figure 12.1). By comparison with 114CI-methylated 
protein standards these cAMP-BP were found to have molecular weights of 52,50, 
48,44,37 and 34 kiloDaltons (kDa) and were therefore termed R52, R50, R47, R37 
and R34 respectively. Binding of [32pl-8-azido-cAMP to all moieties could be 
displaced by the addition of 1000-fold excess cAMP. In all tissues examined the 
predominant cAMP-BP were R52, P-50, R47 with the other species (1144, R37, and 
R34) accounting for less than 15% of the total cAMP-BP present. 
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Figure 12.1 Ilholo-afrinity Labelling and Flectrophoresis of cAMP-111' 
Photoaffinity Labelling of Cyclic AMP Binding Proteins 
















Figure 12.1 shows a typical gel produced by photo-Afinity WAII labellin, t, of 
cAMP with 132pl-8-azido cAMP followed by separation on the basis of' molecular 
weight by clectrophoresis (PA6F, ). Me figure shows PAI, and PAGjF ol'cAMP Bl' 
in lumourand mucosal cytosols where i and indicate assay performed In (tic ahs'ence 
and presence of' I(M-fold excess radlo-inert cAMP respectively. 
Lanes I and 4- tuniour periphery 
Lanes -land 5 adjacent mucosa 
I 
-anes. 1 and 6 distant Mucosa 
I. ane 71 1-ý'j inclityla(ed prolein molecularweighl standards 
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12.2 A Cyclic AMP Binding Protein of 65kDa 
In almost all tissues examined a protein of 65kDa. was found to bind 132pl-8-azido- 
cAMP and termed R65. However, in contrast with the cAMP-BP described above, 
binding of 132p]-8-azido-cAMP was only partially displaced by excess cAMP. Bovine 
serum albumen (fraction V) was found to bind (32pi-8-azido-cAMP, co-migrate with 
R65 in tissue cytosols, and to show partial displacement of binding with excess cAMP 
(Figure 12.2). 
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Figure 12.2 A cAMP-1111 of Molecular Weight 6-; kDa 
Identification of Albumen as an R65 





Figure 12.2 shows PAL of a 40g/l BSA solution In the presence and ahsence mid 
presence ot'different concenlrations of radlo Inert cAMP where: 
I, anes I and S no cAMP 
Lane 2 4mM cAMP 
I'ane 3 0.4mM cAMP 
I "Ific 4 (). (PmM cAMP 
Lane 6 ýIiow, s PAI. of a tuniour cylosol for comparison mid demonstrates an k65 
protem hand within the tuniour cylosols (hat co migrates with BSA as well as Rl mid 
kil 
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12.3 Cyclic AMP Binding Proteins in Membrane Fractions 
Although most cAMP-BP appear, in most tissues, to reside within the soluble 
fraction, cAMP-BP were found in the membrane enriched preparations of both 
colorectal tumour and mucosa. The binding proteins appeared similar to those in the 
soluble fraction in that the predominant bands migrated to the R52, R50 and R48 
positions (Figure 12.3). 0 
I 
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Figure 12.3 Ilhotoaffinity Labelling and Electrophoresis of cAMP in 
Membrane Preparations Derived froin Colorectal Cancers and Related 
Mucosa 
Photoaffinity Labelling of Cyclic AMP Binding Proteins 
in Membrane Fractions 
R11 
Rl 
19 10 11 12 13 14 
Figure 12.3 sho%ks PAI, of cAMP IV III membrane fractions derived from 
colorectal cancers and related mucosa where-, 
Lanes 1, : i. 9,13,14 lumotir centre 
I an es 21' 0, M tumour periphery 
Lanes 3,7,11 adjacent mucosa 
Lanes 4,8,12 distant mucosa 
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12.4 ComRarison of Cyclic AMP Binding Proteins with Commercially Obtained 
Purified R Sub-unit Prel2arations 
Purified bovine RI and rabbit muscle RII sub-unit preparations (Sigma) were 
examined by PAL and PAGE and found to be extremely heterogeneous (Figure 12.5). 
However, the predominant cAMP-BP within the RI preparation had a molecular 
weight of 48kDa and the predominant the RII preparation a molecular weight of 50- 0 Cý. 
56kDa. This suggested that R52 and R50 represented RII moieties and that R47 Z:. Cý 
represented RI as shown in Figure 12.4 
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Figure 12.4 Photoaffinity Labelling of RI and Ril cAMP-BP Within 
Cytosols Derived front Colorectal Cancer and Related Mucosa 
Photoaffinity Labelling of Cyclic AMP Binding Proteins 
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Figure 12.4 show.,; PAI. ofcAMP BPRII (MW -- -50/521) and 
Rl (MW -- 48K) In 
tumour and niticosa cytosols where and ý representassays performed in theabsence 
and presence of IWO fold excess radio inert cAMP respectively. R6-5 (albumen) is 
Aso shown. 
I. anes 1.4 lumourperipliery 
I'alles adjacent 11111cosa 
Lanes 3,6 - distant mucosa 
I 
-ane 7 molecular w, ei,,,, ht markers 
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12.5 Immunoprecil2itation of Cyclic AMP Binding Proteins 
Immunoprecipitation of tumour and mucosal cytosols with specific anti-RI and anti- 
RII antibodies followed by PAL and PAGE (work performed by Dr. Cho-Chung's 
oroup, NIH, Washington, USA on samples provided by the author) confirmed that 
R52 and R50 were both forms of R11 and that R48 represented a single form of RI 
(Figure 12.5). These proteins are therefore termed RII-52, RII-50 and RI-48 
respectively. 
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Figure 12.5 Immunoprecipitation and Photoaffinity Labelling 411' cA NI P 
in Cytosols Derived 1'rom Colorectal Cancer and Related Mucosa 
Photoaffinity Labelling of cAMP-Binding Proteins (R) In 
Human Colorectal Cancer (TP) and Adjacent and Distant 
























Figure 12.5 continued 
Photoaffinity Labelling -Immunoprecipitation of cAMP- 
binding Proteins (R) in Human Colorectal Cancer (TP) 
and Adjacent and Distant Mucosa (MA and MD) with 
Anti-RI and Anti-1111 Antibodies. 
Patient ; Patient! Patient 
123 
RI Ab 10 0 R148 
RU Ab 
R148 R115r, TP MA MD TP MD TP MA MD 
up 
fm 
40 416 *a, *, 40 -- 
RU52 
R1150 
RD,, R14fj TP MA MD TP MD TP MA MD 
Figure 12.5 shovv, ý PAL t'ollowed by 1111111111110precipitatioii with specific antl ki and 
arm kll of- cAMP Bl' present in cylosols derived t'rom three colorectal cancer, ý and 
related adjacent and distant mucosa. The upper photograph shows the results of' 
PAI - 
alone and the lower 1) hot ogra ph shows PAL combined with inuminopreciptation 
applied to cylosols derived t'rom turnour periphery, iId. jiICCIIt 111d (fiStMIt muco,, ýa t'rom 
the same three patients. PAL alone identifies three main cAMP till K52, k5O and 
k48 as well as sinalleraniounts of' 107/34. I'Al. combined %vith muntinoprecipitation 
shows, that, 
I) Commercially obtained partliffly purified Rl and KII danes I and 2) are 
heterogeneous iind i mpure 
") IZ52 and R50 are both I'Orms of' k1l 
3) R48 Is a single t'orm ol'RI 
4) RI is over -c \ pressed in lumour when compared to holh adjacent and distant mucosa 
-5) 
R11 52 expression is markedly depreSSCLI even undetectable in tumour Mien 
compared to mucosa 
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12.6 Loss of RH-52 in Turnour Cytosols 
In cytosols prepared from normal colorectal mucosa RII-52 was identified as an easily 
distinguishable band above and separate from RI-50, By comparison, this protein was 
either feint or absent in cytosols prepared from colorectal tumours (Figure 12.5). 
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12.7 Over-expression of RI in Tumour-Cytosols 
RI expression was significantly greater in the centre and periphery of tumours than in 
either adjacent or distant mucosa (p < 0.008 by Wilcoxon signed rank test). There 
was no sionificant difference in percentage III expression between adjacent and 00 
distant mucosa, or between turnour centre and periphery (Table 12.1 and Figures 12.6 
and 12.7). 
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Table 12.1 Comparison of RI-48 Expression in Cytosols Derived from 
the Centre and Periphery of Colorectal Cancers and from the Related 
Adjacent and Distant Mucosa 
Sta(ye v 




Adjacent Ilmllcosa Distant 
mucosa 
B MO Sl M 63.2 35.7 43.1 52.3 
A MO DC F 63.5 59.6 47.4 43.3 
B PO CA F 77.5 71.2 55.2 60.3 
B PO DC M 57.4 55.6 56.6 47.1 
B MO CA F 72.0 61.0 61.2 65.7 
C MO Sl F 44.5 41.8 35.2 58.3 
A MO Sl F 64.7 67.8 50.8 49.4 
B MO Sl F 40.8 42.8 40.5 38.3 
B PO CA F 53.6 55.4 37.5 29.4 
B MO CA F 71.0 65.4 51.3 56.2 
B MO Sl F 33.0 38.3 52.0 56.0 
B MO AC M 66.0 58.9 36.6 55.7 
A MO St F 62.1 69.4 49.5 54.2 
B PO RE F 65.8 67.7 55.2 57.0 
C PO RE M 68.8 67.4 48.0 57.5 
B PO RE M 73.0 76.0 48.0 51.0 
B WE AC F 52.1 56.4 32.1 43.6 
C MO CA M 59.3 60.6 43.6 41.7 
C MO Sl M 67.2 70.5 38.2 33.8 
C MO Sl M 71.0 74.7 50.3 37.0 
C MO CA F 58.4 58.6 56.7 62.8 
C PO RE F 63.1 59.7 45.5 34.9 
B MO DC 
_ 
M1 58.4 58.6 52.5 43.6 
Table 12.1 continued on next page 
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Table 12.1 continued 








B MO Sl F 54.3 56.8 52.5 43.6 
B MO Sl F 43.6 56.8 33.2 43.4 
c MO Sl F 58.5 52.6 56.7 60.3 
B PO CA F 60.0 57.0 50.0 43.9 
B WE CA F 61.0 57.8 52.1 54.0 
c MO DC M 73.0 71.0 62.0 58.6 
c PO RE F 51.3 70.1 72.4 70.0 
B MO CA M 59.7 57.9 51.7 41.4 
B MO CA M 43.0 41.4 52.7 54.3 
Median 61.2 58.7 50.6 51.7 
Upper quartile 70.3 67.9 55.2 57.3 
Lower quartile 56.3 55.5 43.4 43.4 
Minimum 33.0 26.0 32.1 29.4 
1 Maximum 177.5 76.0 72.4 40.6 
Table 12.1 shows the percentage Rl expression in the centre and periphery of 32 
human colorectal cancers, and in related adjacent and distant histologically benign 
mucosa, by Dukes stage, site of origin within the colorecturn, histological grade and 
sex of patient. Abbreviations are as follows: WE = well differentiated, MO 
moderately differentiated, PO = poorly differentiated, CA = caecum, AC = ascending 
colon, DC = descending colon, Sl sigmoid colon, and RE = rectum. 
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Figure 12.6 11hotoaffinity Labelling of RI-48, RII-SO and RII, 52 ill a 
Colorectal Cancer and Related Mucosa 
R11-52 
Photoaffinity Labelling of Cyclic AMP Binding Proteins 
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Figure 12.6 show,, PAI, ol'cAMP BP in cytosols derived from (milotirand Inticosa 
where 111d 4 denote assays performed in (lie absence and presence of' 101H) fold 
excess of' radto mert cAMP and IV = timiotir centre, TP nimotir periphery, MA 
ad '11, M I) -d I' Stant niticosa. Figtire 12.6 also shows aI btimen (ROS) to he jacent 11111cos
present in all I'mir specimens and to be partially displaccable by excess -AMP. I'lirce 
main cAMP HP are again shomm R11 52, RII -':; 
4) and Rl 48 %Nith minor bands of' 
44,37 and . 
14 kDa. Binding appears to be Inglier In bolh IV and IT v% licit compared 
lo inticosal samples. There is an increase in R1 48 and a rc(Itiction in k1l ý, 2 
expression i it Itimotir cN losols when compared with inticosa. 
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Figure 12.7 Percentage RI Epression in Cytosols Derived from the 
Centre and Periphery of 32 Colorectal Cancers and Related Adjacent 
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centre periphery mucosa mucosa 
Figure 12.7 shows the distribution of percentage RI expression in cytosols derived 
from the centre and periphery of 32 colorectal cancers and related adjacent and distant 
mucosa. Horizontal bars denote median values. 
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12.8 RelationshiR Between RI Expression in Turnour and Mucosa 
There was a significant correlation between RI expression in turnour periphery and 
centre, turnour centre/periphery and adjacent mucosa, adjacent and distant mucosa but 
not between tumour centre/periphery and distant mucosa (Table 12.2 and Figures 12.8 
to 12.13). 
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Table 12.2 Correlation Coefficients Showing the Relationship between 
Percentage RI Expression in the Centre and Periphery of 32 Colorectal 
Cancers and Related Mucosa 






Turnour centre Turnour periphery 0.725 0.0001 
Turnourperiphery Adjacent mucosa 0.407 0.021 
Adjacent mucosa Distant mucosa 0.583 0.0043 
Distant mucosa Turnour periphery 0.101 0.58 
Adjacent mucosa. Turnour centre 0.24 0.067 
Distant mucosa Turnour centre 10.133 0.47 
Table 12.2 shows the correlation coefficients relating percentage RI expression in 
the centre and periphery of 32 colorectal cancers and in related adjacent and distant 
mucosa. 
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Figure 12.8 Correlation Between RI Expression in Tumour Periphery 
and Adjacent Mucosa 
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Ill Expression (%) In Tumour Periphery 
Figure 12.8 shows the relationship between percentage Rl expression in cytosols 
derived from the periphery of 32 colorectal cancers and related adjacent mucosa 
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Figure 12.9 Relationship Between RI Expression in Tumour Periphery 
and Distant Mucosa 
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RI Expression (%) In Tumour Periphery 
Figure 12.9 shows the relationship between percentage RI expression in cytosols 
derived from the periphery of 32 colorectal cancers and related distant mucosa. 
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Figure 12.10 Correlation Between RI Expression in Distant and 
Adjacent Mucosa 
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RI Expression (%) In Adjacent Nlucosa 
Figure 12.10 shows the relationship between percentage RI expression in mucosa 
adjacent to and distant from 32 colorectal cancers, 
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Figure 12.11 Relationship Between III Expression in Tumour Centre 
and Adjacent Mucosa 
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Ill Expression (%) In Tumour Centre 
Figure 12.11 shows the relationship between percentage RI expression in cytosols 
derived from the centre of 32 colorectal cancers and related adjacent mucosa. 
IF 
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Figure 12-12 Relationship Between RI Expression in Tumour Centre 
and Distant Mucosa 


























Rl Expression M In Tumour Centre 
Figure 12.12 shows the relationship between percentage Rl expression in cytosols 
derived from the centre of 32 colorectal cancers and related distant mucosa. 
20 40 60 80 
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Figure 12.13 Correlation Between RI Expression in Tumour Centre 
and Periphery 
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Rl Expression (%) In Tumour Periphery 
Figure 12.13 shows the relationship between percentage RI expression in cytosols 
derived from the centre and periphery of 32 colorectat cancers, 
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12.9 RI Expression in Tumours of Different Dukes Stage 
There was no significant difference in RI expression with respect to Dukes stage in 
either the centre or the periphery of colorectal cancers or in their related adjacent or 
distant mucosa (Table 12.3). 
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Table 12.3 RI Expression in Tumours of Different Dukes Stage and 
their Related Mucosa 
Dukes A Dukes B Dukes C 
tumours turnours tilmours 
(n = 3) (n = 19) (n = 10) 
Tumour centre Median 62.8 56.6 59.3 
Lower quartile 55.8 43.6 51.3 
Upper quartile 64.1 66.0 68.8 
Turnour periphery Median 67.8 56.8 64.0 
Lower quartile 59.6 42.8 58.6 
Upper quartile 69.4 61.0 70.5 
Adjacent mucosa Median 49.5 51.7 49.2 
Lower quartile 47.4 40.5 43.6 
Upper quartile 50.8 55.2 56.7 
Distant mucosa Median 49.4 51.0 57.9 
Lower quartile 43.3 43.6 37.0 
Upper quartile 154.2 156.0 160.3 
Table 12.3 shows the median and quartile values for percentage RI expression in the 
centre, and periphery of colorectal cancer of different Dukes stage-, and in related 
adjacent and distant mucosa. 
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12.10 RI Exl2ression in Tumours of Different Histological Grade 
RI expression was significantly greater in the centre of poorly differentiated tumours 
than in the centre of those that were either moderately or well differentiated (p = 0.0 16 
by Mann-Whitney U-test). There was a similar trend in the periphery of tumours but 
this did not attain statistical significance (p = 0.14 by Mann-Whitney U-test). There 
was no difference in RI expression between well and moderately differentiated 
tumours. RI expression in adjacent and distant mucosa was unaffected by the grade of 
the tumour to which they were related (Table 12.4). 
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Table 12.4 Comparison of RI Expression in Colorectal Tumours of 
Different Grade and in Related Mucosa 
Well Moderately Poorly 
differentiated differentiated differentiated 
turnours turnours turnours 
(n = 2) (n = 21) (n = 9) 
Tumour centre, Median 52.8 56.5 68.4 
Lower quartile 48.3 53.7 64.6 
Upper quartile' 54.1 66.1 74.4 
Tumour periphery Median 57.1 58.6 64.5 
Lower quartile 56.4 42.8 57.0 
Upper quartile 57.8 65.4 70.1 
Adjacent mucosa Median 42.1 50.8 50.0 
Lower quartile 32.1 43.1 48.0 
Upper quartile 52.1 52.7 55.2 
Distant mucosa Median 48.8 52.3 51.0 
Lower quartile 43.6 43.3 43.8 
Upper quartile 154.0 156.2 157.5 
Table 12.3 shows the median and quartile values for percentage III expression in the 
centre and periphery of colorectal cancer of different Dukes stage; and in related 
adjacent and distant mucosa. 
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12.11 Relationship Between Cyclic AMP Binding and RI Expression in Tumour and 
Mucosa 
In 35 patients total cAMP binding levels and percentage RI expression were available 
for comparison (Tables 12.5 and 12.6 and Figures 12.14 and 12.15). There was a 
significant inverse relationship between total cAMP binding and percentage RI 
expression in both tumour centre and periphery (Figures 12.16,12.17 and 12.20) but 
not in either adjacent or distant mucosa (Figures 12.18 and 12.19 and Table 12.7). 
Cyclic AMP binding was significantly higher and RI expression lower in the centre 
and periphery of Dukes B than in Dukes C turnours (Table 12.8). By contrast, RI 
expression was significantly higher in the centre and periphery of moderately 
differentiated tumours when compared to those that were poorly differentiated (Table 
12.9). There was no relationship between histological grade and cyclic AMP binding 
in either the centre of periphery of colorectal cancers. Grade and stage of tumour had 
no significant effect on either cAMP binding or RI expression in related adjacent and 
distant mucosa. 
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Table 12.5 Cyclic AMP Binding and Percentage RI Expression in 
Cytosols Derived from the Centre and Periphery of 36 Colorectal 
Cancers and Related Adjacent and Distant Mucosa by Dukes Stage, 
Histological Grade and Site of Origin within the Colorectum 
Cyclic AMP Binding (fmol/mg protein) and RI 0 
expression (percent) 
Tumour Turnour Adjacent Distant 
centre _ 
periphery mucosa. mucosa 
Dukes Histological Site Binding/RI Binding/RI BindingIRI Binding/RI 
stage grade 
B MO SI 525/63.2 2229/35.7 1123/43.1 949/52.3 
A MO DC 965/63.5 2014/59.6 388/47.4 933/43.3 
B mo RE 1253/49.4 1454/47.8 556/41.3 892/40.5 
B PO CA 641/77.5 843/71.2 1013/55.2 1124/60.3 
B WE CA 4762/44.3 8066155.6 5000/56.6 5233/47.1 
B mo CA 1070/72.0 1121/61.0 1666/61.2 1965/65.7 
B MO S1 2723/54.2 3105/41.8 3083/35.2 3149/58.3 
A mo SI 575/64.7 656/67.8 781/50.8 1198/49.4 
B MO S1 1430/40.8 1369/42.8 556/40.5 892/38.3 
B PO CA 2146/53.6 2283/55.4 1479/37.5 1783/29.4 
B MO CA 920/71.0 1012/65.4 1350/51.3 1291/56.2 
B MO SI 3118/33.0 5670/38.3 3797/52.0 4645/56.0 
B MO AC 1462/66.0 2753/58.9 1779/36.6 1263/55.7 
A MO SI 1421/62.1 1664/69.4 1174149.5 1388154.2 
B PO RE 996/65.8 1397/67.7 1000/55.2 1237/57.0 
C PO RE 843/68.8 1476/67.4 1317/48.0 1667/57.5 
C PO S1 1111/73.0 1448/76.0 1306/48.0 1312/51.0 
B MO AC 2615/52.1 2886156.4 1562/32.0 1727/43.6 
C MO CA 1650/59.3 2162/60.6 1867/43.6 1526/41.7 
C MO SI 602/67.2 1700/70.5 968/38.2 1666/33.6 
C PO SI 887/73.2 1024/74.7 3813/50.3 2822/37.0 
B MO SI 1329/65.7 3269/50.0 2139139.4 2904/40.7 
C MO CA 689/64.4 2345/58.6 1630/56.7 2347/62.8 
C MO CA 2500/43.0 1949/51.0 1350145A 2191140.9 
C PO RE 1003/60.1 1483/59.7 968/45.5 1091/34.9 
LB I MO I DC 12570/58.7 15210/56.8 13080/52.5 14016143.6 1 
Table 12.5 continued on next page 
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Table 12.5 continued 
Cyclic AMP Binding (fmol/mg protein) and RI 
expression (percent) 
Turnour Tumour Adjacent Distant 
centre, 
_ 
periphery mucosa, mucosa 
Dukes Histological Site Binding/RI Binding/R1 Binding/R1 Binding/RI 
stage grade 
B mo SI 4118156.4 4562/56.7 3813/55.4 3997/43.8 
B MO S1 3418/43.6 5000/26.0 1808133.2 2034/43.4 
B MO RE 1802/58.4 1562/52.6 2050/56.7 1973/603 
B mo RE 1300/60.0 2150/57.0 1941/50.0 2030/43.8 
C PO AC 1066/61.0 2600/57.8 1642152.1 2000/54.0 
C PO Sl 985/73.0 1380/71.0 989/62.0 1309/58.6 
B mo Sl 1600/51.3 1676/70.1 1608172.4 1490/70.0 
C PO RE 557/59.7 782/57.9 1364/51.7 1935/41.4 
IB I MO I RE 1598/43.6 2189/41.4 1333/S2.7 1667/54.3 
Mean 1604/59.2 2357/57.4 1751/48.5 1989/49.2 
Standard error 174/1.8 270/2.1 178/1.5 182/1.7 










Figure 12.5 shows cyclic AMP binding (frnol/mg protein) and RI expression (%) in 
cytosols derived from the centre and periphery of 35 colorectal cancers an in related 
adjacent and distant mucosa. Abbreviations are as follows: WE = well differentiated, 
MO = moderately differentiated, PO = poorly differentiated; CA = caecum, AC 
ascending colon, DC = descending colon, Sl = sigmoid colon, RE = rectum. 
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Cyclic AMP was significantly higher in tumour periphery than in turnour centre, (p = 
0.00017), adjacent mucosa (p < 0.002) and distant mucosa (p < 0.03). Binding in 
tumour centre was lower than in distant mucosa (p < 0.005) but not significantly 
different from that in adjacent mucosa. There was no significant difference in cAMP 
binding between adjacent and distant mucosa. 
There was no difference in RI expression between the centre, and periphery of turnours 
or between adjacent or distant mucosa. RI expression was significantly higher in 
tumour centre than in adjacent and distant mucosa (p < 0.0002 and p=0.0005 
respectively). RI expression in tumour periphery was also higher than in adjacent and 
distant mucosa (p < 0.0005 and p<0.002 respectively) 
All statistical comparison are by means of a one-sample west. 
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Table 12.6 Characteristics of Tumours on Which Cyclic AMP Binding 
and RI Expression Data is Available 
Site of 





Caecum 8 A3 Well I 
differentiated 
Ascending 3 B 21 Moderately 24 
colon differentiated 





Table 12.6 shows the site, Dukes stage and histological grade of the 35 turnours on 
which cAMP binding and Rl expression data was available 
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Figure 12.14 Cyclic AMP Binding in the Centre and Periphery of 35 
Colorectal Cancers and Related Adjacent and Distant Mucosa in Which 
There is also Data on RI Expression 


























Tumur Tumour Adjacent Distant 
ccntre periphery mucosa mucosa 
Figure 12.14 shows the scatter of cAMP binding levels in the centre and periphery 
of 35 colorectal cancers and related adjacent and distant mucosa in which data was also 
available on RI expression. Horizontal bars denote mean values. 
169 
Figure 12-15 RI Expression in the Centre and Periphery of 35 
Colorectal Cancers and Related Adjacent and Distant Mucosa in Which 
There is also Data-on RI Expression 
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centre periphery mucosa mucosa 
Figure 12.15 shows the scatter of RI expression in the centre and periphery of 35 
colorectal cancers and related adjacent and distant mucosa in which data was also 
available on RI expression. Horizontal bars denote mean values. 
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Table 12.7 Correlation Coefficients Relating cAMP Binding and 
Percentage RI Expression in Tumour and Mucosa Cytosols 
Specimen type Correlation coefficient 
relating cAMP binding and 
RI expression (r) 
Probability value (p) 
Tumour centre -0.49 0.0013 
Tumour periphery -0.46 0.0053 
Adjacent mucosa 0.07 0.71 
Distant mucosa 0.14 0.41 
Table 12.6 shows the coefficients of correlation relating total cAMP binding (fmol 
cAMP bound/mg. cytosol protein) and RI expression in the centre and periphery of 
colorectal cancers and in their related adjacent and distant mucosa. 
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Figure 12.16 Correlation Between Cyclic AMP Binding and RI 
Expression in Tumour Centre 
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Figure 12.16 shows the inverse relationship between cyclic AMP binding (fmol/mg 
protein) and percentage RI expression in cYtosols derived from the centre of 35 
colorectal. cancers 
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Figure 12.17 Correlation Between Cyclic AMP Binding and RI 
Expression in Tumour Periphery 
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Legend to Figure 12-17 on next page 
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Figure 12.17 shows the inverse relationship between cyclic AMP binding (fmol/mg 
protein) and percentage Rl expression in cytosols derived from the periphery of 35 
colorectal cancers 
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Figure 12.18 Correlation Between Cyclic AMP Binding and III 
Expression in Adjacent Mucoss 
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Figure 12.18 shows the relationship between cyclic AMP binding (fmol/mg 
protein) and percentage RI expression in cytosols derived from mucosa adjacent to 
35 colorectal cancers. 
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Figure 12.19 Correlation Between Cyclic AMP Binding and RI 
Expression in Distant Mucosa 

















13 13 tj 
13 










0 1000 2000 3000 4000 5000 6ý00 
Cyclic AMP Binding (fmol/mg protein) 
In Distant Mucosa 
Figure 12.19 shows the inverse relationship between cyclic AMP binding (frnol/mg 
protein) and percentage RI expression in cytosols derived mucosa distant from 35 
colorectal cancers 
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Figure 12.20 Photoaffinity Labelling and Total CAMP Binding in 
Cytosols Derived from the Centre of' Colorectal Cancers 
Photoaffinity Labelling of cAMP Binding Proteins 








Figure 12.20 shows PAI. of cAMP BP in cytosols derived from a ,, cries of 8 
mmotir centres. The table below shows the percentage Rl expression in relation to tile 
total level of cAMP hinding I'mind in each cytosol, and ttimotir stage and grade 
Lane I 
I anc. 2 
molecular weight standards 
partially punfied, commercially o )(amed RI prepar; hoil 
cAMP binding, Percentage I fistological Dukes 
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Rl expression ,, rade 
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protein) 
I ane 3 3871 -48.6 modcra(e C 
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I ýIne 11) 1,1 ')(-) 65.7 moderate 
I Lalle 10 1 76-5 188.0 1 poor 
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Table 12.8 Cyclic AMP Binding and RI Expression In Tumours of 
Different Dukes Stage 
Mean (and standard error) of cAMP 
binding (fmol/mg protein) in tumour 0 
cytosols 
Dukes B turnours 
(n = 21) 
Dukes C turnours 
(n = I0 
P value 
(unpaired West) 
Turnour centre 1805(256) 1389(118) 0.03 
Turnour periphery 2776(316) 1705(171) 0.05 
Adjacent mucosa 1871(248) 1786(275) ' 0.21 
Distant mucosa 2138(278) 1931(193) 0.62 
Mean (and standard error) of RI 
expression (%) in tumour cytosols 
Dukes B tuMOurs 
(n = 21) 
Dukes C turnours 
(n= 11) 
P value 
(unpai red t-tcst) 
Turnour centre 57.6(2.6) 61.2(t. 8) 0.22 
Tumour periphery 54.1(2-6) 62.6(3.1) 0.09 
Adjacent mucosa 47.5(1-8) 50.4(3.3) 0.41 
Distant mucosa 48.5(t. 9) 50.5(3.9) 0.53 
Table 12.8 shows the mean and standard error of cyclic AMP binding (fmol/mg 
protein) and RI expression (%) in cytosols derived from thre centre and periphery of 
colorectal cancers of different Dukes stage and n related adjacent and distant mucosa. 
Values are compared by means of a two-sample West to give probability values shown 
in the far right column. There were insufficient Dukes A tumours (n = 3) for statistical 
comparison. 
178 
Table 12.9 Cyclic AMP Binding and III Expression in Tumours of 
Different Dukes Stage 
Mean (and standard error) of cAMP 
bindincy (fmol/m(, protein) in turnour 
cytosols 
Moderately Poorly P value 
differentiated differentiated (unpaired West) 
turnours turnours 
(n = 24) (n = 10) 
Turnour centre 1678(141) 1229(144) 0.12 
Turnour periphery 2403(291) 2220(362) 0,76 
Adjacent mucosa 1792(209) 1662(384) 0.75 
Distant mucosa 2057(214) 1827(390) 0.58 
Mean (and standard error) of RI 
expression (%) in turnour cytosols 
Moderately Poorly P value 
differentiated differentiated (unpaired t-test) 
tumours turnouts 
(n = 24) (n = 10) 
Turnour centre 56.7(t. 4) 62.7(2.1) 0.02 
Turnour periphery 53.8(2.5) 65.7(2.2) 0.007 
Adjacent mucosa 46.6(l. 7) 53.0(3.0) 0.06 
Distant mucosa, 48.2(l. 8) 51.0(3.9) 0.47 
Legend to Table 12.9 on next page. 
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Table 12.9 shows the mean and standard error of cyclic AMP binding (fmol/mg 
protein) and RI expression (%) in cytosols derived from thre centre and periphery of 
colorectal cancers of different histological grade and in related adjacent and distant 
mucosa. Values are compared by means of a two-sample t-test to give probability 
values shown in the far right column. There were insufficient Dukes A tumours (n 
1) for statistical comparison. 
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Chapter 13: Results of Western Blotting-for ras P21 Qncolarotel-n 
13.1 Coml2arison of ras 1221 Expression in Tumour and Mucosa 
The level of p2l. expression was determined in membrane-enriched preparations 
derived from the periphery of 21 colorectal cancers and related adjacent and distant 
histologically benign mucosa using aY 13-259 Western blotting technique. Levels of 
p2l were quantified by laser densitometry in relation to a internal standard derived 
from a tumour periphery and against a p2l protein derived from a ras transformed cell 
line (Figure 13.11). 
Detectable levels of p2l were present in all tisssues, examined, However, there was a 
7,8 and 15-fold variation in ras levels within tumour periphery, adjacent and distant 
mucosa respectively. Expression of ras p2l protein in membrane preparations derived 
from the periphery of colorectal cancers was significantly lower than that found in 
membrane preparations from adjacent mucosa (0.008 by paired t-test) but not distant 
mucosa (p, = 0.25 by paired t-test). There was no significant difference between p2l 
expression adjacent and distant mucosa (p = 0.83 by paired West) (Table 13.1 and 
Figure 13.1). In only 3 turnours was p2l expression higher than in ! Lofll related 
mucosal specimens, whereas in II tumours it was lower than in both adjacent and 
distant mucosa. 
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Table 13.1 Comparison of ras p2l in the Periphery of Colorectal 

















B MO 9.2 10.4 12.2 
B MO 12.2 14.5 15.2 
B MO 11.6 12.4 5.4 
B mo 10.6 12.3 6.0 
C mo 6.0 7.5 6.1 
B MO 8.0 15.8 12.3 
B MO 4.0 9.4 16.6 
B WE 4.8 6.8 17.3 
B MO 2.5 2.5 2.3 
B PO 1.7 2.2 1.3 
B WE 2.9 2.7 2.7 
C mo 2.8 4.8 3.9 
C mo 9.9 8.9 6.0 
B MO 8.6 7.7 11.3 
C PO 4.6 5.9 7.3 
B WE 3.7 6.9 4.6 
B MO 5.0 4.8 4.2 
B PO 2.2 2.6 2.7 
C PO 6.5 7.3 8.7 
B PO 5.3 5.1 1.4 
C MO_ 1.6 1.9 1.1 




I 0.73 J 0.89 11.12 
Table 13.1 shows the level of ras p2l expression in membrane-enriched 
preparations of 21 human colorectal cancers and related adjacent and distant mucosa in 
relation to stage and grade of disease where PO = poorly differentiated, MO 0 
moderately differentiated and WE = well differentiated. 
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Figure 13.1 Ras p2l. Expression in Membrane. Enriched Preparations 
Derived from the Periphery of 21 Colorectal Cancers and Related 
Adjacent and Distant Mucosa 














































Twnour Adjacent Distant 
pCriphCry MUCOSa mucosa 
Figure 13.1 shows the distribution of ras p2l. expression (arbitrary units) in 
membrane enriched preparations derived from the periphery of 21 colorectal cancers 
and from related adjacent and distant mucosa. Horizontal bars indictae the mean value 
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13.2 Relationship Between rav V21 Expression -in 
Turnour and Mucoqa. 
There was a significant correlation between ras p2l protein expression between the 
the periphery of colorectal, cancers and adjacent and distant mucosa (Table 13.2 and 
Figures 13.2,13.3 and 13.4). Zý, 
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Table 13.2 Correlation Coefficients Demonstrating the Relationship 
Between ras p2l. Expression in Colorectal Cancers and Related 
Adjacent and Distant Mucosa 
Adjacent mucosa Distant mucosa 
1 
Tumourperiphery 0.86 0.46 
< 0.0001) (p = 0.034) 
Adjacent mucosa 0.65 
1 1 (p < 0.002) 
Table 13.2 shows the correlation coefficients (and probability values) demonstrating 
the significant relationship between ras p2l expression in 21 colorectal. cancers and 
related adjacent and distant mucosa 
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Figure 13.2 Correlation between ras p2l, Protein Expression in Tutuour 
Periphery and Adjacent Mucosa. 
Ras p2l Expression 




Ras p2l Expression (arbitrary units) In 
Tumour Periphery 
Figure 13.2 shows the relationship between p2l expression (arbitrary units) in 
membrane enriched preparations derived from the periphery of 21 colorectal cancers 
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Figure 13.3 Correlation between ras p2l Protein Expression In Tumour 
Periphery and Distant Mucosa. 
Ras p2l Expression 








Ras p2l Expression (arbitrary units) In 
Turnour Periphery 
Figure 13.3 shows the relationship between p2l expression (arbitrary units) in 
membrane enriched preparations derived from the periphery of 21 colorectal cancers 








'r u 0.46 
to 12 14 
13 
187 
Figure 13.4 Correlation between ras p2l. Protein Expression in 
Adjacent and Distant Mucosa. 
Ras p2l, Expression 
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Ras p2l Expression (arbitrary units) In 
Adjacent Mucosa 
Figure 13.4 shows the relationship between p2l expression (arbitrary units) in 
membrane enriched preparations derived from the periphery of 21 colorectal cancers 





13.3 The Relationship between-p I Expression in Colorectal Cancers and Stage-and 
Grade of Disease 
There was no significant difference in ras p2l. expression between turnours of 
different Dukes stage or grade (Table 13.3 and 13.4). Similarly, there was no 
relationship between p2l. expression in mucosa, either adjacent or distant, and the 
stage and grade of the turnours to which they were related Cý 
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Table 13.3 Expression of ras p2l. in Tumours of Different Dukes Stage 
Dukes B turnours Dukes C turnours 
(n = 15) (n = 6) 
Mean p2l expression 6.15 5.32 
(arbitrary units) 
Standard error 0.9 1.5 
Table 13.3 shows the mean and standard error of p2l expression (arbitrary units) in 
membrane enriched preparations derived from the periphery of 15 Dukes B and 6 
Dukes C colorectal cancers 
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Table 13.4 Expression of ras p2l in Tumours of Different Histological 
Grade 
well Moderately Poorly 
differentiated differentiated differentiated 
(n = 3) (n = 13) (n = 5) 
Mean p2l 3.8 7.4 4.1 
expression 
(arbitrary units) 
0.5 1.0 0.9 
Standard error 
Table 13.4 shows the mean and standard error of p2l expression (arbitrary units) in 
membrane nriched preparations derived from the periphery of 3 well, 13 moderately 
and 5 poorly differentiated colorectal cancers. 
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13.4 RelationshiR Between Cyclic AMP Bindingand 1221 Expression in Tumournn 
Mucosa 
There was a significant positive correlation between total cAMP binding levels and 
p2l. expression in tumour periphery (r = 0.50, p=0,0036) but not in either adjacent 
(r = 0.08, p=0.73) or distant (r = 0-39, p=0.11) mucosa (Table 13.5 and Figures 
13.5,13.6 and 13.7). 
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Table 13.5 Cyclic AMP Binding Levels, RI and ras p2l Expression in 




















































































































Table 13.5 shows the mean and standard error of cAMP binding (fmol/mg protein, 
n= 18)) and Rl expression Mn= 11) in cytosols derived from the periphery of 
colorectal cancers and related adjacent and distant mucosa-, and the level of p2l 
expression (arbitrary units) in membrane nriched preparations from the same tissues. 
The stage and grade of each tumour is also shown. 
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Figure 13.5 Correlation Between Cyclic AMP Binding and p2l 
Expression in Tumour Periphery. 
CYclic AMP Binding 
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Ras p2l Expression (arbitrary units) In 
Tumour Periphery 
Figure 13.5 shows that there is a significant positive correlation between total cAMP 
binding (fmol/mg protein) in cytosols preparations and p2l expression (arbitrary 





Figure 13.6 Relationship Between Cyclic AMP Binding and p2l. 
Expression in Adjacent Mucosa 
Cyclic AMP Binding 
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Ras p2l Expression (arbitrary units) In 
Adjacent Mucosa 
Figure 13.6 shows the relationship between total cAMP binding (fmol/mg protein) 
in cytosols preparations and p2l expression in membrane enriched preparations 
derived from mucosa adjacent to 18 colorectal cancers. 
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Figure 13.7 Correlation Between Cyclic AMP Binding and p2l. 
Expression in Distant Mucosa 
Cyclic AMP Binding 
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Ras p2l Expression (arbitrary units) In 
Distant MUCOsa 
Figure 13.7 shows the relationship between total cAMP binding (fmol/mg protein) 
in cytosols preparations and p2l expression (arbitrary units) in membrane enriched 
preparations derived from mucosa distant from 18 colorectal cancers. 
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13.5 Relationship Between Rl and ms p2l Expression in Tumour and Mtico.. -; a 
There was a significant negative correlation between percentage xpression of type I 00 
cAMP binding protein and p2l. expression in the periphery of II colorectal cancers 




Figure 13.8 Relationship between Percentage III and p2l Expression in 
Tumour Periphery 
Ras p2l Expression 






RI Expression M In Tumour Periphery 
Figure 13.8 shows the negative correlation between RI expression M) in cytosols 
and p2l. expression (arbitrary units) in cytosols and membrane enriched preparations 
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Figure 13.9 Relationship between Percentage RI and p2l. Expression in 
Adjacent Mucosa 
Ras p2l Expression 
















30 40 50 60 70 
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Figure 13.9 shows the relationship between RI expression (%) in cytosols and p2l 
expression (arbitrary units) in cytosols and membrane enriched preparations 
respectively derived from mucosa. adjacent to II colorectal cancers 
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Figure 13.10 Relationship between Percentage RI and p2l. Expression 
in Distant Mucosa 
Ras p2l. Expression 
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Figure 13.10 shows the relationship between RI expression (%) in cytosols and 
p2l. expression (arbitrary units) in cytosols and membrane enriched preparations 
respectively derived from mucosa distant from II colorectal cancers 
a 
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Figure 13.11 Western Blotting with V13-259 for ras p2l Protein 
Western Blotting with Y13-259 for ras p21 Protein 
0 
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Figure 13.11 shows a typical Western blot for i-a. v 1) N protein using, the anfihodv 
Y 13 - 2-51). 
Lanes 1,4,7 - tumour periphery 
Lanes 2, 
-5,8 - adjacent niticosa 
Lanes 3,6,9 - distant inticosa 
Lane 10 - p2 1 control using protein from ra% transformed cell kne 13 3 B4 




Chapter 14: Characterisation of the--Cyclic AMP Binding Assay 
The first part of the present study was aimed at establishing a reliable and reproducible 
cAMP binding assay for colorcctal tissues. The method used was based upon that of 
Gilman (1970) as modified by Miller et al (1990). Although the assay had been used 
for some time to determine cAMP binding protein levels in breast cancers, it was felt 
necessary to characterise the assay with respect to colorectal tissues. Although, in 
general, no difficulty. was encountered in adapting the method for use with colorectal 
tissues and cAMP-BP were detected in all tissues examined, several useful 
conclusions were drawn from the characterisation studies. 
In previous assays examining cAMP binding within ýbenign and-malignant breast 
tissues, reaction mixtures had been incubated routinely at room temperature (RT) for 
three hours. 'Although these incubation conditions permitted the detection of cAMP 
binding proteins in all breast tissues examined and provided prognostic information 
(Miller el al 1990), 'temperature and time course experiments applied to both breast 
and color6ctal tissues consistently demonstrated that total cyclic AMP binding was 
higher when specimens were incubated at 40C rather than at room temperature (RT). 
Although, initially, binding did rise more quickly at RT; at 40C binding continued to 
rise for up to 24 hours after the onset of incubation. By contrast, at RT maximum 
binding was usually reached by three hours and then often fell - possibly due to 
degradation of R proteins. It was therefore dbcided to perform all assays at 40C and to 
extend the ipcubation time to overnight. 
Early experiments demonstrated that cytosols derived from colorectal specimens 
contained highly variable amounts of soluble protein, possibly reflecting different 
cellularity. Because of this it was decided to express the cAMP binding in terms of 
cAMP bound per milligram of cytosol protein - as had been the normal practice with 
binding assays previously performed on breast cancers (Miller et al 1990). The protein 
concentration of each cytosol were measured by the method of Bradford (1976) using 
Coomassie Brilliant Blue in a spectrophotometric assay. Studies showed that cytosol 
protein concentrations could be measured reproducibly by this method and that there 
was, for a given cytosol diluted with tissue buffer to different protein concentrations, a
significant linear correlation between cAMP binding and protein content. It was 
therefore concluded that, within the range of concentrations studied, protein 
concentration had no effect per se upon the cAMP binding assay. 
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The assay was also found to be extremely specific for cyclic AMP. Thus several 
alternative ligands were used as cold competitor within the cAMP assay and none were 
found to compete to any extent with the binding of [3HJ-cAMP to cAMP binding eý 
proteins. Cyclic guanosine monophosphatc (cGMP) did produce some displacement 
of [3H]-cAMP but only in very high unphysiologic concentrations (20-8OmM). By 
contrast, bovine serum albumen (BSA), also in high concentrations (40-loog/1), 
caused a slight enhancement of binding. Despite this repeated attempts to demonstrate 
binding of [3H]-cAMP to BSA were unsuccessful. 
Although every attempt was made to remove colorectal specimens from the operating 
theatre as quickly as possible, and under conditions that would minimise proteolysis, a 
degree of degradation is inevitable especially as the resected colon may already have 
withstood a prolonged ischaernic time within the patient prior to remov4 Fortunately, 
cAMP binding proteins within intact colorectal tissues appeared, in tenns of their 
abi li ty to bind cAMP, extremely stable under the storage conditions used in this study 
(liquid nitrogen, or -t7OC freezer). For example, even after several months of storage 
cAMP binding levels in intact tissues were well maintained. Furthermore, even assays 
performed-upon stored and thawed cytosol were reproducible. Suchýstability most 
likely relates to the structure of the R subunit of PK-A. The two cAMP binding sites 
are known to occupy the carboxy-terminus of the R molecule (Taylor 1989) and to be 
relatively insensitive to proteolytic degradation. By contrast, a "hinge" area towards 
the amino-terminal end near the C subunit interaction site is extremely sensitive. Thus 
it is possible for degradation to produce a range of small molecular weight R subunit 
fragments which can still bind cAMP. Certainly, the later photo-affinity labelling 
(PAL) experiments revealed that such fragments increased with storage. 
Cyclic AMP binding assays performed on contiguous areas of the same tumour 
revealed a degree of variation (10-15%) in cAMP binding even once results had been 
corrected for cytosol protein concentration. Specimens taken from quite different areas 
of the tumour (for example, from the centre and the periphery) showed even greater 
differences (up to 100%). For this reason it was decided to perform assays on samples 
taken from as close to the edge of the tumour as possible without risking 
contamination by normal adjacent mucosa, and from the central area of the tumour. 
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Many colorectal turnours contain areas of macroscopic ulceration and necrosis and 
attempts were made to avoid such regions. In addition, the macroscopic edge of 
tumour can be difficult to define and even then does not necessarily correlate well with 
the microscopic extent of the tumour (Black and Waugh 1948). In an attempt to more 
closely define the specimens assayed, haematoxylin and cosin (H & E) stained 
sections of each sample were examined histologically to ascertain their benign or 
malignant nature. Even so, simple H&E would not exclude minor degrees of 
contamination of tumour with normal mucosa or vice-versa. It is also generally 
accepted that most turnours contain an abundance of non-malignant cells originating 
from both supporting stroma and immune lineages. Such potential contamination is 
always a problem when dealing with tissues rather than cell lines and can never be 
eradicated completely. The decision to assay both centre and periphery of tumour was 
justified by the results of the cAMP assays which revealed aconsiderable degree of 
intra-tumour heterogeneity. Such heterogeneity has been described by others with 
respect to steroid receptor expression and cAMP binding in breast cancers (Senbanjo, 
Miller and Hawkins 1985). Preliminary studies 
ýIso demonstrated variation in cAMP 
binding between contiguous areas of mucosa. For this reason it was decided to assay 
mucosa both adjacent to and distant from each tumour. 
In conclusion, therefore, the initial part of the study had: 
1) adapted a cAMP binding assay for use with colorectal tissues. 
2) shown the assay to be specific and reproducible. 
3) optimised the incubation conditions 
4) supported the decision to base the results of the assay on cytosol protein 
concentration 
5) identified heterogeneity within tumour and mucosa - leading to the decision to assay 
the following samples in each patient: 
i) tumour centre 
ii) tumour periphery 
iii) adjacent mucosa 
iv) distant mucosa 
In the next section the results of cAMP binding assays on these four specimen types 





15: Cyclic AMP- Binding Levels in Colorectal Cancers and 
Related Mucosa 
With respect to colorectal carcinogenesis and cyclic AMP metabolism, three main 
questions were addressed: 
1) is an abnormality within the cAMP signalling pathway involved in the pathogenesis 
of colorectal cancer ? 
2) if so, what is the nature of the abnormality and does it entail an under or over- 
activated pathway ? 
3) can such an abnormality be manipulated so as to make the cAMP system a potential 
means of gaining biological control ? 
The cAMP signafling pathway is extremely complex and it was not possible in the time 
available to examine all aspects of the system with respect to colorectal cancer. Work 
had already been done by others on Protein Kinase A activity and cAMP levels in 
colorectal tissues and their findings will be discussed below. However, to my 
knowledge no work had previously examined the expression of PK-A regulatory sub- 
units within benign and malignant human colorectal tissues. The second part of the 
study was therefore aimed at applying the cAMP assay to specimens of tumour (centre 
and periphery) and related mucosa (adjacent and distant) obtained from a series 69 
patients undergoing elective surgery for colorectal cancer. It was hoped that these 
studies would answer the first and second questions and determine whether further 
work aimed at answering question 3 was justified. 
The principal finding of the study was that cAMP binding levels were significantly 
higher in the periphery (but not the centre) of human colorectal cancers when 
compared to those levels of cAMP binding found in either adjacent or distant related 
mucos. Thus, of the 69 tumour-mucosa pairings examined, binding in tumour 
periphery was lower than that in both adjacent and distant mucosa in only 10 patients. 
These "low-binding" tumours had the following characteristics. 
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Stage- Of the 10 "low-binding" tumours identirted, 6 were Dukes B, 2 were Dukes C 
and 2 were Dukes A. Given that there were only 4 Dukes A turnours in the whole 
series, these early cancers were well represented in the "low-binding" group. 
However, due to small numbers, it is not possible to attribute statistical significance to 
this observation. The low incidence of Dukes A tumours within unscreened 
populations of colorectal cancers means that a very much larger series of patients 
would be required to address the question of cyclic AMP binding protein expression 
in these early tumours. However, the effect of stage of disease on binding in Dukes B 
and Dukes C tumours is discussed in more detail below. 
Site of Origin Six of the "low-binding" turnours were caecal in origin, two arose in 
the sigmoid and the remaining two originated in the rectum. These "low-binding" 
tumours were therefore signif"icantly more likely to arise from the right colon than the 
left (p = 0.03 by Chi-squared test). Taking the series of 69 turnours as a whole, 
however, there was no significant difference in the total level of cAMP binding in 
turnours arising from different regions of the colorecturn. 
By contrast, 59 colorectal cancers over-expressed the regulatory subunits of Protein 
Kinase A in their periphery when compared to histologically benign, adjacent and 
distant mucosa taken from the colorectum in which they arose. Although this is the 
first study of cAMP binding proteins with respect to benign and malignant colorectal 
tissues, a small number of papers have addressed other aspects of the cAMP system . 
For example, both DeRubertis et al (1976) and Latner et al (1979) found reduced 
levels of both cAMP and PK-A activity in human adenocarcinomas when compared to 
normal mucosa. Margolis et al (1976) found that cAMP/cGMP ratios were lower in 
both human adenocarcinomas and adenomas than in normal mucosa. Stevens el al 
(1979) and DeRubertis and Craven (1980) found that dimethylhydrazine (DMH) 
induced colorectal carcinogenesis in rats was also associated with a reduction in 
mucosal cAMP content and PK-A activity. Interestingly, however, there was a relative 
increase in PK-A type I (see Chapter 16). 
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More recently, Alexandrov et al (1986) found that both cAMP levels and Protein 
Kinase A activity were significantly reduced in human colorectal cancers when 
compared to premalignant colorectal adenomas. However, unlike the present study, 
the adenocarcinomas nd adenomas compared were not from the same patient. This is 
an important point as the current study has shown a wide variation in total cAMP 
binding in both cancers and mucosa between different individuals. There may well be 
similar variation with respect to cAMP and PK-A activity making interpretation of 
results obtained from unpaired tissues difficult. Furthermore, these workers made no 
comparison with normal mucosa. Nevertheless, the authors do conclude that low 
levels of cAMP-dependent kinase activity, in relation to levels of cAMP-independent 
kinase activity, allows the differentiation between premalignant and malignant 
colorectal tissues. 
Prior to the present work, therefore, the available studies, albeit small in number, 
suggest that both within the human colorecturn and within experimental animal 
models, colorectal carcinogenesis is associated with an undeL-active cAMP system in 
terms of cAMP levels and kinase activity. This is keeping with the observations that: 
1) many, but not all, transformed cells contain reduced levels of cAMP (Pastan et al 
1975, Chayoth et al 1972). 
2) cAMP analogs can apparently "switch-on" the cAMP system within a wide range 
of cell lines, including those of human colorectal cancer origin, so promoting their 
differentiation and inhibiting their growth (Cho-Chung 1990). 
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By contrast the present study has identified an increase in the expression of another 
component of the cAMP system, namely cAMP binding proteins, within colorectal 
cancers when compared to benign mucosa. Such increased cAMP binding initially 
suggests the presence of an over-active not underactivc, cAMP system with malignant 0 
tissues arising in the human colorecturn. There are a number of possible explanations 
for this apparent discrepancy: 
1) colorectal cancer is associated with an over-active cAMP system, perhaps at an 
early stage during the generation of a neoplastic hyperproliferative or adenornatous 
epithelium. 
2) increased cAMP binding in colorectal cancers is associated, in some way, with an 
underactive cAMP system in terms of kinase activity and cAMP levels. 
3) cAMP binding within the periphery of colorectal cancers is artificially raised due to 
contamination with non-malignant cells, and malignant cells actually express low 
levels of cAMP binding (as found in tumour centre - see below) 
4) low levels of cAMP within tumours when compared to mucosa (as found by 
previous authors) means that there is less endogenous cAMP to compete with [31-11- 
cAMP in the binding assay so leading to apparently increased levels of [3H]-cAMP 
binding within tumour. 
These possibilities will nowbe discussed in more detail 
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1) What evidence is there to support a role for an over-active cAAIP system in the 
generation of neoplastic growth ? 
As discussed in Chapter 4, despite the initial association of cAMP with growth 
inhibition, there is no doubt that cAMP is able to act as a promoter of cellular 
proliferation within a wide range of tissues. Furthermore, an overactive cAMP system 
has been implicated in the generation of certain neoplastic non-malignant adenomatous 
growths. 
For example, human pituitary adenomas fall in to two groups with respect to the 
cAMP system. Group I adenomas produce growth hormone (GH), show no response 
to GH-releasing hormone (GHRH acting through cAMP) in terms of GH production, 
and have constitutively activated adenyl cyclase (AC) activity. Group 11 adenomas do 
not produce GH except in response to cAMP and have normal basal AC activity. The 
abnormally high levels of AC activity found in group I adenornas results from 
mutations within the cc-subunit of the stimulatory G protein (Gs) that mediates the 
signal from cxtracellular bound ligand to AC (Landis et al 1989). These "activating" 
mutations occur either at codon 61 (a site identical to the mutation site within the ras 
p2l protein known to inhibit GTPase activity through interfering with the interaction 
with GAP protein (Cales et al 1988)) or at codon 201 (previously identified as the site 
of ADP-ribosylation by cholera toxin). Both mutations result in the a-subunit 
remaining "switched-on" in a GTP-bound state (Vallar et al 1987). Such activation 
represents the first clear demonstration of 'a potential oncogene within the cAMP 
system and, in a number of ways, activated Gs resembles quite closely other members 
of the oncogene family. For example, mutant Gs mimics the action of an externally- 
binding growth factor, namely GHRH; the mutation stabilises the protein in an active 
GTP-bound conformation, the mutation is found only within tumour and not within 
somatic DNA; and the tumours contain both mutated and wild-type Gs indicating that 
the mutated Gs is capable of acting in a dominant manner. 
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A second example of the association between the cAMP system and neoplastic growth 
comes from the effects of thyroid stimulating hormone (TSH) on the thyroid gland. 
TSH acts through cAMP and PK-A to stimulate both the growth and function of the 
thyroid gland. Prolonged over-sti mutation by TSH leads to swelling of the thyroid 
(goitre) and to over-production of thyroxine (thyrotoxicosis). TSH is also capable of 
stimulating the proliferation of malignant thyroid cells in vitro as well as following 
transplantation in to nude mice. Furthermore, thyroxine (T4) can be administered to 
patients with thyroid cancer to suppress TSH levels by means of a direct feedback 
action of T4 on the hypothalamic-pituitary axis, Such TSH suppression may be 
associated with a reduction in the rate of recurrence as well as with an increase in 
overall survival. It is clear therefore that cyclic AMP, by acting as a second messenger 
for TSH, can support the growth of both benign overactive, and frankly malignant, 
thyroid tissue. Of particular relevance to the present study is the recent observation that 
both autonomous thyroid nodules and certain thyroid cancers possess abnormally high 
AC levels when compared to normal thyroid tissue taken from the same patient (Endo 
et al 1990). This may be due to either activating mutations within Gs as described 
above, or possibly due to an increase in the expression of TSH receptors (Duh et al 
1989). 
Cyclic AMP has also been associated with neoplastic growth within the kidney. Renal 
cysts arise from nephrons and collecting ducts and progressively enlarge as a 
consequence of abnormal neoplastic epithelial proliferation and fluid secretion. Despite 
being entirely benign, such cysts can cause death from renal failure secondary to 
destruction of surrounding renal parenchyma. In an in vitro model of cyst formation 
the hyperprol ife ration of cyst-forming MDCK cells has been found to be cAMP 
dependent (Mangoo-Karim et al 1989) suggesting over-activity of the cAMP system 
is, at least partly, involved in the generation of these cysts within the kidney. 
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These examples provide evidence that an over-active cAMP system may be associated 
with neoplastic and autonomous, albeit not truely malignant, growth within certain 
human tissues. There are several other targets organs for trophic hormones that act 
through cAMP including the adrenal cortex and the gonads and "it is easy to imagine 
how tumours of these cells could result from activating mutation of Gs or in other 
elements of the cAMP signalling pathway" (Bourne 1987). The present work is the 
first to describe the over-expression of a: component of the cAMP signalling pathway 
within a common malignant human tumour when compared to the tissue in which it 
has arisen. It is possible therefore that an over-active cAMP system contributes to the 
early stages of carcinogenesis through favouring the generation of a neoplastic 
hyperproliferative or adenomatous epithelium that may then be acted upon by other 
factors. Thus, colorectal cancer is pre-dated by the appearance of a hyperproliferative 
mucosa and later by the formation of macroscopically identifiable adenomatous polyps 
(see Chapters I and 6). 
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2) Can the over-expression of cAMP binding proteins within colorectal cancers 
identified in the present stuqý, be reconciled with the reduced levels of cAAIP and PK- 
A kinase activityfound ky others ? 
Increased expression of cAMP binding proteins could be associated with reduced 
cAMP levels and PK-A kinase activity through a number of mechanisms. For 
example, a low level of cAMP generation may lead to over-expression of PK-A sub- 
units through a positive feedback loop. Although the mechanisms controlling R 
subunit expression within tissues are poorly understood, cAMP regulates its own 
generation and degradation at a number of different points, Such feedback loops 
presumably exist to provide "damping" or a degree of "fine tuning" within the system. 
For example, cyclic AMP stimulation of Chinese Hamster fibroblasts leads to a decline 
in the translation of mRNA for the P-adrenergic receptor (BAR) and promotes 
phosphorylation, with subsequent inactivation, of BAR by P-adrenergic receptor 
kinase (BARK) (Bouviere et al 1987,1989, Collins et al 1988,1989). Agonist 
hormones acting through cAMP also up-regulate phosphodiesterase gene transcription 
leading to increased cAMP degradation (Conti et al 1981). Furthermore, cyclic AMP 
acting through PK-A leads to phosphorylation of phosphodiesterases so increasing 
their activity (Grant et al 1988). In addition to cAMP regulating its own generation 
and degradation, it is clear that cAMP regulates the different regulatory and catalytic 
subunits of PK-A in a very specific manner (Oyen et al 1988a, b, c). It is likely that 
PK-A subunit genes contain cAMP response elements (see Chapter 3). All these 
feedback mechanisms act to return the signalling system to equilibrium. If, as seems 
the case, malignant cells in general contain abnormally low levels of cAMP, perhaps 
due to changes in receptor expression or trans-membrane signalling events, it is 
possible that feedback mechanisms act to increase the level of R subunit transcription 
in order to "compensate" for the low level of signal. 
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Alternatively, PK-A R subunits may be generated in excess of C subunits. Although 
the ratio of catalytic td regulatory subunits is often assumed to be unity. it appears that 0 
the two subunits are expressed and regulated independently (see above). Free R 
subunits, in excess of C subunits, have been described (Prashad 1988) and it is 
possible to imagine a mechanism by which the generation of excess R subunits within 0 
a tumour might lead to binding of intra-cellular cAMP and subsequent "quenching" the 
cAMP signal. Sequestering cAMP in this way might then prevent full activation of 
kinase (Doskeland and Ogreid 198 1). 
A similar situation may arise if R subunits are mutated in such a way as to impair their 
ability to bind cAMP and/or dissociate from C subunit. Such mutated R subunits 
(interestingly, to date, exclusively of the RI protein) have been identif ted in a range of 
malignant cell lines including those derived from lymphoma, neuroblastoma, the 
adrenal, macrophages, the ovary, choriocarcinoma, and mammary carcinoma 
(Williams and Schimmer 1983). These mutant R subunits confer resistance to the 
effects of cAMP and to other agents that would increase intra-cellular cAMP 
concentrations (Buskirk et al 1985, Singh et al 1985). As a result, mutant clones can 
exhibit quite different characteristics from those of their wild-type counter-parts 
including much a more aggressive malignant behaviour (Lester et al 1987). Most, but 
not all, of these mutations involve one or other of the tandem cAMP binding sites 
lying towards the carboxy terminus of the R subunit. Although the two sites are highly 
related, they are functionally distinct. For example, they possess different binding 
affinities for cAMP analogs and cAMP dissociates much more rapidly from site A 
than from site B. Mutant R subunits that contain one or other of two point mutations at 
the B cAMP-binding site (one at amino acid 324 (B2) and the other at position 332 
(B 1)) have been cloned and sequenced (Clegg et al 1987). Dissociation of cAMP 
from either wild-type or BI mutant is bipbasic. whereas dissociation from B2 is 
extremely rapid and monophasic. Thus the BI but not the B2 mutant has an intact B 
binding site. The holoenzyme containing the B2 mutant requires a far greater 
concentration of cAMP to demonstrate half-maximal activation of kinase and does not 
demonstrate positive co-operativity. The expression of the B2, and to a lesser extent 
the BI mutant, within AT20 pituitary and JEG-3 choriocarcinoma cells therefore 
results in a suppression of cAMP stimulated PK-A activity (Correll et al 1989). 
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Similar mutants have been found in S49 mouse lymphoma cells (Woodford et al 
1989, Oaried et al 1988), human osteosarcoma cell lines (Bringhurst et al 1989), 
Cloudman melanoma cells (Pawalek et al 1979), and in the phaeochromocytoma cell 
line PC12. They have also been identified in YI adrenocortical cancer cell line where 
increased levels of mutant RI subunits are associated with a 20400 fold decrease in 
PK-A activity. These cells are resistant to the differentiating and steroidogenesis- 
inducing effects of cAMP. Interestingly, the mutant cells contain both mutated and 
wild-type RI protein indicating that the mutant RI protein acts in a dominant manner to 
suppress the cAMP system (Correll et al 1989). The possession of such a mutant RI 
protein may also have a bearing upon other important characteristics of the cell 
including succeptibility to chernotheraputic agents. Thus Chinese Hamster Ovary 
(CHO) wild-type cells transfected with a RI protein bearing a mutant site A cAMP- 
binding site, and possessing impaired cAMP binding properties, show an increased 
sensitivity to Adriamycin. This is thought to be because defective cAMP signalling 
impairs the induction of the cAMP-dependent multidrug efflux pump gene (mdr) 
coding for a P-glycoprotein that removes drug from the cell (Abraham et al 1990). 
Not all mutations involve the cAMP binding sites. For example, certain mutant RI 
subunits described within cAMP-resistant S49 lymphoma, cells display normal [3H]- 
cAMP binding and are therefore presumed to have mutations at other important 
regions within the molecule such as the C subunit interaction site. Similar mutations 
have been identified in YI adrenocortical cancer cells where despite normal cAMP 
binding, both basal and cAMP stimulated PK-A activity is markedly reduced (Doherty 
el al 1982). Other mutations may affect the ability of R subunits to undergo 
conformational change in response to cAMP binding so preventing dissociation of the 
holoenzyme. R subunits may also contain more than one type of mutation. Thus RI 
mutants have been described in Chinese Hamster Ovary cells that exhibit not only 
defective cAMP binding but a decreased ability to dissociate from C subunits 
(Abraham et al 1985). 
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3) Is it possible that cAMP binding in the periphety of colorectal cancers is artificialkv 
elevated due to contwnination of tumour with non-malignant cells ? 
It is generally accepted that many of the cells lying within cancers are non-malignant 
and belong either to supporting stroma or to the wide range of immune cells, such as 
macrophages and lymphocytes, known to infiltrate malignant tissues. Although 
routine histology was performed on every specimen assayed, simple H&E 
preparations would not be able reliably to exclude or quantify such contamination. It is 
possible, therefore, that the high levels of cAMP binding detected in the periphery of 
colorectal cancers were actually due to high levels of binding within contaminating 
rather than malignant cells. This possibility will be covered in more detail below when 
the heterogeneity of cAMP binding within turnours is discussed. 
4) Could low levels of endogenous cAMP within tumours artificialky elevate cAAfP 
binding ? 
The cyclic AMP binding assay depends crucially upon the ability of different 
concentrations of radio-inert cAMP to displace [3H]-cAMP from the binding sites 
within R subunits. The concentrations of radio-inert cAMP used in the assay varied 
fom 0 to 8OnM with non-specific binding being quantified by the degree of [3H]- 
cAMP binding in the presence of great excess (10, OOOnM) cAMP. Are the levels of 
endogenous cAMP in tumour and mucosa likely to effect the binding assay ? 
DeRubertis'etal (1976) found the average basal cAMP content of colorectal tumours 
to be 0.61 nM and that of related mucosa to be 0.45 nM. The level of endogenous 
cAMP within colorectal tissues therefore appears to be low in comparison to the 
concentrations of cAMP used in the assay system and one would not expect there to be 
any significant effect on the binding result. However, cAMP levels were not measured 
in the present study and so the possible effect of endogenous cAMP on the binding 
results must be bourne in mind. 
In summary, therefore, the present study is the first to have examined the level of 
cAMP binding in colorectal cancers and has shown that cAMP-BP are over-expressed 
in the periphery of such cancers. Other workers have looked at other aspects of the 
cAMP system have consistently shown a lower level of cAMP and Protein Kinase A 
activity in colorectal tumours when compared to normal mucosa. At the present time 
studies are underway to look at the level of kinase activity within colorectal cancers 
and compare these with R subunit expression. 
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Although cAMP binding levels were markedly raised in the periphery of colorectal 
cancers, this was not the case in the turnour centre, where binding levels were not 
significantly different from those in adjacent mucosa and actually significantly lower 
that those in distant mucosa. Such low binding may simply be a reflection of low 
cellularity and cell viability as histological examination of specimens derived from 
tumour centres did show them to contain considerable amounts of necrotic, fibrotic 
and non-neoplastic debris. However, one might expect that any reduction in cAMP 
binding due to the small amount of cellular material available would be negated, at 
least in part, by expressing the results in terms of cytosol protein. Alternatively, as 
suggested above, cAMP binding levels within tumour periphery may have been 
artificially elevated due to contamination with stromal cells, immune cells or even 
normal mucosa that may have a high level of binding per se. One might then conclude 
that colorectal cancers in fact express less cAMP binding proteins than normal 
mucosa. However, as adjacent mucosa had the lowest binding of all, significant 
contamination of tumour periphery with normal mucosal cells would be expected to 
reduce binding in turnour periphery, rather thaý elevate it. Furthermore, the fact that 
the specimens with the highest and lowest binding, namely tumour periphery and 
adjacent mucosa respectively, are adjacent also makes it unlikely that cAMP binding is 
being significantly affected by contamination one way or the other. This is reassuring 
as early studies showed that the rolled margin of colorectal cancers does not accurately 
mark the extent of the tumour which may extend 1-2 cm, from the macroscopic edge, 
particularly in the submucosa (Black and Waugh 1948). 
It is possible that the difference in binding between centre and periphery represents a
true biological heterogeneity within the tumour. For example, Senbanjo et al (1986) 
compared cAMP binding in the periphery (P) and centre (C) of breast cancers and also 
from an intermediate area (A). Histological examination found little or no variation in 
the degree of pleomorphism, differentiation, necrosis, or extent of lymphocytic 
infiltration across the tumour although there was a tendency for increased cellularity 
towards the periphery. Whereas DNA content and steroid receptor concentrations on a 
wet weight basis were significantly lower in the C and A portions, cAMP binding and 
soluble protein content did not significantly alter between centre and periphery. 
Furthermore, they found that whereas DNA content correlated well with cellularity 
there was no significant correlation between cellularity and soluble protein content. 
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When expressed in terms of soluble protein content there was no difference in cAMP 
binding between C, A and P but when expressed in terms of DNA content cAMP 
binding was significantly higher in the centre than the periphery of tumour. The 
authors conclude that cAMP binding reflects variations in the viability and behaviour 
of the malignant cell population between periphery and centre. 
Cyclic AMP binding was significantly lower in mucosa adjacent to tumour than in 
mucosa that was distant from tumour revealing a zone of depressed cAMP binding 
surrounding the tumour. This may simply reflect an area of atrophic mucosa (see 
below), perhaps caused by nutrient steal, although there is no direct evidence for this. 
Alternatively, one might postulate that the cancer is releasing some, as yet 
unidentified, humoral substance that is acting to suppress the cAMP system in 
surrounding mucosa. There is considerable evidence that colorectal cancers rele , 
ase not 
only growth stimulating factors that perhaps act in a paracrine or autocrine manner 
(Pommier 1988), but also tumour inhibitory factors. For example, Levine, Lamaziere 
and Broxmeye (1985) showed that a human colon cancer cell line MOSER synthesised 
not only TGF-a but also a tumour inhibitory peptide that was able to prevent the 
anchorage-independent growth of other differentiated but not undifferentiated human 
colon cancer cell lines in vitro. 
Whatever the reason for the depressed cAMP binding in adjacent mucosa it is in 
keeping with the long held view that colorectal cancers are surrounded by a zone of 
abnormal mucosa, often called "transitional mucosa" (TM) (Williams 1985, Hamilton, 
Watt and Allen 1985). Transitional mucosa is both histologically and biochemically 
distinct from normal mucosa. (Bresalier, Boland and Kim 1985) in that it contains a 
higher proportion of immature cells within elongated and branching crypts as well as 
an altered pattern of surface mucin. The pathogenesis of TM, as well as its 
significance, remains a matter of controversY. Of particular relevance to the present 
study is the question of whether or not TM is a pre-malignant condition (Filipe and 
Branfoot 1974, Dawson and Filipe 1976, Oohara el al 1980, Sharnsuddin et al 1981, 
Williams 1985, Bresalier, Boland and Kim 1985, Hamilton, Watt and Allen 1988). 
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Features in favour of a malignant association are as follows: 
i) TM is found surrounding colorectal cancers. 
ii) TM contains immature cells. 
iii) TM, like colorectal cancers, expresses mainly sialomucins on its surface whereas 
normal mucosa expresses predominantly sulphomucins. 
iv) TM is found in patches throughout colons bearing cancers, in the colons of patients 
with FAR but apparently not in colons without tumour. 
v) the extent of TM has been claimed to relate to the prognosis of the tumour in 
question and to its Duke's stage. 
vi) TM precedes the development of tumour in DMH-induced animal colorectal 
carcinogenesis. 
vii) TM is also found at high risk sites for malignancy such as colorectal anastomoses 
and ureterosigmoidostomy sites. 
Features against an exclusively malignant association include: 
i) TM has none of the usual features of malignancy such as epithelial dysplasia. 
ii) TM has been claimed to surround other colorectal malignancies uch as squamous 
anal cancer, lymphomas, metastatic deposits, malignant melanoma; as well as non- 
malignant lesions such as endometriosis, solitary ulcers, polypectomy scars and 
diverticular disease. 
iii) TM does not show aneuploidy when adjacent o an aneuploid tumour (Wersto et al 
1988). 
At present the question of whether TM is a premalignant condition or whether it is 
merely a secondary regenerative phenomenon remains unanswered. However, in the 
context of this study it may well be that TM expresses a different level of cAMP 
bindingperse. Adjacent mucosa certainly expresses ignificantly lower cAMP binding 
than the periphery of the turnour to which it relates (which is perhaps evidence against 
it being a pre-malignant condition) as well as lower cAMP binding than distant 
mucosa. 
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Despite the significant differences in cAMP binding between the four different samples 
examined, within individuals binding levels were highly interrelated. Thus, patients 
with turnours expressing high levels of cAMP binding proteins also possessed mucosa 
that bound high levels of cAMP. This suggests that the expression of cAMP-BP 
within turnours is superimposed upon a background level of cAMP binding that is 
unique to each individual. Furthermore, binding of cyclic AMP by mucosa was related 
to the stage but not the grade of tumour arising within that particular colorecturn. That 
is, cAMP binding in both adjacent and distant mucosa from colons supporting the 
growth of a Dukes B tumour was significantly higher than binding in similar 
specimens from colons supporting the growth of Dukes C turnours. Dukes B turnours 
also had significantly higher binding than Dukes C turnours (see below). Similar pan- 
colonic variations with respect to mucosal proliferation have been detected by other 
workers. For example, Terpstra et al (1987) using autoradiography after pulsed 
labelling with tritiated thymidine compared cell proliferation in endoscopically obtained 
samples of histologically normal mucosa from six predetermined sites within the 
colorectum. of patients with macroscopically normal colons and of patients with 
neoplastic disease (adenocarcinomas and adenomas). Labelling indices were 
significantly increased throughout the colons supporting neoplastic growth when 
compared to normal colons. The highest levels of proliferation were within normal 
mucosa found in patients having large adenomas, then small adenomas then 
adenocarcinomas. Borkje et al (1987) and Maskens and Deschner (1977) also found 
that the proliferative activity of mucosa from colons supporting the growth of cancers 
and adenomas was higher than that of mucosa taken from macroscopically normal 
colons. The results from these and the present studies would suggest that both 
adenomas and adenocarcinomas are able to influence, or are influenced by, the 
proliferative characteristics of normal mucosa present in the colorecturn in which they 
arise. One may postulate that the presence of tumour influences the rest of the colon by 
releasing as yet unidentified growth factors (see above). Alternatively, it may be the 
body's response to the presence of tumour that influences the proliferative 
characteristics of the remaining colorectal mucosa. Agents that elevate cAMP reduce 
thymidine incorporation in to rabbit colonic mucosa (Alpers and Philpott 1975), and 
cAMP and PK-A levels are lower in the proliferative zones of colonic crypts than in 
surface cells (Craven and DeRubertis 1976). Thymidine labelling is also higher in 
colorectal cancers than in normal surrounding mucosa and within turnours proliferative 
activity is highest towards the periphery (Bleiberg and Galand 1976). To examine the 
relationship between cAMP and proliferation, studies are underway to compare cAMP 
binding with cell cycle analyses derived from flow cytometry. 
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Cyclic AMP binding levels within tumours were also related to Duke's stage. Thus, 
Duke's B tumours bound significantly more cAMP than those that were Duke's C. 
Paradoxically, therefore, although cAMP binding was significantly higher in tumour 
periphery than in normal mucosa, primary turnours that had spread to involve lymph 
nodes bound less cAMP than those that had not. This was true for cAMP binding in 
both the centre and the periphery of the turnours examined. There was also a tendency 
for cAMP binding to be lower in tumours of poor rather than moderate histological 
grade although this trend did not attain statistical significance. Taken together the 
results suggest that as colorectal cancers become more advanced so they express lower 
levels of cAMP binding proteins. This may lend support to the hypothesis that 
increased cAMP-BP are associated with the early steps of colorectal carcinogenesis 
(see above). To my knowledge, the only other human cancer to have been examined 
with regard to cAMP binding is breast cancer where, by contrast, high levels of cAMP 
binding are associated with a decreased isease free interval and overall survival. In 
addition, cyclic AMP binding levels within breast cancers were independent of stage 
and grade of disease; but then so too was the patients prognosis (Miller et al 1990). 
Although there is a wide variation in overall survival between patients in the same 
Duke's category, the presence of lymph node metastases (Duke's Q is generally 
accepted to be a poor prognostic sign (Fielding et al 1986, Wiggers et al 1988). Thus 
it would appear that the situation with regard to cAMP binding and prognosis in 
colorectal and breast cancer is quite different. However, the study on breast cancer 
was carried out on a group of highly selected turnours and the methods used to 
determine the levels of binding were different with regard to incubation conditions. 
The possible reasons for the discrepancy between colon and breast are further 
discussed below. One interesting point, however, is that whereas in colorectal cancer 
there appears to be a positive correlation between RI expression and low levels of 
binding quite the opposite appears to be true in breast cancer where high levels of 
binding are associated with turnours rich in RI (Dr W. R. Miller, personal 
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communication). In both tissues, however, it is the turnours with high levels of RI that 
one would expect to do badly. Perhaps then it is the level of RI expression, not the 
total level of binding that will prove to be of most prognostic value. Nevertheless, the 
relationship between total cAMP binding and stage of disease in colorectal cancer 
suggests, that the binding levels may provide prognostic information. Consequently, 
the present cohort of patients is being followed up to ascertain whether this is the case. 
Both [32p]-8-azido-cAMP and [3H]-cAMP were used as ligand within the cAMP 
binding assay. Assays using the azido analog were performed in the dark in an attempt 
to minimise photo-activated covalent bonding. The two ligands yielded similar total 
binding and dissociation constants in both tumour and mucosal specimens uggesting 
that both bind to cAMP binding proteins with similar characteristics. Nevertheless, it
became clear from photo-affinity labelling experiments that, when photo-activated, 
[32pi-8-azido-cAMP was able to label moieties that would not bind [3H]-cAMP. For 
example, whereas [32pl-8-azido-cAMP non-specifically photolabelled albumen it does 
not bind albumen physiologically; nor does'[3H]-cAMP. So although the total 
competitive binding assay and the photo-labelling assays provided useful and 
complementary information on tumour and mucosal cAMP binding proteins, the 
results of the two assays are not directly interchangeable. 
Although in most tissues the majority of PK-A activity resides in the soluble fraction, 
in certain tissues such as the central nervous tissue, this is not the case. One important 
role of R subunits would appear to be the localization of kinase to fixed cellular 
compartments, cellular membranes and cytoskeletal structures (Corbin et al 1977, 
Bregman, Bhattacharya nd Rubin 1989). Such localization presumably influences the 
range of substrates to which the kinase is exposed. There is also increasing evidence 
that R subunits can move kinase activity to the nucleus (Clair et al 1987) and bind to 
DNA (Wu and Wang 1989) so possibly influencing the pattern of cAMP-dependent 
gene transcription. In contrast to total binding within the soluble fractions of colorectal 
tissues, the highest level of binding to membrane fractions was found in adjacent 
mucosa and was lowest in tumour. Thus there appears to be an inverse relationship 
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between the expression of soluble and particulate cAMP binding proteins. Following 
activation of the cAMP system within human colon cancer cell lines, R11 proteins have 
been observed to enter the nucleus and this has been associated with an improvement 
in morphological differentiation (Cho-Chunc, 1989). Earlier in the discussion it was 
postulated that colorectal cancer was associated with an under-active cAMP system 
and the over-expression of incompetent R subunits. Although the membrane fractions 
prepared in this study are extremely crude it is interesting to speculate that the 
significantly lower level of particulate cAMP-BP together with the significantly higher 
soluble level of cAMP-BP is due to a failure of R subunits to migrate from the cytosol 
to the nucleus and perhaps to other fixed sites. 
In conclusion, therefore, the present study has shown that the regulatory subunits of 
PK-A are over-expressed in the periphery, but not the centre, of human col. orectal 
cancers when compared to both adjacent and distant histologically benign mucosa. 
Within turnours however low levels of binding are associated with increased 
malignancy in terms of stage and grade of disease. 
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Chapter 16: Photoaffinity- Labelling of cAMP--Eindina 
-Proteins--in Colorectal Cancer and Mucosa 
Photoaffinity labelling (PAL) has been widely used to study nucleotide receptor-ligand 
interactions. The technique depends on the formation of an irreversible covalent bond 
between the highly reactive azido group of [32p]-8-azido-cAMP and amino acids D 
lining the two cAMP receptor pockets on the regulatory moiety of PK-A (Kerlavage 00 Co 
and Taylor 1980, Bubis and Taylor 1987) following exposure to UV light. The ligand 
[32pl-8-azido-cAMP has been shown to bind both RI and RII and is capable of 
labelling all four cAMP binding sites under saturating conditions (Walter and 
Greengard 1983). One ofthe main advantages of [32p]-8-azido-cAMP PAL is that it is 
applicable to very crude tissue preparations. Early work confirmed that of the many 
proteins present in the soluble fraction of cells only a few bound [32p]-8-azido-cAMP 
to any significant extent and of these only two, with molecular weights of 48kDa and 
50-54kDa, were common to all tissues and bound [32p]-8-azido-cAMP specifically 
as shown by the inhibition of incorporation by excess cAMP. These proteins have 
since been shown to be the RI and RII subunits of PK-A respectively. Although there 
are a number of other proteins that also specifically bind cAMP for example, 
phosphodiesterases, phosphofructokinase (Kemp and Krebs 1967) and S- 
adenosylhomocysteine hydrolase (Saebo and Ueland 1978), binding of nucleotide to 
the latter two proteins is of unknown physiological significance. and in general 
phosphodiesterases are poor substrates for 132pj-8-azido-cAMP. The result is that 
specific binding of [32pl-8-azido-cAMP to proteins other than RI and RlI has not 
been a problem with the PAL technique. However, certain proteins do bind [32pl-8- 
azido-cAMP non-specifically and this will be discussed below. Although Haley 
(1975) was the first to synthesize and use 8-azido-cAMP to label cAMP binding sites 
on the surface of human erythrocytes, Pomerantz et at (1975) was the first to use 8- 
azido-cAMP to label partially purified cAMP-dependent protein kinase. It is an 
adaptation of that technique that was employed in the present study. 
Photoaffinity labelling (PAL) with [32pi-8-azido-cAMP followed by polyacrylamide 
ggel electrophoresis (PAGE) was used to identify specific cAMP binding proteins 
(cAMP-BP) in the centre and periphery of 32 colorectal cancers and related adjacent 
and distant mucosa. Specific cAMP-BP were identified in all the tissues examined. 
These proteins had molecular weights of 52,50,48,44,37 and 34kDa and were 
initially termed R52, R50, R48, R44, R37 and R34. Binding of [32pl-8-azido- 
cAMP to all moieties could be displaced by the addition of 1000-fold excess radio- 
inert cAMP so demonstrating the specificity of binding. 
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In all tissues examined the predominant cAMP-BP were R52, R50 and R48 with the 
smaller proteins contributing less than 15% ofthe total binding present. These smaller 
fraoments have been previously described by a number of other workers and are 
generally considered to be degradation products of RI (R44, R37) and RII (R34) 
(Rannels and Corbin 1979). Both RI and RII appear particularly sensitive to 
proteolysis around the "hinge" site (Nimmo and Cohen 1977, Taylor 1989). Such 
degradation results in the production of lower molecular weight moieties that contain 
both cAMP binding sites but that are no longer capable of combining with the C 
subunit (Sugden and Corbin 1976, Rannels and Corbin 1979, Potter and Taylor 
1979b). This may explain why the results of total cAMP binding assay, but not PAL 
experiments, changed very little following prolonged storage of tissues. Although 
freshly prepared cytosols contained low amounts of these degradation products 
(<15% of all cAMP-BP activity), prolonged storage caused them to increase 
markedly. 
In most tissues a protein of 65kDa was also found to bind [32pl-g-azido-cAMP and 
was initially termed 65kDa. However, in contrast to the other cAMP-BP, binding 
was only partially displaced by excess radio-inert cAMP. In other experiments, 
bovine serum albumen was also found to bind [32pi-8-azido-cAMP, to co-migrate 
with R65 from tumour and mucosal cytosols and to show only partial displacement 
with cAMP. R65 was therefore felt to represent binding of [32P]-S-azido-cAMP to 
contaminating albumen and not a novel specific cAMP-BP. Non-specific binding of 
[32p]-8-azido-cAMP to albumen has been *described by other workers (Walter et al 
1977a). 
Although RI is generally recognized to have a molecular weight of 47/48kDa and RII a 
molecular weight of 50-56kDa depending on the tissue and species in question, it was 
felt necessary to define the nature of R52, R50 and R48 more closely. Partially 
purified preparations of RI and RII were obtained commercially and run alongside 
tumour and mucosal cytosols. Although the preparations were extremely 
heterogeneous, the predominant protein from the RI preparation had a molecular 
weight of 48kDa and co-migrated with RI whilst the predominant bands within the Rif 
preparation were 50-56kDa and co-migrated with R50 and R52. The only other study 
of R subunits in colorectal tissues was performed on a human colon cancer cell line 
LS-174T (Tagliaferri et al 1988). By means of PAL, PAGE and immunoprecipitation 
with specif ic anti-RI and anti-RII antibodies this cell line was found to express a single 
form of RI (47kDa) and two forms ofR11 (52 and 54kDa). Tumour and mucosal 
specimens provided by the author were kindly examined in the same way by Dr. Cho- 
Chung and her group. This confirmed that R48 was RI whilst both RSO and R52 
were forms of RII. 
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The difference in molecular weights may be simply a reflection of small differences in 
technique, or, the R proteins may differ in structure between the cell line and actual 
turnour material. The nature ofthe two RIT isoforms is discussed in more detail below. 
The main finding in the present study was that RI expression was significantly higher 
in both the centre and periphery of colorectal cancers when compared to both adjacent 
and distant mucosa. There was no difference in RI expression between the centre and 
periphery of tumours or between adjacent and distant mucosa. Most ofthe pre-exising 
work on RI and RII expression in malignancy has been performed on cell lines and 
few attempts have been made to compare malignant tissues with their normal 
counterparts. However, in general, the results obtained would appear to support the 
findings of the present study with respect to the colorectum. For example, RI is the 
major or sole R subunit detected in a number of human cancer cell lines including 
those derived from breast, lung, and colorectal cancer (HT-29 and LS-174T), 
fibrosarcoma, glioma, and leukaemia (Katsaros et al 1987, Cho-Chung et al 1989). In 
addition, glioma cells express more RI than foetal brain cells (Ekanger et al 1985) and 
malignant osteoblasts express predominantly RI whilst benign cells express mainly 
RII (Livesy et al 1982). In primary breast cancers, as compared to normal breast 
tissue, there have been conflicting reports. Some workers report significantly higher 
PK-AI/PK-AII kinase activity (Eppenberger et al 1980), others found no change in 
RI/RII ratios (Handschin et al 1983) whilst other workers found increased RI (Weber 
et al 1988). The ratio of PK-AI to PK-AI1 and RI to RII in renal carcinomas and 
Wilms'tumours was twice that found in normal renal cortex, although the total kinase 
level was similar (Fossberg et al 1978, Nakajima el al 1984). Similarly, Yasui el al 
(1985) found that whilst normal gastric mucosa had a PK-Al/11 ratio of 0.2, this was 
increased to 0.6 in a human xenotransplantable gastric carcinoma. Taken together, 
these and the present studies provide evidence for an increase in RI expression and 
PK-AI kinase in range of different human malignancies. It would appear, therefore, 
that such an alteration may be general phenomenon associated with the malignant 
process rather than being specific to the colorecturn. 
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The second major observation with regard to cAMP-BP patterns in tumour and 
mucosa was that in tumour nearly all the RII was in the form of R50 whilst, in 
mucosa, R52 was a separate and prominent band. This may be due to a reduction in 
RII autophophosporylation. Early experiments howed that there was a small decrease 
in the electrophoretic mobility of RII when PAL was carried out in the presence of 
ATP. Thus, in the presence of ATP, Hofmann (1975) found rabbit muscle RII to 
migrate to the 57K position whilst in the absence of ATP it migrated as a 54Kda 
complex. Studies on a wide range of normal tissues suggest that normally the majority 
of RII is in the autophosphorylated, presumably activated, form (Rangel-Aldao et al 
1979). The loss of RII-52 in maligant tissue may therefore indicate that RII is under- 
active. In support of this hypothesis is the finding that autophosphorylated RII 
reassociates more slowly with C sub-unit (Rangel-Aldao and Rosen 1977). The 
alternative explanation is that RII-52 and RII-50 are distinct gene products. Evidence 
for this comes from the identification of RII-52 within LS- 174T cell line as RII-P and 
RII-54 as RII-a (Cho-Chung 1990). Interestingly, Weber et al (1981) also found 
normal kidney adjacent to carcinoma to contain R148 and RII-50 and 52 whilst in the 
renal carcinoma itself the RIT-52 moiety was absent. A similar loss of RII-52 has 
been found in leukaemic lymphocytes (Wielckens et al 1980). 
The present study also demonstrates that there is strong correlation between RI 
expression within tumour tissue and mucosa from the same patient. This is similar to 
the relationship found for total cAMP binding and again suggests that changes in the 
cAMP system within turnour are super-imposed upon a background state that may 
vary considerably between individuals 
There was no significant difference in RI expression between turnours of different 
Dukes stage. By contrast RI expression was significantly higher in the centre of 
turnours of poor histological gradewhen compared to turnours that were moderately or 
well differentiated. There was a similar trend in tumour periphery but this did not 
attain statistical significance (p = 0.14). RI expression in adjacent and distant mucosa 
was unaffected by stage or grade of the related tumour. It has been postulated for 
some time that RI is a marker for proliferating, transfonned and malignant cells whilst 
RII might programme for a differentiated state. In many systems, however, it is 
difficult to separate proliferation from differentiation. To overcome this difficulty 
Wielckens et al (1980) separated normal from neoplastic lymphocytes in patients with 
chronic lymphatic leukaemia (CLL). Neither cell type demonstrates any proliferative 
activity but the CLL cells are less differentiated as shown by an extended life span and 
reduced response to mitogens. In normal lymphocytes RI-48 and 1111-52 cAMP-BP 
were identified whilst in CLL cells Rif-52 was absent and replaced by an RII-50 and 
R148 was relatively increased, 
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The observation that colorectal tumours, and particularly those of poor grade, possess 
high RI/RII ratios is especially interesting given the ability of cAMP analogs to inhibit 
the growth and promote the differentiation of a wide range of normal cells (Vintermyr 
et at 1989) and cell lines (Cho-Chung et al 1989, Yang et at 1989). For example, 
treatment of the human colon cancer cell line LS- 174T with 8-chloro-cAMP induces 
morphological differentiation. Similarly, treatment of Friend erythroleukaemic cells 
with 8-Br-cAMP leads to erythroid differentiation. Both these cell types contain both 
RII-52-P and RII-54-ct isoforms as separate gene products (see above) as well as Rl- 
47/48. Differentiation is associated a reduction in RI, a 12 to 14-fold increase in R11- 
52-P but no change in RII-54-ct. The results ofthe present study suggest that 
abnormalities in the cAMP system within these cell lines are also present in colorectal 
cancers. It is interesting to speculate, therefore, whether cAMP analogs might be 
capable of promoting the differentiation of colorectal cancers and provide a m. eans of 
gaining biological control. 
In the majority of tissues it would appear that most cAMP-BP reside in the soluble 
fraction (Hofmann et at 1977). Photoaffinity labelling of cAMP-BP from both 
particulate and soluble fractions has shown them to have similar molecular weights 
and cross-reactivity to antibodies. Consequently, it has been assumed that these 
proteins are only distinguished by their subcellular localization (Walter et at 1978, 
Rubin et at 1979a, b). Results from this study would tend to support these findings. 
Thus in colorectal cancer and mucosa less than 25% of total cAMP binding appears to 
reside in the particulate fraction and there was no difference in the molecular weights 
of the proteins identified by PAL in either soluble or membrane extracts, However, 
certain tissues, for example brain, that do contain significant amounts (>65% of total 
cAMP) of particulate cAMP-BP appear to express a distinct gene product. Thus 
although RII from bovine heart (RII-H) and brain (RII-B) share common physical 
and functional properties in vitro , they are distinct polypeptides that are can 
discriminated by different antibody affinities, unique peptide maps and amino acid 
sequences (Takio et al 1984). More recently the genes for the two different RII 
molecules have been cloned and RII-H is now termed RlI-a (Scott et al 1987) and 
RII-B is termed RII-P (Jahnsen et at 1986, Sandberg et at 1988). RII-P is also found 
in neuroendocrine tissues (Erlichman et at 19SO) and ovarian granulosa cells (Jahnsen 
et al 1986a, b, Kwast-Welfeld and Jungmann 1988) whilst RII-a is found in heart, 
kidney, liver and skeletal muscle (Erlichman et at 1980, Hemmings et at 1986). 
Furthermore RII-P is associated with membranes and binds tightly to several proteins 
that are relatively enriched in brain (Theurkaufand Vallee 1982, Sarkar et at 1984, 
Leiser et at 1986) suggesting that RII-P adapts PK-A for certain unique tasks in the 
tissues in which it is found (Dudai 1987, Stein et at 1987, Buxbaum and Dudai 
1989). 
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Certain cell types, for example Friend erythroleukaernia cells and the colonic cell line 
LS- 174T possess both RII-ct and R11-0 (Gross et al 1990). The results of the present 
study would suggest that human colorectal cancers also express both R11 forms. More 
recently, it has become clear that brain also has a unique RI molecule. The original Rl 
protein, now termed RI-a which was detected in a wide range of tissues was initially 
purified and sequenced from bovine skeletal muscle (Titani et al 1984) and had its 
cDNA cloned from bovine testis (Lee et al 1983). Clegg et al (1988) subsequently 
characterized adifferent RI gene, now termed RI-P. RI-ot appears to be expressed in 
all tissues whilst RI-A is limited to brain. 
Walter et al (1977a) showed that the photoactivated incorporation of [32pl-8-azido- 
cAMP in to RI and RII agreed well with the total amount of reversible binding sites as 
detennined by the reversible binding of cAMP itself. In support of this is the present 
finding that when [32P]-8-azido-cAMP is substituted for [3HJ-cAMP in a total cAMP- 
BP assay the total cAMP binding levels and the Scatchard plots are very similar. Thus, 
within certain provisos relating to the non-specific labelling of proteins by [32pl-8- 
azido-cAMP, the cAMP binding assay and PAL appear to be detecting binding to the 
same subunits. Interestingly, there was a strong negative correlation between cyclic 
AMP binding and RI expression in tumour but not in either adjacent or distant 
mucosa. This suggests that, within tumour but not mucosa, the cAMP binding assay 
is detecting binding to R11 proteins in preference to RI. This could be because the RI 
subunits within the tumour are defective in their ability to bind cyclic AMP; possibly 
because they are mutated (see Chapter 15). The inverse relationship between RI and 
total cAMP binding is perhaps to have been expected with regard to the relationship of 
binding and RI to stage and grade of disease. Thus, tumours of advanced stage have 
significantly lower cAMP binding. There is also a tendency for turnours of poor grade 
to have lower binding although this did not attain statistical significance. By contrast 
turnours of poor grade had statistically higher levels of RI expression with no 
apprarent relationship to stage. The results of the two assays therefore provide 
separate but complementary information on the biology of colorectal cancer with 
regard to both the degree of invasion and the degree of differentiation. It will be 
interesting to follow-up this cohort of patients to deten-nine whether cAMP binding or 
RI expression could provide useful prognostic information. 
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Chapter 17: Ras 1! 21 and cAMP-BP Expression In-Colorectal Cancers 
and Mucosa 
Although ras p2l is almost certainly acts as a signal-transducing protein and has been 
linked to the cAMP, Protein Kinase C, and the receptor tyrosine kinase pathways 
(see Chapter 5 and below), its precise function remains unknown. However, with 
respect to the malignant state, ras proteins may become oncogenic or "activated" by 
undergoing mutations that affect their interaction with guanine nucleotides and there is 
little doubt that such activated ras proteins are present in a wide range of human 
tumours (Tanaka et al 1986, Nishimura and Sekiya 1987) such as lung (Santos et al 
1982), bladder (Der et al 1982), pancreas (Almoguera et al 1988), kidney (Fujita et al 
1988), thyroid (Lemoine et al 1988), acute myeloblastic leukaemia (Gambke et al 
1985) and colon (Bos et al 1987, Forrester et al 1987, Burmer and Loeb 1989, 
Meltzer et al 1987, Ravikumar et al 1989, Michelassi et al 1989). Furthermore, as 
techniques become more sensitive they are being detected in a higher proportion of 
such turnours. By contrast, whether over-expression of normal p2l protein can lead 
to malignancy is uncertain. Thus, tumours do not consistently express more p2l than 
their normal counterparts (see below), and amplification of ras genes appears to be 
uncommon (Nishimura and Sekiya 1987), although a 10-fold increase in ras 
expression has been described in a colorectal cancer cell line (Alitalo et al 1984). 
Despite the common association of ras with malignancy, some of the highest p2l 
levels are found in cells that are fully differeptiated, non-proliferating and functioning. 
For example, Furth, Aldrich and Cordon-Cardo (1987) found ras p2l within virtually 
all adult and foetal tissues studied, and although in some lineages proliferating cells 
contained more p2l. than differentiated cells, in other tissues the converse was true. 
With respect to the foetal colon, p2l staining decreased as cells differentiated towards 
the lumen. In the adult colon a similar pattern was observed but, in addition, there was 
intense staining of the apical brush border. Chesa et al (1987) also found that, in 
general, terminally differentiated cells contained more p2l than rapidly proliferating 
cells. In that study colonic surface cells also stained strongly but crypt cells contained 
low levels of immunoreactivity. Rav p2l would therefore seem to have somewhat of a 
Jekyll and Hyde character, apparently possessing two completely different, and in 
some respects contradictory, aspects to its nature. 
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The decision to examine p2l levels in colorectal tissues was prompted by the 
observation that cAMP analogs induce the differentiation a wide range of cell lines, 
including those of human colorectal cancer origin (Cho-Chung 1989), together with a 
reduction in p2l expression. In order to determine whether there was any relationship 
between cAMP-BP and p2l expression, p2l protein levels were determined in 
membrane fractions derived from the periphery of 21 colorectal tumours, and related 
adjacent and distant histologically benign mucosa. This was achieved by means of 
Western blotting using Y13-259. This antibody binds to residues within a highly 
conserved region common to all ras proteins (Lacal and Aarosnson 1986, Barbacid 
1987) and so will detect both wild-type and "activated" forms. 
Ras p2l protein was detected in all specimens assayed with levels being significantly 
lower in tumour periphery than in adjacent mucosa. Expression in tumour periphery 
was also lower than that in distant mucosa this did not attain statistical significance. 
There was no significant difference in expression between adjacent and distant 
mucosa. There was an almost 8-fold difference between the lowest and highest levels 
of tumour p2 1. Furthermore, there was a strong correlation between the level of p2l 
within individual tumours and that found their related adjacent and distant mucosa 
demonstrating that there is also a wide variation in the expression of p2l in the 
colorectal mucosa of different individuals. The level of p2l found within tumours in 
this study appears therefore, like total cAMP binding and RI expression, to be super- 
imposed upon the inherent level of expression within that individual. 
Previous studies have also examined p2l expression in colorectal tissues and 
produced conflicting results. For example, De Biasi, Sal and Hand (1989), using a 
direct liquid competition radioimmunoassay (RIA) with Y13-259, examined p2l 
levels in 5 colorectal cancer/mucosa, pairs. Four of the tumours exhibited higher p2l 
levels than related mucosa, with percentage differences ranging from 19.5 to 74.1 %, 
and the fifth tumour showed no difference. Similarly, Hand et al (1987) using the 
same technique found enhanced levels of p2l in all 13 colorectal carcinomas 
examined. However, comparisons were made with only three samples of mucosa and 
these samples were also from different patients. Interestingly, however, two of the 
samples of normal mucosa were adjacent to a colorectal cancer and showed 3-4 times 
higher p2l levels than the third sample of normal mucosa that was taken from a patient 
without cancer. They found no difference in p2l levels between primary tumours and 
metastases from 5 patients. By contrast, Gallick et al (1985) using Western blotting 
with Y13-259 to compare p2l levels in 17 colorectal cancer/mucosa pairs, found 
elevated levels in only 9 turnours. Seven tumours had equivalent levels and one 
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tumour has less p2l than its related mucosa. They also note that there was a 
considerable difference in expression between indivual turnours and that, overall, 
tumours expressed less than twice the amount of p2l found in normal mucosa. 
Williams et al (1985), in an immunohistochernical study using Y 13-259, also found 
that human colonic carcinomas and mucosa showed similar staining intensity. 
Spandidos and Kerr (1984) found higher levels of Ha-ras and Ki-ras mRNA in 
adenomas than in carcinomas. Messenger RNA levels in carcinomas and adenomas 
were also higher than that in related mucosa. 
In the present study there was no significant difference in p2l expression between 
turnours of different Duke's stage or histological grade. However, p2l expression 
has been correlated with the biological behaviour of, and clinical outcome from, 
several tumour types including colorectal cancer. For example, Tahara et al (1986) 
found that c-Ha-ras p2l expression was higher in metastases than in primary human 
gastric carcinomas. Furthermore, patients with turnours containing higher levels of ras 
p2l were found to have a significantly worse prognosis. Similarly, Karayiannis et al 
(1989) studied 88 gastric carcinomas immunýhistochemically using Y13-259 and 
found that although only 34% contained immunoreactivity, staining was commoner 
and more intense in tumours of advanced stage and poor grade. By contrast, Noguchi 
et al (1986) found that 65/96 gastric carcinomas stained positively for p2l, that 
poorly differentiated cancers tended to stain less frequently and less intensely, and that 
there was no correlation with stage. In breast cancer, Clair, Miller and Cho-Chung 
(1987) found that p2l expression was higher in turnours of advanced stage and in 
those with lymph node involvement. Furthermore low p2l levels appeared to be 
associated with a prolonged disease-free interval. Viola et al (1986) were unable to 
detect p2l antigen in normal prostate or in benign prostatic hyperplasia but in prostatic 
carcinoma p2l. levels were found. to correlate positively with nuclear anaplasia and 
glandular de-differentiation. With respect to the colon, Gallick et al (1985) detected 
less p2l in advanced turnours and speculated that over-expression may be an early 
event in carcinogenesis. Metastatic tissue from 9 patients was also available for 
comparison and in all cases expressed less p2l. than the primary tumour from which 
they were derived. Augenlicht et al (1987) studying p2l levels in HT29 colorectal 
cancer cell line variants found that high levels of p2l were associated with low tumour 
forming ability in nude mice. They concluded that a high level of ras p2l. expression is 
a marker for a differentiated state in colonic cells rather than being associated with the 
development of carcinoma. Williams et al (1985) found that human colonic 
carcinomas and mucosa showed similar staining intensity but that high levels of ras 
I 
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p2l. were present in adenomas. They speculated that ras over-expression may be 
important early in carcinogenesis but that high levels need not necessarily be sustained 
for the progression to invasive cancer. Kerr et al (1985) using the same technique 
found ras p2l in both premalignant and malignant tumours, and in the normal adult 
and foetal colorectal crypt epithelial cell population. Interestingly, metastatic deposits 
showed less staining than the surrounding normal liver. However, Thor el al (1994) 
found p2l expression to be a late feature of colorectal carcinogenesis and that p2l 
levels correlated with the depth of bowel wall invasion. 
In 18 patients data was available on both membrane p2l expression and total 
cytoplasmic cAMP binding levels. There was a significant positive correlation between 
p2l. expression and cAMP binding in tumour periphery but not in either adjacent or 
distant mucosa. By contrast, there was a significant but negative correlation between 
p2l expression and RI expression in tumour but again not in adjacent or distant 
mucosa. It appears, therefore, that within malignant, but not benign tissue, there is a 
relationship between the cAMP signalling system and ras p2l expression. Such a 
relationship might occur in a number of ways. 
Firstly, ras p2l might act directly as aG protein acting directly to control the activity 
of adenyl cyclase (AC) . Such direct control of AC is exerted in the yeast 
Saccharom 
' yces cerevisiae 
by homologous RAS proteins (DeFeo-Jones et al 1985, 
Temeles et al 1985, Kataoka et al 1985, Fraenkel 1985). Furthermore, human ras p2l 
can substitute for yeast RAS proteins and activate yeast AC (Broek ct al 1985) and 
phosphorylation of RAS proteins by mammalian PK-A inhibits there ability to activate 
AC (Resnick and Racker 1988). In mammalian cells there is also some evidence that 
ras proteins might directly or indirectly control AC activity (Saltarelli, Fisher and 
Gacon 1985, Broek et al 1985, Franks, Whitfield and Durkin 1987,1989, Konishi- 
Immamura, Noda. and Nomura 1987, Gorman, Benjamin and Tarpley 1987) but there 
is also evidence to the contrary (Birchmeier, Broek and Wigler 1985, Beckner, Hattori 
and Shih 1985) (see Chapter 5). 
Secondly, the cAMP system may be able to control the activity of ras proteins 
through reversible phosphorylation. For example, PK-A phosphorylates a small 
molecular weight G protein (smg2l) with functional homology to c-Ki-ras p2l 
(Hoshijima et al 1988. Ballester, Furth and Rosen 1987, Kawata et al 1989). 
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Thirdly, genes coding for small molecular weight G proteins such as ras might be 
cAMP-dependcnt. Thus, cAMP is able to promote the differentiation of PC12 cells 
together with an increase the transcription of mRNA coding for smg-25A, a novel 
GTP-binding protein related to ras p2l. (Sano et al 1989). Although it is not known 
whether ras genes are cAMP-dependent, the treatment of a wide range of cell lines 
and certain animal turnours with cAMP or its analogs is associated with a decrease in 
p2l. expression, growth inhibition, and differentiation. For example hormone- 
dependent growth of chemically-induced rat mammary carcinomas is associated with 
increased Ha-c-ras expression whilst a marked suppreesion of this oncogene 
accompanies hormone withdrawl or treatment with dibutryl-cAMP (Huang and Cho- 
Chung 1984). In the human salivary gland cell line HSG, reversible differentiation 
into myocpithelial cells could be achieved with dB-cAMP and was associated with a 
reduction in rav p2l. expression (Azurna et al 1988) 
Defining the exact role of ras proteins is further complicated by the high level of 
cross-talk between signalling systems and in particular between the cAMP, receptor 
tyrosine kinase (RTK) (Wharton et al 1982, Kacich et al 1988) and the inositol 
phosphate/PK-C pathways (Druker, Mamon and Roberts 1989, Horn, Baum and 
Ambudkar 1989, Yada et al 1989, Murayama et al 1989). It may be that the ras 
proteins take part in several different signalling pathways or perhaps mediate part of 
this cross-talk. For example, over-expression of p2l in T15 NlH/3T3 cells reduces 
the normal increase in cAMP associated with bombesin-stimulated increases in 
phosphoinositol metabolism (Davies et al 1988) and PK-C can directly phosphorylate 
the both the C subunit of PK-A (Yoshimasa et al 1987) and the c-Ki-ras p2l protein 
(Ballester, Furth and Rosen 1987). Furthermore, PK-A mediated phosphorylation of 
low molecular weight GTP-binding proteins can lead to inhibition of phospholipase C 
activity (McAtee and Dawson 1990) and Lazarowski et al (1990) found that 
phosphorylation of rapt, a ras-related 24kDa GTP-binding protein, lead to an 
inhibition of inositol phosphate metabolism in human erythroleukaemia cells. The 
initiation of proliferation and the induction of c-fos and c-nkyc mRNA by epidermal 
growth factorin A31 M cells and H41 lEhepatoma cells is cAMP dependent (Ran et 
al 1986, Squinto, Block and Doucet 1989) and cAMP is able to modulate EGF signal 
transduction by phosphorylating the EGF receptor (EGF-R) (Ghosh-Dastidar and Fox 
1984, Iwashita et al 1990, Carpenter and Cohen 1990). In addition, tyrosine 
phosphorylation of the PK-A inhibitor protein results in a 6-9 fold decrease in its 
inhibitory capacity suggesting that the RTK molecules can up-regulate PK-A (Van 
Pattern Fletcher and Walsh 1996). 
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In conclusion, there is abundant evidence to link ras p2l, albeit indirectly, with the 
cyclic AMP and several other signalling pathways. Perhaps what is particularly 
interesting in the present study is that ras p2l expression was related to both total 
cAMP binding and RI expression within turnours but not in normal mucosa. This 
suggest that there is a fundamental difference in the relationship between the cyclic 
AMP system and p2l in malignant tissue when compared to benign. There is however 
no indication at present as to what that difference might be although it is interesting to 
speculate that it arises, at least in part, from the presence of mutated ras within tumour 
but not mucosa. That there should be such a marked difference between ras in 
malignant and benign tissue is perhaps not all that surprising given the somewhat 
conflicting association between ras and both transformation and differentiation - In 
this context it is also interesting that, although p2l levels in tumour were not directly 
related to stage or grade of disease, the relationship of high p2l levels to high levels of 
cyclic AMP binding but low RI expression would suggest that p2l expression is likely 
to be higher in turnours of early stage and grade. 
Chapter 18: Conclusions 
-and 
Suggestions for Further Work 
Although only one aspect of the cAMP secondary messenger system has been 
examined, namely the regulatory subunits of PK-A, the results presented in this 
Thesis indicate that there are differences between the cAMP/PK-A system of human 
colorectal cancers and related histologically benign mucosa. In particular, the levels of 
cAMP-BP are higher in the periphery of colorectal cancers when compared to mucosa. 
In addition, there is an association between tumour cAMP binding and both Dukes 
stage and histological grade. To my knowledge, these findings are novel and indeed, 
with the exception of breast cancer, cAMP-BP have not previously been studied in any 
other human tumour type. Similarly the observation that colorectal cancers, and 
particularly those of poor histological grade, over-express Rl with respect to normal 
mucosa has not been previously reported. 
The main difficulty with studying resected tumour material rather than cell lines, on 
which the vast majority of work on the cAMP system has so far been carried out, is 
the uncertaintly of what one is assaying. Thus, although every attempt was made to 
ensure the histological nature of the specimens being examined, one cannot be 
absolutely sure that results are not being affected by contamination with other cell 
types or by differences in cellularity or cell viability. On the other hand, one cannot be 
sure that what applies to a cell line cultured in vitro is relevant to tumours growing 
within patients, Nevertheless, there are marked similarities between the findings of the 
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present studies on R subunit expression in resected colorectal cancers and the findings 
of Dr Cho-Chung and her colleagues with respect to human colorectal cancer cell 
lines. For example, the R subunits identified possess very similar molecular weights 
and cross-react with the same antibodies. More importantly, however, both cell lines 
and resected turnours showed a predominance of RI when compared to benign tissue. 
The fact that human colorectal cancer cell lines can be made to differentiate in vitro by 
cAMP analogs, and that such cell lines show a reduction in their malignant phenotype 
when innoculated in to mice treated with the same analogs, together with a reduction in 
RI expression in each case, suggests that it may be possible to modulate the cAMP 
system in an attempt to gain biological control over malignant growths. To date, 
studies have shown the analogs to have minimal toxicity in laboratory animals and at 
the present time human Phase I studies of cAMP analogs are underway in 
Washington D. C. Further work looking at the effects of cAMP analogs on the growth 
and R subunit expression of tumours grown in laboratory animals are also being 
carried out in Edinburgh. Such studies will indicate whether the in vivo effects of 
cAMP analogs on tumour growth are associated with the reduction in RI expression 
seen in cell lines treated with analogs in vitro. 
This Thesis is also the first work to have demonstrated a relationship between ras P21 
and PK-A R subunit expression in a resected human cancer. This observation 
provides for the first time a possible mechanism by which cAMP and it analogs might 
achieve the effects on malignant growth discussed above. Of particular interest is the 
finding that this relationship could not be demonstrated in related benign mucosa, 
suggesting that there has either been a change in the cAMP system or in the nature of 
rav expression between benign and malignant tissues. It is already known that mutated 
ras proteins are present in a large proportion of colorectal cancers, and the results 
presented above have shown differences in the cAMP system. Further studies 
examining more closely the relationship between R subunit expression and mutated 
and wild-type ras p2l, made possible by the availability of selective antibodies, 
would be very interesting. It would also be interesting to examine the relationship 
between the cAMP system and other oncogenes. 
In conclusion, this Thesis has generated a number of novel findings supporting the 
increasingly held perception of the cAMP system as a worthwhile area of study with 
respect to human cancer. At the same time, as discussed above, the work has raised a 
number of important questions. At the present time, the author is continuing his 
collaboration with workers in both Scotland and the United States, who are 




Abraham L, Brill S., Hyde J., Fleischmann R., et al. (1985). DNA-mediated gene 
transfer of a mutant regulatory subunit of cAMP-dependent protein kinase. J. Biol. 0 Chem. 260: 13934-13949. 
Abraham I., Chin K-V., Gottesman M. M., et al. (1990). Transfection of a mutant 
regulatory subunit gene of cAMP-dependent protein kinase causes increased drug 
sensitivity and decreased expression of P-glycoprotein. Exp. Cell. Res. 189: 133-141. 
Adavani S. R., Schwarz M., Showers M. O., et al. (1987). Multiple mRNA species 
code for the catalytic subunit of the cAMP-dependent protein kinase from LLC-PKI 
cells. Eur. J. Biochem. 167: 221-226. 
AhIgren R., Simpson E. R., Waterman M. R. and Lund J. (1990). Characterization of 
the promoter/regulatory region of the bovine CYPIIA (P-450scc) gene. J. Biol. 
Chem. 265: 3313-3319. 
Ajiro K., Shibata K. and Nishikawa Y. (1990). Sbbtype specific cclic AMP-dependent 
histone HI phosphorylation at the differentiation of mouse neuroblastoma cells. J. 
Blol. Chem. 265: 6494-6500. 
Alexandrov V. B., Levi N. MKh., Minaev B. N., et al. (1986). Determination of cyclic 
AMP and protein kinases in the diagnosis of colonic tumours, Vopr-Onkol. 32: 45-53. 
Alford T. C., Do H. M., Geelhoed G. W., et al. (1979). Steroid hormone receptors in 
human colon cancers. Cancer 43: 980-984. 
Ally S., Tortora G., Clair T., et al. (1988). Selective modulation of protein kinase 
isoenzymes by site-selective 8-Cl-cAMP provides a biological means for the control of 
human colon cancer cell growth. Proc. Natl. Acad. Scl. USA 8S: 6319-6322. 
Ally S., Clair T., Katsaros D., et al. (1989). Inhibition of growth and modulation of 
gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic 
adenosine monophosphate. Cancek Res. 49: 5650-5655. 
Almoguera C., Shibata D., Forrester K., et al. (1988). Most human carcinomas of the 
exocrine pancreas contain mutant c-Ki-ras genes. Cell S3: 549-5.54. 
Al-Nafusi A. L. and Wright N. A. (1982). The effect of epidermal growth factor (EGF) 
on cell proliferation of the gastrointestinal mucosa in rodents. Vichows. Arch. Cell. 
Pathol. 40: 63-69. 
Alpers D. H. and Philpott G. W, (1975). Control of DNA synthesis in normal rabbit 
colonic mucosa. Gastroenterology 69: 951-959. 
Andersen B., Milsted A., Kennedy G. and Nilson J. H. (1988) Cyclic AMP and 
phorbol esters interact synergistically to regulate expression of the chorionic, 
gonadotrophin genes. J. Blol. Chem. 263: 15578-15583. 
237 
Andersson K. K., Haavik J., Martinez A., et al. (1989) Evidence from EPR 
spectroscopy that phosphorylation of Ser-40 in bovine adrenal tyrosine hydroxylase 
facilitates the reduction of high-spin Fe(III) under turnover conditions. FEBS Lett. 
258: 9-12 
Andrisani O. M., Zhu Z., Pot D. A. and Dixon J. E. (1989). In vitro transcription 
directed from the somatostatin promoter is dependent upon a purified 43-kDa DNA- 
binding protein. Proc. Natl. Acad Sci. USA 86: 2181-2185. 
Astler V. B. and Coller F. A. (1954). The prognostic significance of direct extension of 
carcinoma of the colon and rectum. Ann. Surg. 139: 846-852. 
Augenlicht L. H., Augeron C., Yander G., and Laboise C. (1987). Overexpression of 
ras in mucus-secreting human colon carcinoma cells of low turnourigenicity. Cancer 
Res. 47: 3763-3765. 
Avery T. L., Finch R. A., Robbins R. K., et al. (1988). Treatment of murine and 
human neoplasms in vivo with the site-selective cAMP analog, 8-Cl-cAMP. Proc. 
Am. Assoc. Cancer Res. 29: 354. 
Azuma M., Yoshida H., Kawamata H., et al. (1988). Cellular proliferation and ras 
oncogene of p2l 21,000 expression in relation to the intracellular cyclic adenosine 0 3', S'-monophosphate l vels of a human salivary gland adenocarcinorna cell line in 
culture. Cancer Res. 48: 2898-2903. 
238 
0 m 
Ball R. L., Tanner K. D. and Carpenter G. (1990). Epidermal growth factor potentiates 
cyclic AMP accumulation in A-431 Cells. J. Blol Chem. 265: 12836-12845. 
Ballester R., Furth M. E. and Rosen O. M. (1987). Phorbol-ester and protein kinase 
C-mediated phosphorylation of the cellular Kirsten ras gene product. J. Biol Chem. 
262: 2688-2695, 
Banjeree, D. K., Kousvelari E. E. and Baum B. J. (1987). Cyclic AMP-mediated 
protein phosphorylation of microsomal membranes increases mannosyl- 
phosphodolichol synthase activity. Proc. Natl. Acad Sci. USA 84: 6389-6393. 
Barbacid M. (1987). ras Genes. Ann. Rev. Biochem. 56: 779-827. 
Barker W. C. and Dayhoff M. O. (1982). Viral src products are related to the catalytic 
chain of mammalian cAMP-dependent protein kinase. Proc. Natt. Acad. Sci. USA. 
79: 2836-2839. 
Bar-Sagi D. and Feramisco J. R. (1985) Microinjection of the ras oncogene protein 
into PC 12 cells induces morphological differentiation. Cell 42: 841-848 
Bar-Sagi D., Fernandez A. and Feramisco J. R. (1987). Regulation of membrane 
turnover by ras proteins. Bioscience Reports 7: 427-433. 
Bar-Sagi D. (1989). Ras proteins: Biological effects and biochemical targets. 
Anticancer Res. 9: 1427-1438. 
Beart R. W., Melton L. J., Maruta MI, et al. (1983). Trends in right and left-sided 
colon cancer. Dis. Colon Rectum 26: 393-398. 
Beauchamp R. D., Townsend C. M. Jr., Singh P., et al. (1985). Progitimide, a gastrin 
receptor antagonist inhibits the growth colon cancer and enhances urvival in mice, 
Ann. Surg. 202: 303-309. 
Beavo J. A., Betchel P. J. and Krebbs E. G. (1974). Activation of protein kinase by 
physiological concentrations of cyclic AMP. Proc. NatI. Acad. Sci. USA 71: 3580- 
3583. 
Beckner S. K. (1984). Decreased adenylate cyclase responsiveness of transformed 
cells correlates with the presence of a viral transforming protein. FEBS Lett. 
166: 170-176. 
Beckner S. K., Hattori S. and Shih T. Y. (1985) The ras oncogene product is not a 
regulatory component of adenylate cyclase. Nature 317: 71-73. 
Beebe S-J., Holloway R., Rannels S. R., and Corbin J. D. (1984). Two classes of 
cAMP analogues which are selective for two different cAMP binding sites of type 11 
protein kinase demonstrate synergism when added together to intact adipocytes. J. 
Mot. Chem. 259: 3539-3547. 
Beebe S. J. and Corbin J. D. (1986). Cyclic n ucleot ide-de pendent protein kinases. In: 
The Enzymes; control by phosphorylation, part A, vol 17. Eds. Boyer P. D. and Krebs 
E. G. Academic, New York. 
239 
Beebe SI, Koch S. R., Chu D. M., et al. (1987). Regulation of phosphopyruvate 
carboxylase gene transcription in H41 IE hepatorna cells - evidence for a primary role 0 of the catalytic sub-unit of 3'5'-cyclic adenosine monophosphate -dependent protein kinase. Afol. Endocrinol. 1: 639-647. 
Berry A. R., Souter R. G., Campbell W. B., et al. (1990). Endoscopic trans-anal 
resection of rectal turnours -a preliminary report of its use. Br. J. Surg. 77-134-137. 
Beynon J., Mortensen N. J. McC.. et al. (1989). Preoperative assessement of 
mesorectal lymphnode involovement in rectal cancer. Br. J. Surg. 76: 276-279. 
Bhatnagar D., Burton A. A. and Roskoski R. (1988). Differential sensitivity of neural 
and non-neural protein kinase isoenzymes to cyclic AMP. Biochem. Biopkv. v. Res. 
Comm. 156: 801-806. 
Birchmeier C., Brock D. and Wigler M. (1985). RAS proteins can induce meiosis in 
Xenopus oocytes. Cell 43: 615-621. 
Bizzozero G. (1894). Growth and regeneration of the organism. Br. Med, J. 028- 
730. 
Black W. A. and Waugh J. M. (1948). The intramural extension of carcinoma of the 
descending colon, sigmoid, and rectosigmoid. Surg. Obstet. Gynaecol. 87: 457-464. 
Bleiberg H. and Galand P. (1976). In vitro autoradiographic determination of cell 
kinetic parameters in adenocarcinomas and adjacent healthy mucosa of the human 
colon and rectum. Cancer Res. 36: 325-328. 
Blomhoff H. K., Smeland E. B., Beiske K., et al. (1987). Cyclic AMP-mediated 
suppression of normal and neoplastic B cell proliferation is associated with regulation 
of nkvc and Ha-ras protooncogenes. J. Cell. Pkvsiol. 131: 426-433. 
Blosser J. C. and Appel S. H. (1980). Regulation of acetylcholine receptor by cyclic 
AMP. J. Biol. Chem. 255: 1235-1238. 
Bockhus H. L., Tachdjian V., Ferguson L. K., et al. (1961). Adenomatous polyps of 
the colon and rectum: its relation to carcinoma. Gastroenterology 41: 225-232. 
Bodmer W. F., Bailey U., Bodmer J., et al. (1987). Localization of the gene for 
familial adenomatous polyposis on chromosome 5. Nature 328: 614-616. 
Bombi J. A. (1988). Polyps of the colon in Barcelona, Spain. An autopsy study. 
Cancer 61: 1472-1476. 
Bomszstyk K., Toivola B., Emery D. A., et al. (1990). Role of cAMP in interleukin- 
1-induced k light chain gene expression in murine B cell line. J. Biol. Chein. 
26S: 9413-9417. 
Boney C., Fink D., Schlicter D., et al. (1983). Direct evidence that the protein kinase 
catalytic subunit mediates the effects of cAMP on tyrosine aminotransferase synthesis. 
J. Blol. Chem. 258: 4911-4918 
Bork-je B., Hostmark J., Skagen D. W., el al. (1987). Flow cytometry of biopsy 
specimens from ulcerative colitis, colorectal adenomas, and carcinomas. Scand. J. Gastroenterol. 22: 1231-1237. 
240 
Bos U., Fearon E. R., Hamilton S. R., et al. (1987). Prevalence of ras gene 
mutations in human colorectal cancers. Nature 327: 293-297. 
Bourne H. R. (1987) Discovery of a new oncogene in pituitary turnours. Nature 
330: 517-518. 
Bouvier M., Collins S., O'Dowd B. F., et al. (1989). Two distinct pathways for 
cAMP-mediated down-regulation of the P2-adrenergic receptor. J. Biol. Chem. 
264: 16786-16792. 
Boyle P., Zaridze D. G. and Smans M. (1985). Descriptive epidemiology of colorectal 
cancer. Int. J. Cancer 36: 9- 18. 
Boynton A. L. and Whitfield IF (1980). A possible involvement of type 11 cAMP- 
dependent protein kinase in the initiation of DNA synthesis by rat liver cells. Exp. 
Cell. Res. 126: 477-482. 
Boynton A. L., Whitfield J. F., MacManus J. P., et al. (1981). Involvement of cAMP 
and cAMP-dependent protein kinase in the initiation of DNA synthesis by rat liver 
cel Is. Exp. Cell Res. 135: 199-211. 
Boynton A. L. and Whitfield J. F. (1983). The role of cyclic AMP in cell proliferation: 
a critical assessment of the evidence. Adv. Cyclic Nucleotide Res. 15: 193-294. 
Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 
72: 248-53 
Bradley SJ., Garfinkle G., Walker E., et al. (1986). Increased expression of the 
epidermal growth factor receptor on human colon carcinoma cells. Arch. Surg. 
121: 1242-1247. 
Brahme F., Ekelund G. R., Norden J. G. and Wenckert A. (1974). Metachronous 
colo-rectal polyps: comparison of development of colorectal polyps and carcinomas in 
persons with and without histories of polyps. Dis. Colon Rectum 17: 166-171. 
Bravo R., Neuberg M., Burckhardt J., et al. (1987). Involvement of common and 
cell-type specific pathways in c-jos gene control: stable induction by cAMP in 
macrophages. Cell 48: 251-260. 
Bregman D. B., Bhattacharyya N. and Rubin C. S. (1989). High affinity binding 
protein for the regulatory subunit of cAMP-dependent protein kinase II. B. J. Riol. 
Chem. 264: 4648-4656. 
Bresalier R. S. and Yim Y. S. (1985): Diet and colon cancer (editorial). N. Eng. J. 
Med. 313: 1413-1414. 
Bresalier R. S., Boland C. R. and Kim Y. S. (1985). Regional differences in normal 
and cancer-associated glycoconjugates of the human colon. J. Nall. Cancer. Inst. 
75: 249-53. 
Bringhurst F. R., Zajac J. D., GDaggett A. S.. et al. (1989). Inhibition of parathyroid 
hormone responsiveness in clonal ostcoblastic ells expressing a mutant form of 3': S- 
cyclic adenosine monophosphate-dependent protein kinase. A161. Endocrinol. 3: 60- 
67. 
241 
Brion D. E., Raynaud F., Piet A., et al. (1986). Deficiency of cyclic AMP-dependent 
protein kinases in psoriasis. Proc. Natl. Acad. Sci. USA 83: 5272-5276. 
Bristol J. B., Emmet P. M., Heaton K. W. and Williamson R. C. N. (1985). Sugar, fat 
and the risk of colorectal cancer. Br. Afed. J. 291: 1467-1470. 
Broek D., Samiy N., Fasano 0., et A (1985) Differential activation of yeast adenyl 
cyclase by wild-type and mutant RAS proteins. Cell 4,1: 763-9. 
Brown H. D., Chattopadhyay S. K., Morris H. P. and Pennington S. N. (1970). 
Adenyl cyclase activity in Morris hepatomas 7777,7794A and 9618A. Cancer Res. 
30: 123-126. 
Brown N. A., Stofko R. E. and Uhler M. D. (1990). Induction of alkaline phosphatase 
in mouse L cells by overexpression of the catalytic subunit of cAMP-dependent 
protein kinase. J. Biol. Chem. 265. -13181-13189. 
Brown P. C. and Papaconstantinou J. (1979). Co-ordinated modulation of albumen 
synthesis and mRNA levels in cultured hepatoma cells by hydrocortisone and cyclic 
AMP analogues. J. Biol. Chem. 254: 9379-9384. 
Brown T-A and DeLuca H. F. (1990) Phosphorylation of the 1,25-dihydroxyvitamin 
D3 receptor. J. Biol. Chem. 265: 10025-10029, 
Browning M. D., Bureau M., Dudek E. M. and Olsen R. W. (1990). Protein kinase C 
and cAMP-dependent protein kinase phosphorylate the P-subunit of the purified y- 
amino-butyric acid A receptor. Proc. Natl. Acad. Sci USA 87: 1315-1318. 
Bubis I and Taylor S. S. (1987). Correlation of photolabelling with occupancy of 
cAMP binding sites in the regulatory sub-unit of cAMP-dependent protein kinase. 
Biochemistry 26: 3478-3486. 
Buchler W., Walter U., Jastorff B. and Lohmann S. M. (1988). Catalytic subunit of 
cAMP-dependent protein kinase is essential for cAMP-mediated mammalian gene 
expression. FEBS Lett. 228: 27-32. 
Buick R. N., Filmus J. and Quaroni A. (1987). Activated H-ras transforms rat 
intestinal epithelial cells with expression of TGF. Erp. Cell Res. 170: 300-309. 
Builder S. E., Beavo J. A. and Krebs E. G. (1980). Stoichiometry of cAMP and 1, N6- 
etheno-cAMP binding to protein kinase. J. Biol. Chem. 255: 2350-2354. 
Bulow S., Svendsen L. B. and Mellemgaard A. (1990). Metachronous colorectal 
carcinoma. Br. J. Surg. 77: 502-505. 
Burmer G. C. and Loeb L. A. (1999). Mutations in the K-ras-2 oncogene during 
progressive stages of human colon carcinoma. Proc. Nail. Acad. Scl. USA 86: 24,03- 
2407. 
Burt R. W., Bishop D. T., Cannon L. A., el al. (1985). Dominant inheritance of 
adenomatous colonic polyps and colorectal carcinoma. N. Eng. J. Med. 312: 1540- 
1544. 
242 
Butcher D., Hassanein K., Dudgeon M., et al. (1985). Female gender is a major 
determinant of changing subsite distribution of colorectal cancer with age. Cancer 
56: 714-716. 
Butcher F. R., Scott D. F., Potter V. R. and Morris H. P. (1972). Endocrine control of 
cyclic adenosine 3', 5'-monophosphate levels in several Morris hepatomas. Cancer 
Res. 32: 2135-2140. 
Butley M. S., Beer D. G. and Malkinson A. M. (1984). Functional changes in the 
regulatory sub-unit of the t pe I cyclic adenosine 31,5'-mono phosphate dependent 0y protein kinase isoenzyme during normal and neoplastic lung development. Cancer 
Res. 44: 2689-2697. 
Butley M. S., Stoner G. D., Beer D. G., et al. (1985). Changes in cyclic adenosine 
3', 5'-monophosphate dependent protein kinases during the progression of urethan- 
induced mouse lung tumors. Cancer Res. 45: 3677-3685. 
Buxbaurn J. D. and Dudai Y. (1989). A quantitative model for the kinetics of cAMP- 
dependent protein kinase (type H) activity. J. Biol. Chem. 264: 9344-9351. 
Byus C. V., Chubb J. M., Huxtable R. J. and Russell D. H. (1976). Increase in type I 
adenosine 3'5'-monophosphate-dependent protein kinase during isoproterenol- 
induced cardiac hypertrophy. Blochem. Biopkys. Res. Commun. 73: 694-702. 
Byus C. V., Hedge G. A. and Russell D. H. (1977). The involvement of cyclic AMP- 
dependent protein kinase(s) in the induction of ornithine decarboxylase in the 
regenerating rat liver and in the adrenal gland after unilateral adrenalectomy. Biochim 
Biopkys. Acta 498: 39-45. 
Byus C. V. and Fletcher W. H. (1982). Direct cytochemical localization of catalytic 
sub-units dissociated from cAMP-dependent protein kinase in Reuber H-35 hepatoma 
cells. It. Temporal and spatial kinetics. J. Cell. Biol. 93: 727-734. 
243 
C 
Cales C., Hancock U., Marshall C. J. and Hall A. (1988). The cytoplasmic protein 
GAP is implicated as the target for regulation by the ras g 
332: 548-550. , 
ene product. Nature 
Campisi J., Gray H. E., Pardee A. B., et al. (1984). Cell-cycle control of c-mYc but 
not c-rav expression is lost following chemical transformation. Cell 36: 241-247. 
Canivet J-L., Damas P., Desaive C. and Lamy M. (1989). Operative mortality 
following surgery for colorectal cancer. Br. J. Surg. 76-745-747. 
Cannon-Albright L. A., Skolnick M. H., Bishop T., et al. (1988). Common 
inheritance of succeptibility to colonic adenomatous polyps and associated colorectal 
cancers. N. Eng. J. Aled. 319: 533-537. 
Capasso J. M., Abeijon C., Hirschberg C. B. (1985). Phosphoproteins and protein 
kinases of the Gogi apparatus membrane. J. BIN Chem. 260: 14879-14884. 
Capon D. J., Chen E. Y., Levinson A. D., et at. (1983a). Complete nucleotide 
sequences of the T24 human bladder carcinoma oncogene and its normal homologue. 
Nature 302: 33-35 
Capon D. J., Seeburg P. H., McGrath J. P., et al. (1983b). Activation of Ki-ras-2 gene 
in human colon and lung carcinomas by two different point mutations. Nature 
304: 507-510. 
Carchman R. A., Johnson G. S. and Pastan 1. (1974). Studies on the levels of cyclic 
AMP in cells transformed by wild-type and temperature-sensitive Kirsten sarcoma 
virus. Cell 1: 76-79. 
Carmichael D. F., Geahlen R. L., Allen S. M. and Krebs E. G. (1982). Type 11 
regulatory subunit of cAMP-dependent protein kinase. J. Biol. Chem. 257: 10440- 
10445. 
Carpenter G. and Cohen S. (1990). Epidermal growth factor. J. Biol. Chem. 
265: 7709-12 
Chan D., Goate A. and Puck T. T. (1989). Involvement of vimentin in the reverse 
transformation reaction. Proc. Nad. Acad. Sci. USA 86: 2747-2751. 
Chayoth R., Epstein S. and Field J. B. (1972). Increased cAMP levels in malignant 
hepatic nodules of ethionine treated rats. Blochem. Biqpkys. Res. Comm. 49: 1663- 
1670. 
Chen Z-Q., Ulsh L. S., DuBois G. and Thomas T. Y. (1985). Post-translational 
processing of p2l ras proteins involves palmitylation of the C-terminal tetrapeptide 
containing cysteine- 186. J. Virol. 56: 607-612. 
Chcng H. C., Van Patten S. M., Smith AJ. and Walsh D. A. (1985). An active twenty 
amino acid residue peptide derived from the inhibitor protein of cyclic-AMP dependent 
protein kinase. Biochem J. 231: 655-661. 
244 
Cheng H. C., Kemp B. E., Pearson R. B., et al. (1986). A potent synthetic peptide 
inhibitor of the cAMP-dependent, protein kinase. J. Biol. Chem. 261: 989-992. 
Chesa P. G., Rettio W. J., Melamed M. R., et al. (1987). Expression of p2l-ras in 0 normal and malignant tissues. Lack of association with proliferation and malignancy. 
Proc. Natl. Acad. Sci. USA 84: 3234-3238. 
Chiarugi V., Porciatti F., Pasquall F. and Bruni P. (1985). Transformation of 
Balb/3T3 Cells with FJ/T24/H-rus oncogene inhibits adenylate response to P- 
adrenergic agonists while increases muscarinic receptor dependent hydrolysis of 
inositol lipids. Blochem. Blophys. Res. Comm. 132: 900-907 
Chiarugi V. P., Pasquali F., Vannuchi S. and Ruggiero M. (1986). Point-mutated p2l 
ras couples a muscarinic receptor to calcium channels and polyphosphoinositide 
synthesis. Blochem. Blophys. Res. Comm. 141: 591-599. 
Cho-Chung Y. S., Clair T., Yi P. N. and Parkison C. (1977). Comparative studies on 
cyclic AMP binding and protein kinase in cyclic AMP-responsive and -unresponsive Walker 256 Mammary Carcinomas. J. Biol. Chem. 252: 6335-6341. 
Cho-Chung Y. S., Tortora G. and Clair T. (1988). Nuclear location signal and nuclear 
translocation of type If protein kinase regulatory sub-unit in site-selective cAMP 
analog-induced growth control and differentiation. J. Cell. Biol. 107: 492a. 
Cho-Chung Y-S. (1989). Site-selective 8-chloro-cyclic adenosine 3,5'- 
monophosphate as a biologic modulator of cancer: restoration of normal control 
mechanisms. JNCI 81: 982-987. 
Cho-Chung Y. S., Clair T., Tagliaferri P.. et al. (1989). Site-selective cyclic AMP 
analogs as new biological tools in growth control, differentiation and proto-oncogene 
regulation. Cancer Invest. 7: 161-177. 
Ciardiello F., Tortora G., Kim N, et al. (1990). 8-chloro-cAMP inhibits transforming 
growth factor a transformation of mammary epithelial cells by restoration of the 
normal rnRNA patterns for cAMP-dependent protein kinase regulatory subunit 
isoforms which show disruption upon transformation. J. Biol. Chem. 265: 1016- 
1020. 
Cimbala M. A., Lamers W. H., Nelson K., et al. (1982). Rapid changes in the 
concentration of phosphoenolpyruvate carboxykinase mRNA in rat liver and kidney. 
I Biol. Chem. 257: 7629-7636. 
Clair T. and Cho-Chung Y. S. (1979). Role of cyclic adenosine 3'5'-monophosphate 
receptor protein in honnone-dependent marnmary tumour regression. Fed. Proc. 
38: 332. 
Clair T., Ally S., Tagliaferri P., et al. (1987). Site-selective cAMP analogs induce 
nuclear translocation of R11 cAMP receptor protein in Ha-MuSV-transformed 
NlIi/3T3 cells. Febs Lett. 224: 377-384. 
Clair T., Miller W. R. and Cho-Chung Y. S. (1987). Prognostic significance of the 
expression of a ras protein with a molecular weight of 21,000 by human breast 
cancer. Cancer Res. 47: 5290-5293. 
245 
Clarke P. R. and Hardie D. G. (1990). Regulation of HMG-CoA reductase. 
identification of the site phosphorylated by the AMP-activated protein kinase in vitro 
and in intact rat liver. EAIBO J. 9: 2439-2446. 
Claycomb W. C. (1975). Biochemical aspects of cardiac muscle differentiation. J. 
Biol. Chem. 2SO: 3229-3235. 
Clego C. H, Correll L. A., Cadd G. G. and McKnight G. S. (1987). Inhibition of intra- I "ý' cellular cAMP dependent protein kinase using mutant genes of the regulatory type I 
sub-unit. J. BIN. Chem. 262: 13111-13119. 
Clegg C. H., Cadd G. G., and McKight G. S. (1988). Genetic characterization of a 
brain-specific form of the type I regulatory subunit of cAMP-dependent protein 
kinase. Proc. Nad. Acad. Sci. USA 85: 3703-3707. 
Clegg C. H., Ran W., Uhler M. D. and McKnight G. S. (1989), A mutation in the 
catalytic subunit of protein kinase A prevents myristylation but does not inhibit 
biological activity. J. Blol. Chem. 264: 20140-20146. tý 
Cobb C. E., Beth A. H. and Corbin J. D. (1987). Purification and characterization of an 
inactive form of cAMP dependent protein kinase containing bound cAMP. J. Mot. 
Chem. 262: 16566-16574. 
Cochet C., Gill G. N.. Meisenhelder J., et al. (1984). C-kinase phosphorylates the 
epidermal growth factor receptor and reduces its epidermal growth factor stimulated 
protein kinase activity. J. Blol. Chem. 259: 2553-2558. 
Cockcroft S. (1987). Polyphosphoinositide phosphodiesterase: regulation by a novel 
guanine nucleotide binding protein Gp. TIBS 4: 23-28 
Coffey R. J., Shipley G. D. and Moses H. L. (1986). Production of transforming 
growth factors by human colon cancer cell lines. Cancer Res. 46: 1164-1169. 
Coffey R. J. Jr., Goustin A. S., Soderquist A. C., et al. (1987). Transforming growth 
factor a and P expression in human colon cancer cell lines: implications for an 
autocrine model. Cancer Res. 47: 4590-4594. 
Colicelli J., Birchmeier C., Michaeli T., el al. (1989). Isolation and characterization 
of a mammalian gene encoding a high-affinity cAMP phosphodiesterase. Proc. Nall. 
Acad. Scl. USA 86: 3599-3603. 
Collins S., Caron M. G. and Lefkowitz R. J. (1988). 02-adrenergic receptors in 
hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. J Biol. 
Chem. 263: 9067-9070. 
Collins S., Bouvier M., Bolanowski M. A., et al. (1989). cAMP stimulates 
transcription of the P2-adrenergic receptor gene in response to short-term agonist 
exposure. Proc. Nati. Acad. Sci. USA 86: 4853-4857. 
Combest W. L., Chiasson R. B. and Russell D. H. (1980). Alterations in type I and 
type 11 protein kinases in the thyroid and adenohypophysis in response to a dietary 
, goitrogen. Gen. Comp. Endocrinol. 40: 494-502. 
246 
Combest W. L. and Russell D. H. (1983). Alteration in cyclic AMP-dependent protein 
kinases and polyamine biosynthetic enzymes during hypertrophy and hyperplasia of 
the thyroid in the rat. A161. Pharmacol. 23: 641-647. 
Connelly P. A., Hastings T. G. and Reimann E. M. (1996). Identification of a ternary 
complex between cAMP and a trimeric form of cAMP-dependent protein kinase. J. 
Biol. Chem. 261: 2325-2330. 
Conti M., Geremia R., Adamo S. and Stefanini A. (1981). Regulation of Sertoli cell 
adenosine 3': 5' monophosphate phosphodi este rase by follicle stimulating hormone 
and dibutryl cyclic AMP. Biochem. Biopkvs. Res. Comm. 98: 1044-50 
Coode P. E., Chan K. W. and Chan Y. T. (1985). Polyps and diverticula of the large 
bowel: a necropsy survey in Hong Kong. Gut 26: 1045-1048. 
Corasanti J. G., Celik C., Camiolo S. M., et at. (1980). Plasminogen activator content 
of human colon turnours and normal mucosae: separation of enzymes and partial 
purification. JNCI 65: 345-351. 
Corbin J. D., Soderling T. R. and Park C. R. (1973). Regulation of Adenosine 3': S- 
Monophosphate-dependent Protein Kinase. J. Biol. Chem. 248: 1813-182 1. 
Corbin J. D., Keely S. L. and Park C. R. (1975), The distribution and dissociation of 
cyclic adenosine 3'5'-monophosp hate dependent protein kinases in adipose, cardiac 
and other tissues. J. Not Chem. 250: 218-225. 
Corbin J. D., Sugden P. H., Lincoln T. M. and Keely S. L. (1977). Comp- 
artmentalization of adenosine 3'5'-monophosphate and adenosine 3'5'- 
monophosphate dependent protein kinase in heart tissue. J. Blol. Chein. 2S2: 3854- 
3861. 
Corbin J. D. and Keely S. L. (1977). Characterization and regulation of heart 
adenosine 3'5'-monophosphate dependent protein kinase, isoenzymes. J. Blol. Chem. 
252: 910-918. 
Corbin I. D. and Lincoln T. M. (1978). Comparison of cAMP- and cGMP-dependent 
protein kinases. Adv. Cyclic Nuckotide Res. 9: 159-170. 
Corbin J. D., Rannels S. R., Flockhart D. A., et al. (1982). Effect of cyclic nucleotide 
analogues on intrachain site I of protein kinase isoenzYmes. Eur. J, Blochem. 
125: 259-266. 
Corbin J. D., Beebe SJ. and Blackmore RE (1985). cAMP-dependent protein kinase 
activation lowers hepatocyte cAMP. J. Biol. Chein. 260: 8731-8735. 
Cordon-Cardo C., Lloyd K. O., Sakamoto J., el al. (1986). Immunohistologic 
expression of blood group antigens in normal human gastrointestinal tract and colonic 
carcinoma. Int. J. Cancer 37: 667-676. 
Cori G. T. and Cori C. F. (1945). The enzymatic conversion of phosphorylasc a to b. J. Biol. Chem. 158: 321-332. 
Correa P. and Haenszel W. (19778). The epidemiology of large bowel cancer. Adv. Cancer Res. 26: 1-141. 
247 
Correa P., Strong J. P. and Reif A. (1977). The epidemiology of colorectal polyps: 
Ppevalence in New Orleans and international comparisons. Cancer 38: 2258-2264. 
Correll L. A., Woodford T. A., Corbin J. D., et al. (1989). Functional characterization 
of cAMP-binding mutations in type I protein kinase. J. Biol. Chem. 264*. 16672- 
16678. 
Costa M., Gerner E. W. and Russell D. H. (1976). GI specific increase in cAMP and 
protein kinase activity. Biochem. Biophys. Acta 425: 246-255. 
Covett E. (1976). Family studies in cancer of the colon and rectum. Int. J. Surg. 
63: 13-18. 
Craven P. A. and DeRubertis F. R. (1980). Cyclic AMP metabolism in colonic 
epithelial cells with different proliferative activity (abstract). Clin. Res. 28: 274A. 
Craven P. A. and DeRubertis F. R. (1981). Cyclic nucleotide metabolism of rat colonic 
epithelial cells with different proliferative activities. Biochim. Biophys. Acta 
676: 155-169. 
Culouscou J-M., Remacle-Bonnet M. and Garrouste F. (1987). Simultaneous 
production of IGF-l and EGF competing growth factors by HT-29 human colon 
cancer cell line. Int. J. Cancer 40: 646-652. 
Culouscou J-M., Remacle-Bonnet M., Garbouste F., et al. (1990). Production of 
Insulin-Like Growch Factor If (IGF-110 and different forms of IGF-binding proteins 
by HT-29 human Colon carcinoma cell line. J. Cell. Pkvslol. 143: 405-415. 
Curren R. D., Putman D. L., Yang L. L., el al. (1987). Genotoxicity of faecapentaene- 
12 in bacterial and mammalian cell assay systems, Carcinogenesis 8: 349-352. 
248 
D 
Damon D. H., D'Amore P. A. and Wagner J. A. (1990). Nerve Growth Factor and 
Fibroblast Growth Factor regulate neurite outgrowth and gene expression in PC 12 
cells via both protein kinase C- and cAMP-independent mechanisms. J. Cell Blol. 
110: 1333-1339. 
Dano K., Andreasen P. A., Grondahl-Hansen J., et al. (1985). Plasminogen 
activators, tissue degradation and cancer. Adv. Cancer Res. 44: 139-266. 
Davidson M., Yoshizawa C. N. and Kolonel L. N. (1985). Do sex hormones effect 
colorectal cancer? Br. Med. J. 290: IW 
Davis F. G., Furner S. E., Persey V. and Koch A (1989). The influence of parity and 
exogenous female hormones on the risk of colorectal cancer. Int. J. Cancer 43: 587- 
590 
Dawson P. A. and Filipe M. I. (1976). An ultrastructural and histochemical study of 
the mucous membrane adjacent to and remote from carcinoma of the colon. Cancer 
37: 2388-2398. 
Day D. W. (1984). The adenoma-carcinoma sequence. Scand. J. Gastroenterol. 19 
(Suppl 104): 99-107. 
Day R. N., WaIder J. A., and Maurer R. A. (1989). A protein kinase inhibitor gene 
reduces both basal and multi-hormone-sti mutated prolactin gene transcription. J. Biol. 
Chem. 264: 431-436. 
Dean D. C., McQuillan J. J. and Weintraub S. (1990). Serum stimulation of fibronectin 
gene expression appears to result from rapid serum-induced binding of nuclear 0 proteins to a cAMP response element. J. Biol. Chem. 265: 3522-3527. 
De Biasi F., Sal G. D. and Hand P. H. (1989). Evidence for enhancement of the ras 
oncogene protein product (p2l) in a spectrum of human turnours. Int. J. Cancer 
43: 431-435. 
DeBruin P. A., Griffloen G., Verspaget H. W., et al. (1987). Plasminogen activators 
and tumor development in the human colon: activity levels in normal mucosa, 
adenomatous polyps, and adenocarcino mas. Cancer Res. 47: 4654-4657 
DeBruin P. A., Verspaget H. W., Gfiffloen G., et al. (1987). Plasminogen activator 
activity and composition in human colorectal carcinomas. Fibrinoýysls 1: 57-62. 
DeCamilli P., Moretti M., Donini S. D., et al. (1986). Heterogeneous distribution of 
the cAMP receptor protein R11 in the nervous system: evidence for its intra-cellular 
accumulation on microtubules, micro-tubule organizing centres, and in the area of the 
golgi complex. J. Cell. Blol. 103: 199-203. 0 
DeCosse JJ. (1984). Malignant colorectal polyps. Gut 25-. 433-436, 
DeCosse J. J. (1982):. Potential for chemoprevention. Cancer 50: 2550-2553. 
DeCosse J. J. (1988). Early cancer detection. Colorectal cancer. Cancer 62: 1787- 
1790. 
249 
De Crombrugghe B., Busby S. and Buc H. (1984). Cyclic AMP receptor protein: role V in transcription activation. Science 224: 831-35 
DeFeo-Jones G. (1985). Mammalian and yeast ras gene products: biological function 
in their heterologous systems. Science 228: 179-82 
DeJonge H. R. and Rosen O. M. (1977). Self-phosphorylation of cyclic guanosine 
3'5'-monophosphate dependent protein kinase from bovine lung. J. Biol. Chem. 
252: 2780-2783. 
DeLuca H. F. and Ostrern V. (1987) The relationship between the vitamin D system 
and cancer. Adv. Exp. Med. Biol. 206: 413-429. 
Der C. J., Krontiris T. J. and Cooper G. M. (1982). Transforming genes of human 
bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and 
Kirsten sarcoma viruses. Proc. Nati. Acad. Sci. USA 79: 3637-40. 
Dere W. H., Hirayu H. and Rappaport B. (1986). Thyrotropin and cyclic AMP 
regulation of ras proto-oncogene xpression in cultured thyroid cells FEBS Lett. 
196: 305-308. 
DeRubertis F. R., Chayoth R. and Field J. B. (1976). The content and metabolism of 
cyclic adenosine YS monophosphate and cyclic guanosine 3'5' monophosphate, in in 
adenocarcinorna of the human colon. J. Clin. Invest. 57: 641-649. 
DeRubertis F. R. and Craven P. A. (1980). Early alterations in rat colonic mucosal 
cyclic nucleotide metabolism and protein kinase activity induced by 1,2- 
dimethy1hydrazine. Cancer Res. 40: 4589-4598. 
DeRubertis F. R. and Craven P. A. (1987). Relationship of bile salt stimulation of 
colonic epithelial phospholipid turnover and proliferative activity: role of activation of 
protein kinase C. Prev. Afed. 16: 572-579. 
Dery C., Cooper S., Savageau M. A. pand Scanlon S. (1979). Identification and 
characterization of the cAMP binding Proteins of yeast by photoaffinity labeling. 
Blochem. Biopkvs. Res. Comm. 90: 933-939. 
Derynck R., Goeddle D. V. and Ullrich A. (1987). Synthesis of messenger RNA's for 
transforming growth factor ce and P and the epidermal growth factor receptor by 
human turnours. Cancer Res. 47: 707-712. 
Deschner E. E. and Lipkin M. (1966). An autoradiographic study of the renewal of 
argentaffin, cells in human rectal mucosa. Exp. Cell Res. 43: 661-665. 
Deschner E. E., Lewis C. M. and Lipkin M. (1963). In vitro study of human rectal 
epithelial cells. 1. Atypical zone of thymidine 3H incorporation in mucosa, of multiple 
polyposis. J. Clin. Invest. 42: 1922-1928. 
Deschner E. E. and Lipkin M. (1975). Proliferative patterns in colonic mucosa in familial polyposis. Cancer 35: 413-418. 
Deschner E. E., Winawer S. I., Katz S. and Kahn E. (1983). Proliferative defects in 
ulcerative colitis patients. Cancer Invest. 1: 4147. 
250 
Deschner E. E. (1983). Adenomas: preneoplastic events, growth and development in 
man and experimental systems. Pathol. Ann. 18: 205-219. 
Deschner E. E., Long F. C., Hakissan M. and Cupo S. H. (1984). Differential 
succeptibilty of inbred mouse strains forecast by acute colonic proliferative response to 
methylazoxymethanol. JNCI 72: 195-198. c 
Deschner E. E. (1987), Cell turnover and colon tumour development. Prev. Med. 
16: 580-585, 
Deschner E. E., Gobold J. and Lynch H. T. (1988). Rectal epithelial cell proliferation 
in a group of young adults. Cancer 61: 2286-2290. 
Deschner E. E., Long F. and Hakissian M. (1988). Susceptibility to 1,2- 
dimethy1hydrazine-induced colonic turnours and epithelial cell proliferation 
characteristics of Fl, F2, and reciprocal backcrosses derived from SWR/J and AKR/J 
parental mouse strains. Cancer 61: 478-482. 
Deshpande A. K. and Kung H-F. (1987). Insulin induction of Xenopus laevis oocyte 
maturation is inhibited by monoclonal antibody against p2l ras proteins. Mol. Cell. 
Biol. 7: 1285-88. 
Desigan G., Wang M., Alberti-Flor J., et al. (1985). De novo carcinoma of the 
rectum: a case report. Am. J. Gastroenterol. 80: 553-554. 
Deutsch P. J., Hoeffler J. P.. Jameson J. L. and Habener J. F. (1988). Cyclic AMP and 
phorbol ester-stimulated transciption mediated by similar DNA elements that bind 
distinct proteins. Proc. Natl. Acad. Sci. USA 85: 7922-7926. 
Deutsch P. J., Sun Y., and Kroog G. S. (1990). Vasoactive Intestinal Peptide 
increases intracellular cAMP and gonadotrophin-a gene activity in JEG-3 syncytial 
trophoblasts. J. Biol. Chem. 265: 10274-10281. 
De Vos A. M., Tong L., Milburn M. V., et al. (1988). Three-dimensional structure of 
an oncogene protein: catalytic domain of human c-H-ras p2l. Science 239: 888-893. 
Dickson C. and Pters G. (1987). Potential oncogene products related to growth 
factors (letter). Nature 326: 833. 
Dimino MJ., Bieszczad R. R. and Rowe M. J. (1981). Cyclic AMP-dependent protein 
kinase in mitichondria and cytosol from different sized follicles and corpora lutea of 
porcine ovaries. J. Biol. Chem. 256: 10876-10882. 
Dixon B. S., Breckon R., Kachny M. M., et al. (1990). Histidine regulation of cyclic 
AMP metabolism in cultured renal epithelial LLC-PKI cells. J. Biol. Chem. 265-. 760- 
766. 
Dockray G. J. Vaillant C. and Walsh J. H. (1979). The neuronal origin of Bombesin- 
like immunoreactivity in the rat gastro-intestinal tract. Neurosclence 4: 1561-1568. 
Doherty P. J., Tsao J., Schimmer BY, el al. (1982). Alteration of the regulatory 
subunit of type I cAMP-dependent protein kinase in mutant YI adrenal cells resistant 
to 8-bromoadenosine 3': 5-monophosphate. J. Blol. Chein. 257: 5877-5883. 
251 
Dohlman H. G., Caron M. G. and Leefkowitz RIA. (1987). A family of receptors 
coupled to guanine nucleotide regulatory proteins. Biochemistry 26: 2657-2664. 
Doskeland S. O. and Ueland P. M. (1975). A cAMP Receptor from mouse liver 
cytosol whose binding capacity is enhanced by Mg++-ATP. Biochem. Biopikys. Res. 
Comm. 66: 606-611. 
Doskeland S. O., Ueland P. M. and Haga H. J. (1977). Factors affecting binding of 
13HI adenosine 3', 5'-cyclic monophosphate to protein kinase from bovine adrenal 
cortex. Biochem J. 161: 653-665. 
Doskeland S. O. (1978). Evidence that rabbit muscle protein kinase, has two kinetically 
distinct binding sites for adenosine TS - cyclic monophosphate. Blochein. Bioplkys. 
Res. Commun. 83: 542-549. 
Doskeland S. O. and Ogreid D. (1981). Binding proteins for cyclic AMP in 
mammalian tissues. Int. J. Biochem. 13: 1-19. 
Dostmann W. R. G., Taylor S. S., Genieser H-G., el at. (1990) Probing the cyclic 
nucleotide binding sites of cAMP-dependent protein kinases I and 11 with analogs of 
adenosine 3', 5'-cyclic phosphodiesterases. J. Blot. Chem. 265: 10484-1049 1. 
Dreyfuss G., Schwartz K. J. and Blout E. R. 0978). Compartmentalization of cyclic 
AMP-dependent protein kinases in human erythrocytes. Proc. Nad. Acad. Scl. USA 
75: 5926-5930. 
Droms K. and Sueoka N. (1989). Cell-type-specific responses of RT4 neural cell 
lines to dibutryl-cAMP: branch determination versus maturation. Proc. Nad. Acad. 
Scl. USA 84: 1309-1313. 
Droms K. A., Haley BE, Smith G. J. and Malkinson A. M. (1989). Decreased 8-N3- 
[32pl-GTP photolabeling of Gs-a in turnorigenic lung cpithelial cell lines: association 
with decreased hormone responsiveness and loss of contact-inhibitcd growth. Exp- 
Cell. Res. 182: 330-339. 
Druker B. J., Mamon H. J. and Roberts T. M. (1989). Oncogenes, growth factors and 
signal Transduction. N. Eng. J. AIed. 321: 1383-1390 
Druckner D. J., Philippe J., Moj-sov S., et al. (1987). Glucagon-like peptide I 
stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell 
line. Proc. Nall. Acad. Sci, USA 84: 3434-3438, 
Druckner D. J. and Brubaker P. L. (1989). Proglucagon gene expression is regulated 
by a cyclic AMP-dependent pathway in rat intestine. Proc. NatI. Acad. Sci. USA 
86: 3953-3957. 
Dudai Y. (1987). The cAMP cascade in the nervous system: molecular sites of action 
and possible relevance to neuronal plasticity. CRC Crit. Rev. Biochein. 22: 221-281. 
Dufai M. L., Tsuruhara T., Homer K. A., et al. (1977). Intermediate role of adenosine 
3': 5'-cyclic monophosphate and protein kinase during gonadotropin-induced 
steroidogenesis in testicular interstitial cells. Proc. SM. Acad. Sci. USA 74-3419- 
3423. 
252 
Duh Q-Y., Siperstein A. E., Miller R. A., et al. (1989). TSH binding correlates with 
TSH-stimulated thyroid adenylate cyclase activity in hunian thyroid tissues. Surgeq 
106: 967-974. 
Dukes C. E. (1932). The classification of cancer of the rectum. J. Pathol. 616: 315- 
321. 
Dumont J. E., Jauniaux J-C. and Roger P. P. (1989). The cyclic AMP-mediated 
stimulation of cell proliferation. TIBS 14: 69-71 
Dwarki VI, Montminy M. and Verma I. M. (1990). Both the basic region and the 
'leucine zipper'domain of the cyclic AMP response element binding (CREB) protein 
are essential for transcriptional activation. EAIBO J. 9: 225-232. 
2S3 
E 
Edelman A. M., Blumenthal D. K. and Krebs E. G. 0987). Protein serine and 
threonine kinases. Ann. Rev. Blochein. 56: 567-613. 
Eide T. J. ( 1983). Remnants of adenomas in colorectal carcinomas. Cancer 5 1: 1866- 
1872. 
Eide T. J. (1986). Risk of colorectal cancer in adenoma-bearing individuals within a 
defined population.. Int. J. Cancer 38: 173-176. 
Eide T. J. (1986). The age-, sex-, and site-specific occurrence of adenomas and 
carcinomas of the large intestine within a defined population. Scand. J. Gastroenterol. 
21: 1083-1088 
Eisman J. A., Barkla D. H. and Tutton P. J. (1987). Suppression of the in vivo growth 
of human cancer solid tumour xenocyrafts by 1,25-dihydroxyvitamin DI Cancer Res. 
47: 21-25. 
Ekanger R., Vintermyr O. K., Houge G., et al. (1989). The expression of cAMP- 
dependent protein kinase subunits is differentially regulated during liver regeneration. 
J. Blol. Chem. 264: 4374-4382. 
Elias L., Li A. P. and Longmire 1 (1981). Cyclic adenosine 3': S'-monophosphate 
dependent and independent protein kinase in acute myeloblastic leukaernia. Cancer 
Res. 41: 2182-2188. 
Elwyn K. E., Jones R. D. and Romsdahl M. M. (1985). Inhibitory effects of secretin 
on gastrin-stimulated rat colon neoplasms. Cancer 55: 1186-1189. 
Endo T., Shimura H., Saito T. and Onaya T. (1990). Cloning of malignantly 
transformed rat thyroid (FTRL) cells with thyrotropin receptors and their growth 
inhibition by 3', 5'-cyclic adenosine monophosphate. Endocrinology 126: 1492-1497. 
Erlichman J., Sarkar D., Fleischer N. and Rubins C. N. (1980). Identification of two 
subclasses of type 11 cAMP-dependent protein kinascs. J. Biol, Chein. 255: 8179- 
8184. 
Ernest M. J. and Feigelson P. (1979) Increase in hepatic tyrosine am i notransfe rase 
mRNA during enzyme induction by N6,020-dibutryl cyclic AMP. J. Blol. Chein, 
253: 319-322. 
Escribano J. and Rozengurt E. (1988). Cyclic AMP increasing agents rapidly 
stimulate Vimentin phosphorylation in quiescent cultures of Swiss 3Uýcells. J. Cell. 
Pkvsiol. 137: 223-234. 
Eskin A., Garcia K. S. and Byrne J. H. (1989). Information storage in the nervous 
system of Aplysia: Specific proteins affected by serotonin and cAMP. Proc. Natt. Acad. Sci. USA 86: 2458-2462. 
Exton J. H., Friedman N., Wong E., et al. (1972). Interaction of glucocorticoids with 
glucagon and epinephrine in the control of gluconeogenesis and glycogenolysis in 0 liver and lipolysis in adipose tissue.. J. Biol. Chem. 247: 3579-3588. 
254 
F 
Fearon E. R., Hamilton S. R. and Vogelstein B. (1987). Clonal analysis of human 
colorectal turnours. Science 238: 193-197. 
Fei ge J-J. and Baird A. ( 1989). Basic fibroblast growth factor is a substrate for 
protein phosphorylation and is phosphorylated by capillary endothelial cells in culture. 
Proc, Nati. Acad. Scl. USA 86: 3174-3178. 
Feinberg A. P. and Vogelstein B. (1983). Hypomethyl-ation of ras oncogens in 
primary human cancers. Biochem. Biophys. Res. Comin. 111: 47-54. 
Feramisco J. R., Gross M., Kamata T., et al. (1984). Microinjection of the oncogene 
form of the human H-ras (T-24) protein results in rapid proliferation of quiescent 
cells. Cell 38: 109-117. 
Fielding L. P., Philips R. K. S., Fry J. S. and Hittinger R. (1986). Prediction of 
outcome after curative resection for large bowel cancer. Iancet ii: 904-906. 
Figueiredo F., Uhing R. J., Okonog K., et al. (1990). Activation of the cAMP cascade 
inhibits an early event involved in murine macrophage la expression. J. Biol. Chem. 
26S: 12317-12323. 
Filipe M. I. and Branfoot A. C. (1974). Abnormal patterns of mucus secretion in 
apparently normal mucosa of large intestine with carcinoma. Cancer 34: 282-290, 
First E. A., Bubis I and Taylor S. S. (1988). Subunit interaction sites between the 
regulatory and catalytic subunits of cAMP-dependent protein kinase. J. Blol. Chem. 
263: 5176-5182. 
Flockhart D. A. and Corbin J. D. (1982). Regulatory mechanisms in the control of 
protein kinases. CRC Crit. Rev. Biochem. 12: 133-186. 
Fontana J. A., Miksis G., Miranda D. M. and Durham J. P. (1987). Inhibition of 
human mammary carcinoma cell proliferation by retinoids and intracellular cAMP- 
elevating compounds. JNCI 78: 1107-1112. C, 
Forrester K., Almoguera C., Han K., Grizzle W. E. and Perucho M. (1987). 
Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. 
Nature 327: 298-302. 
Forsburg P-O., Martin S. C., Nilsson B., et al. (1990). In vitro phospho lation of 
human complement factor 0 by protein kinase A and protein kinase 
T 
J. Blol. 
Chem. 265: 2941-2946. 
Fossberg T. M., Doskeland S. O. and Ueland P. M. (1978), Protein kinase in human 
renal cell carcinoma and renal cortex. Arch. Biochein. Blopkys. 189: 372-381. 
Fraenkel D. G. (1985). On ras gene function in yeast. Proc. Nafl. Acad. Sci. USA 
82: 4740-44. 
2ss 
Frampton R. J., Suva L. J., Eisman J. A. (1982). Presence of 1,25-dihydroxyvitamin 
D3 receptors in established human cancer cell lines in culture. Cancer Res. 42: 1116- 
1119. 
Francavilla A., DiLeo A. and Polimeno L. (1987). Nuclear and cytosolic oestrogen 
receptors in human colon carcinoma and in surrounding non-cancerous colonic tissue. 
Gastroenterology 93: 1301-1306. 
Franks D. J., Plamaondon J. and Hamet P. (1984). An increase in adenylate cyclase, 
activity precedes DNA synthesis in cultured vascular smooth muscle cells. J. Cell. 
Plkysiol. 119: 41-45. 
Franks D. J., Whitfield JR and Durkin J. P. (1987). Viral p2l. Ki-ras protein- A 
potent intracellular mitogen that stimulates adenylate cyclase activity in early GI phase 
of cultured rat cells. J. Cell. Biochem. 33: 87-94. 
Franks D. J., Durkin J. P. and Whitfield JR (1989). Protein kinase C and a viral K- 
RAS protein cooperatively enhance the response of adenylate cyclase to stimulators. I 
Cell. Pkysiol. 140: 409-417. 
Friedman D. L., Johnsen R. A., Zeilig C E. (1976) The role of cyclic nucleotides in 
the cell cycle. Adv. Cyclic Nucleotide Res. 7: 69-114. 
Freidman E., Gillin S. and Lipkin M. (1984). 12-0-tetradecanoyi-phorbot- 13 -acetate 
stimulation of DNA synthesis in cultured pre-neoplastic familial polyposis colonic 
epithelial cells but not in normal epithelial cells. Cancer Res. 44: 40764086. 
Fuh V. L., Burrin J. M. and Jameson U. (1989). Cyclic AMP (cAMP) effects on 
chorionic gonadotropin gene transcription and mRNA stability: Labile proteins mediate 
basal expression whereas stable proteins mediate cAMP stimulation. Afol. Endocrinol. 
3: 1148-1156. 
Fujita J., Kraus M., Onoue H., et al. (1988). Activated H-ras oncogenes in human 
kidney tumours. Cancer Res. 48: 5251-5255. 
Furner S. E. Davis F. G., Nelson R. L. and Haenzel W. (1989). A case-control study 
of large bowel cancer and hormone exposure in women. Cancer Res. 49: 4936-4940. 
Furth M. E., Aldrich T. H. and Cordon-Cardo C. (1987) Expression of ras proto- 
oncogene proteins in normal human tissues, Oncogene 1: 47-58. 
256 
Gabbay R. A. and Lardy H. A. (1987). Insulin inhibition of hepatic cAMP-dependent 
protein kinase: decreased affinity of protein kinase for cAMP and possible differential 
regulation of intrachain sites I and 2. Proc. Narl. Acad. Sci. USA 84: 2218-2222. 0 
Gallick G. E., Kurzrock R., Kloetzer W. S., et al. (1995). Expression of p2l-ras in 
fresh primary and metastatic human colorectal tumours. Proc. Nati. Acad. Sel. USA 
82: 1795-1799. 
Galloway D. J., Cohen A. M., Shank B. and Friedman M. A. (1989). Adjuvant 
multimodality treatment of rectal cancer. Br. J. Surg. 76: 440447. 
Galons J-P., Fantini J., Vion-Dury J., et al. (1990). Effect of VIP on the glycogen 
metabolism of human colon adenocarcinoma cells studied by 13C nuclear magnetic 
resonance spectroscopy. Int. J. Cancer 4S: 168-173. 
Gambke C., Hall A. and Moroni C. (1985). Activation of N-ras gene in acute 
myeloblastic leukaemia through somatic mutation of the first exon. Proc. Natt. Acad. 
Sci. USA 82: 879-882. 
Gard D. L. and Lazarides E. (1982). Cyclic AMP-modulated phosphorylation of 
intermediate filament proteins in cultured avian myogenic cells. Mol. Cell. Blol. 
2: 1104-1114. 
Gardner E. J., Rogers S. and Woodward S. (1982). Numerical and structural 
abberrations in cultured lymphocytes and cutaneous fibroblasts of patients with 
multiple adenomas of the colorecturn. Cancer 49: 1413-1419. 
Garland C. F. and Garland F. C. (1980). Do sunlight and vitamin D reduce the risk of 
colon cancer ? Int. J. Epidemiol. 9: 227-23 1. 
Garland C. F., Shekelle R. B., Baffet-Connor E., et al. (1985). Dietary vitamin D and 
calcium and the risk of colorectal cancer. a 19-year prospective study in men. Lancet 
i: 307-309. 
Garland C. F., Comstock G. W., Garland F. C., et al. (1989). Serum 25- 
hydroxyvitamin D and colon cancer. Eight year prospective study. Lancet H: 1176- 
1178. 
Garret M. D., Self AI, van Oers C. and Hall A. (1989). Identification of distinct 
cytoplasmic targets for rasIR-ras and rho regulatory proteins. J. Biol. Chem. 264: 10- 
13. 
Geisler N. and Weber K. (1988) Phosphorylation of desmin in vitro inhibits 
formation of intermediate filaments: identification of three kinase A sites in the 
aminoterminal head domain. EMBO J. 7: 15-20. 
Gentleman S., Hemmings B. A., Russell P. and Chader G. J. (1989a). Developmental 
expression of the RI subunit of cyclic AMP-dependent protein kinase in retina. Exp. 
Eýye. Res. 48: 717-73 1. 
257 
Gentleman S., Russell P., Hemmings B. A. and Chader G. J. (1989b). Abnormal 
expression of the RI subunit of cyclic AMP-dependent protein kinase in Y-79 
retinoblastoma cells. Exp., Iýye Res. 48: 497-507. 
Georgatos S. D. and Blobel G. (1987). Two distinct attachment sites for vimentin 
along the plasma membrane and nuclear envelope in avian erythrocytes: A basis for 
vectorial assembly of intermediate filaments. J. Cell. Blol. 105: 105-115. 
Gerard C. M., Lefort A., Christophe D., el al. (1989). Control of thyroperoxidase and 
thyroglogulin transcription by cAMP: Evidence for distinct regulatory mechanisms. 
Mol. Endocrinol. 3: 2110-2118. 
Gettys T. W., Blackmore RE, Redmon J. B., et al. (1987). Short-term feedback 
regulation of cAMP by accelerated degradation in rat tissue. J. Blot. Chem. 262: 333- 
339. 
Gharrett G., Malkinson A. M. and Sheppard J. R. (1976). Cyclic AMP-dependent 
protein kinases from normal and SV40-transformed 3T3 cells. Nature 264: 673-675. 
Ghosh A. K., Moore M. and Harris M. (1986). Immunohistochernical detection of ras 
oncogene p2l product in benign and malignant mammary tissue in man. J. Clin. 
Pathol. 39: 428-434. 
Ghosh-Dastidar P. and Fox CA (1984). cAMP-dependent protein kinase stimulates 
epidermal growth factor-dependent phosphorylation of epidermal growth factor 
receptors. J. Biol. Chem. 259: 3864-3869. 
Gibbs J. B., Sigal I. S., Poe M. and Scolnick E. M. (1994). Intrinsic GTPase activity 
distinguishes normal and oncogenic ras p2l molecules. Proc. Natl. Acad. Sci. USA 
81: 5704-5708. 
Gilbertson V. A. and Nelms J. M. (1978). The prevention of invasive cancer of the 
rectum. Cancer 41: 1137-1139. 
Gilman A. G. (1970). A protein binding assay for adenosine 3', S'-cyclic 
monophosphate. Proc. NatI. Acad. Scl. USA 67-305-312. 
Gilman A. G. (1987). G proteins: transducers of receptor generated signals. Ann. 
Rev. Biochem. 56-. 615-649. 
Giuffre L., Schreyer M., Mach J-P. and Cartel S. (1988). Cyclic AMP induces 
differentiation in vitro of human melanoma cells. Cancer 61: 1132-1141. 
Glass D. B. and McPherson J. M. (1986). In vitro phosphorylation of type I collagen 
by cyclic AMP-dependent protein kinase. I Biol. Chem. 261: 5674-5679. 
Glickman L. T., Suissa S. and Fleiszer D. M. (1987). Proliferative characteristics of 
colonic crypt cells in C57BL/6J and A/J Mice as predictors of subsequent tumour 
formation. Cancer Res. 47: 4766-4770. 
Goh H. S. and Jass J. R. (1986). DNA content and the adenorna-carcinorna sequence 
in the colorecturn. J. Clin. Pathol. 39: 387-392. 
258 
Goldberg M. L., Burke G. C. and Morris H. (t974). Cyclic AMP and cyclic GMP 
content and binding in malignancy. Biochem Biopkys. Res. Comm. 62: 320-324. 
Gonzales G. A. and Montminy M. R. (1989). Cyclic AMP stimulates somatostatin gene 
transcription by phosphorylation of CREB at serine 133. Cell 59: 675-680. 
Gonzales G. A., Yamamoto K. K., Fischer W. H., el al. (1989). A cluster of 
phosphorylation sites on the cyclic AMP-regulated nuclear factor CREB predicted by 
its sequence. Nature 337: 749-752. 
Gorman R. R., Benjamin C. W. and Tarpley W. G. (1987). Inhibition of adenylatc 
cyclase and phospholipase A2/C in NIH-3T3 cells expressing the EJ-ras oncogene. 
Adv. Prostaglandin, Thrombox. Res. 17: 963-968 
Goyette M., Petropoulos U., Shank P. R. and Fausto N. (1984). Regulated 
transcription of c-Ki-ras and c-myc during compensatory growth of rat liver. Afol. 
Cell. Biol. 4: 1493-1498. 
Granner D. K. (1972). Protein kinase: altered regulation in a hepatoma cell line 
deficient in adenosine 3'5'-cyclic monophosphate-binding protein. Blochem. 
Biopkvs. Res. Comm 46: 1516-1521. 
Granner D. K., Lee A. and Thomson E. B. (1977). Interaction of glucocorticoid 
hormones and cyclic nucleotides in induction of tyrosine aminotransferase in cultured 
hepatoma cells. J. Blot. Chem. 252: 3891-3897. 
Granqvist S. (1981). Distribution of polyps in the large bowel in relation to age: a 
colonoscopic study. Scand. J. Gastroenterol. 16: 1025-103 1. 
Grant P. G., Mannarino A. F. and Colman R. W. (1988). cAMP-mediated 
phoshorylation of the low-Km cAMP phosphodi e ste rase markedly stimulates its 
catalytic activity. Proc. Nati. Acad. Sci. USA 85: 9071-9075, 
Greenberg M. E. and Ziff E. B. (1984). Stimulation of 3T3 cells induces transcription 
of the c-fos proto-oncogene. Nature 311: 433438. 
Gross R. E., Lu X., and Rubin C. S. (1990). Regulation of the expression of the 
regulatory subunit of cAMP-dependent protein kinase 11-0 in Friend erythroleukaemic 
cells. J. Biol. Chem. 265: 8152-8158. 
Grove J. R., Price D. J., Goodman H. M. and Avruch J. (1987). Recombination 
fragment of protein kinase inhibitor blocks cyclic AMP dependent gene transcription. 
Science 238: 530-533. 
Grove J. R., Deutsch P. J., Price D. J., et al. (1989). Plasmids encoding PKI(1-3 1), a 
specific inhibitor of cAMP-stimulated gene expression, inhibit the basal transcriptional 
activity of some but not all cAMP-regulated DNA response lements in JEG-3 cells. J. 
Blol. Chem. 264: 19506-19513. 
259 
H 
Hadcock J. R., Ros M. and Malbon C. C. (1989). Agonist regulation of P-adrenergic 
receptor mRNA. J. Biol. Chem. 264: 13956-13961. 
Haddox M. K., Roeske W. R. and Russell D. H. (1979). Independent expression of 
cardiac type I and 11 cyclic AMP-dependent protein kinase during murine 
embryogenesis and post-natal development. Blochim Biopkvs. Acta 585: 527-534. 
Haddox. M. K., Magun B. E. and Russell D. H. (1980). Differential expression of type 
I and type 11 cyclic AMP-dependent protein kinases during cell cycle and cyclic AMP- 
induced growth arrest. Proc. Natl. Acad. Sci. USA 77: 3445-3449. 
Haenzel W. and Correa P. (1971). Cancer of the colon and rectum and adenomatous 
polyps. A review of epidemiological findings. Cancer 28: 14-24. 
Hagag N., Halegoua S. and Viola M. (1986). Inhibition of growth factor-induced 
differentiation of PC12 cells by microinjection of antobody to ras p2l. Nature 
319: 680-683. 
Hagag N., Lacal J. C., Graber M., et at. (1987). Microinjection of ras p2l induces a 
rapid rise in intracellular pH. Mol. Cell. Blol. 7: 3984-1988 
Halbrugge M., Freidrich C., Eigenthaler M., el al. (1990). Stoichiometric and 
reversible phosphorylation of a 46-kDa protein in human platelets in response to 
cGMP- and cAMP-elevating vasodilators. J. Blol. Chem. 265: 3088-3093. 
Halvorsen T. B. and Seim E. (1988a). Degree of differentiation in colorectal 
adenocarcinomas: a multivariate analysis of the influence on survival. J. Clin. Pathol. 
41: 532-537. 
Halvorsen T. B. and Seim E. (1998b). Influence of mucinous components on survival 
in colorectal adenocarcinomas: a multivariate analysis. J. Clin. Pathol. 41: 1068- 
1072. 
Halvorsen T. B. and Seim E. (1989). Association between invasiveness, inflammatory 
reaction, desmoplasia and survival in colorectal cancer. J. Clin. Pathol. 42: 162-166. 
Hamada S., Namura K. and Fujita S. (1988a). The possibility of non-polypoidal 
carcinogenesis in the large intestine as inferred from frequencies of DNA aneuploidy 
of polypoidal and crater-shaped carcinomas. Cancer 62: 1503-1510. 
Hamada S., Itoh R. and Fujita S. (1988b). DNA distribution pattern of the so-called 
severe dysplasias and small carcinomas of the colon and rectum and its possible 
significance in the tumor progression. Cancer 61: 155515-1562. 
Hamilton P. W., Watt P. C. H. and Allen D. C. (1988). A morphometric assessment of 
transitional mucosa in the colon. Histopathology 13: 519-530. 
Hanauske A. R., Buchok J., Scheithauer W. and Von Hoff D. D. (1987). Human 
colon cancer cell lines secrete ct-TGF-like activity. Br. J. Cancer 55: 57-59. 
260 
Hand A. R. and Mednieks M. I. (1989). Regulatory subunits of cyclic AMP-dependent 
protein kinase: presence in granules and secretion by exocrine and endocrine cells. J. 
Cell. SO. 93: 675-681. 
Hand P. H., Thor A., Wunderlich D., el al. (1984). Monoclonal antibodies of 
predefined specificity detect activated ras gene expression in human mammary and 
colon carcinomas. Proc. Natl- Acad. Sci. USA 81: 5227-523 1. 
Hand P. H., Vilasi V., Thor A., et al. (1987). Quantification of Harvey ras p2l 
enhanced expression in human breast and colon carcinomas. JNCI 79: 59-65. 
Handschin J. C. and Eppenberger U. (1979). Altered cellular ratio of type I and type 11 
cyclic AMP-dependent protein kinase in human mammary tumours. FEBS Lett. 
106: 301-307. 
Handschin J. C., Handloser k., Takahashi A. and Eppenberger U. (1983). Cyclic 
adenosine 3', 5'-monophosphate receptor proteins in dysplastic and neoplastic human 
breast tissue cytosol and their inverse relationship with estrogen receptors. Cancer 
Res. 43: 2947-2954. 
Hanks S. K., Quinn A. M. and Hunter T. (1988). The protein kinase family: conserved 
features and deduced phylogeny of catalytic domains. Science 241: 42-52 
Hanley M. R. and Jackson T. (1987). Transformer and transducer. Nature 328: 668- 
669 
Hardcastle J. D. and Pye G. ( 1989). Screening for colorectal aancer: A critical review. 
World J. Surg. 13: 38-44. 
Harden T. K., Foster S. J. and Perkins J. P. (1979). Differential expression of 
components of the adenylate cyclase system during growth of astrocytoma cells in 
culture. J. Blol. Chem. 254: 4416-4422. 
Hashimoto E., Takeda M., Nishizuka Y., et al. (1976). Studies on the sites in 
histones phosphorylated by adenosine 35'-monophosphate-dependent and guanosine 
3'51-monophosphate-dependent protein kinases. J. Biol. Chem. 251: 6287-6293. 
Hashimoto S., Scmidt W. and Schutz G. (1988). Transciptional activation of the rat 
liver tyrosine aminotransferase gene by cAMP. Proc. Natl. Acad. Sci. USA 81: 6637- 
6641. 
Hayashi K., Sala G., Catt K. and Dufau M. L. (1979). Regulation of steroidogenesis 
by adrenocorticotropic hormone in isolated adrenal cells. J. BIoL Chem. 254: 6678- 
6683. 
Hayes J. S., Brunton L. L. and Meyer S. E. (1980). Selective activation of particulate 
cAMP-dependent protein kinase by isoproterenol and prostaglandin El. J. Biol. 
Chem. 255: 5113-5119. 
Hedin L., McKnight G. S., Lifk-a J., et al. (1987). Tissue distribution and hormonal 
regulation of messenger ibonucleic acid for regulatory and catalytic subunits of 
adenosine 3', 5'- monophosphate-de p ndent protein kinases during ovarian follicular 
development and luteinization in the rat. Endocrinology 120: 1928-1935. 
261 
Heighway J., Thatcher N., Cerny T. and Hasleton P. S. (1986). Genetic 
predisposition to human lung cancer. Br. J. Cancer 53: 453-457. 
Helson L., Helson C., Peterson R. F. and Das S. K. (1976). Rationale for treatment of 
metastatic neuroblastoma. JNCI 57: 727-729. 
Hemmings H. C., Nairn A. C., McGuiness T. L., et al. (1989a). Role of protein 
phosphorylation in neuronal signal transduction. FASEB J. 3: 1583-1592. 
Hemmings H. C., Girault J-A., Williams K., et al. (1989b). ARPP-21, a cyclic AMP- 
regulated phosphoprotein (Mr = 21,000) enriched in dopamine-innervated brain 
regions. J. Biol. Chem. 264: 7726-7733. Cý 
Heuschneider G. and Schwartz R. D. (1989). cAMP and forskolin decrease gamma- 
aminobutyric acid gated chloride flux in rat brain synaptoneurosomes. Proc. Nall. 
Acad. Sci. USA 86: 2938-2942. 
Hickie R. A., Walker C. M. and Croll G. A. (1974). Decreased basal cyclic adenosine 
31,5'-monophosphate l vels in Morris hepatoma, 5123 t. c. (h). Biochem. Biophys. 
Res. Comm. 59: 167-172 
Hickie R. A., Walker C. M. and Datta A. (1975). Increased activity of low-Km cyclic 
adenosine, 3', 5'-monophosphate phosphodiesterase in plasma membranes of Morris 
hepatoma 5123tc (h). Cancer Res. 35: 601-605. 
Hiraki Y., MeMorrow I. M. and Birnbaum M. J. (1989). The regulation of glucose 
transporer gene expression by cyclic adenosine monophosphate in NIH 3T3 
fibroblasts. Afol. Endocrinol. 3: 1470-1476. 
Hiwasa T., Sakiyama S., Noguchi S., et at. (1987). Degradation of a cAMP-binding 
protein is inhibited by human c-Ha-ras gene products. Biochem. Biopkys. Res. 
Commun. 146: 731-738. 
Hoeffler J. P., Deutsch P. J., Lin J and Habener IF (1989). Distinct adenosine 3': S'- 
monophosphate and phorbol ester responsive signal transduction pathways converge 
at the level of transcriptional activation by the interactions of DNA-binding proteins. 
Afol. Endocrinol. 3: 868-880. 
Hoff M. B., Chang W. W. and Mak K. M. (1981). Effect of estrogen on cell 
proliferation in colonic mucosa of the mouse. Virchows Arch. Cell Pathol. 35: 172- 
177. 
Hoffman F., Beavo J. A., Betchel P. P., and Krebs E. G. (1975). Comparison of 
adenosine 3', 5monophosphate dependent protein kinases from rabbit skeletal and 
bovine heart muscle. J. Biol. Chem. 2SO: 7795-780 1. 
Hoffmann F., Betchel P. J. and Krebs E. G. (1977). Concentrations of cyclic AMP- 
dependent protein kinase sub-units in various tissues. J. Biol. Chem. 252: 1441- 
1447. 
Hohmann P. and Greene R. S. (1990). Retinoid induced changes in cAMP-dependent 
protein kinase activity detected by a new minigel assay. FEBS Lett. 261: 81-84. 
262 
Horiuchi A., Williams K. R., Kurihara T., et al. (1990). Purification and cDNA 
cloning of ARPP-16, a cAMP-regulated phosphoprotein enriched in basal ganglia, and 
of a related phosphoprotein, ARPP- 19. J. Biol. Chem. 265: 9476-9484. 
Hom U., Baum B. J. and Ambudkar I. S. (1989). Evidence for the convergence of 
P-adrenergic and muscarinic signalling systems at post-receptor site. FEBS Lett. 
258: 13-16. 
Hornsby P. J., Hancock J. P., Vo T. P., et al. (1987). Loss of expression of a 
differentiated function gene, steroid 17 ct-hydroxylase, as adrenocortical cells senesce 
in culture. Proc. Natl. Acad. Sci. USA 84: 1590-1584. 
Horwitz J. and Perlman R. L. (1994). Activation of tyrosine hydroxylase in the 
superior cervical ganglion by nicotinic and muscarinic agonists. J. Neurochem. 
43: 546-552. 
Hoshijima M., Kikuchi A., Kawata M., et al. (1988). Phosphorylation by cyclic 
AMP-dependent protein kinase, of a human platelet Mr 22,000 GTP-binding protein 
(smg p2l) having the same putative effector domain as the ras gene product. Biochem C Biopkys. Res. Comm. 157: 851-860. 
Huang F. L. and Cho-Chung Y. S. (1984). Hormone-regulated expression of cellular rý 
ras-H oncogene in mammary carcinomas in rats. Biochem. BiophyS. Res. Comm. 
123: 141-147. 
Hunzicker-Dunn M., Lorenzini N. A., Lynch L. L. and West D. E. (1985). Coelution 
of the type 11 holoenzyme form of cAMP-dependent protein kinase with regulatory 
subunits of the type I form of cAMP-dependent protein kinase. J. Biol. Chem. 
260: 13360-13369. 
Hunzicker-Dunn M., Maizels E. T., Kern L. C., et al. (1989). Separation of the 
complexes formed between the regulatory and catalytic subunits of cyclic adenosine 
monophosphate-dependent protein kinase, and topoisomerase I activity in preovulatory 
follicle-enriched immature rat ovaries. Mol. Endocrinol. 3: 780-789. 
263 
I 
lishi H., Tatsuta M., Baba M., Okuda S. and Taniguchi H. (1987). Enhancement by 
vasoactive intestinal peptide of experimental carcinogenesis induced by azoxymethane 
in rat colon. Cancer Res. 47: 4890-4893. 
Imagawa M., Chiu R. and Karin M. (1987). Transcription factor AP-2 mediates 
induction by two different signal transduction pathways: protein kinase C and cAMP. 
Cell 51: 251-260. 
Inagaki M., Nishi Y., Nishizawa K., Matsuyama M. and Sato C. (1987). Site- 
specific phosphorylation induced dissassembly of vimentin filaments in vitro. Nature 
328: 649-653. 
lynedjian P. B. and Hanson R. W. (1977). Increase in level of functional messenger 
RNA coding for phosphoenolpyruvate carboxykinase (GTP) during induction by 
cyclic adenosine 3': S'-monophosphate. J. Biol. Chem. 2S2: 655-662. 
Iwashita S., Mitsui K., Shoji-Kasai Y. and Senshu-Miyaike M. (1990). cAMP- 
mediated modulation of signal transduction of epidermal growth factor (EGF) receptor 




Jacobsen B. K. and Thelle D. S. (1987). Coffe, cholesterol, and colon cancer: is there 
a link ? Br. Afed. J. 294: 4-5. 
Jahnsen T., Lohmann S. M., Walter U., et al. (1985). Purification and characterization 
of hormone- resulted isoforms of the regulatory sub-unit of type 11 cAMP-dependent 
protein kinase from rat ovaries. J. Biol. Chem. 260: 15980-15987. 
Jahnsen T., Hedin L., Kidd U., et al. (1986a). Molecular cloning, cDNA structure, 
and regulation of the regulatory subunit, of type 11 cAMP-dependent protein kinase 
from rat ovarian granulosa cells. I Biol. Chem. 261: 12352-12361. 0 
Jahnsen T., Hedin L., Lohmann S. M., Walter U. and Richards J. S. (1986b). The 
neural type 11 regulatory subunit of cAMP-dependent protein kinase is present and 
regulated by hormones in the rat ovary. I Biol. Chem. 261: 6637-6639. 
James D. E., Hiken J. and Lawrence J. C. (1989). Isoprotenerol stimulates 
phosphorylation of the insulin-regulatable glucose transporter in rat adipocytes. Proc. 
Nall. Acad. Sci. USA 86: 8368-8372. 
Jameson J. L., Powers A. C., Gallagher G. D. and Habener U. (1989). Enhancer and 0 promoter element interactions dictate cyclic adenosine monophosphate mediated and 
cell-specific expression of the glycoprotein hormone alpha-gene. A161. Endocrinol. 
3: 763-772. 
Janne J., Poso H. and Raina A. (1978). Polyamines in rapid growth and cancer. 
Biochim Blopkys. Acta 473: 241-293. 
Jass J. R. (1989). Do all colorectal adenomas arise in preexisting adenomas ?. I'Vorld 
J. Surg. 13: 45-5 1. 
Jeng A. Y., Srivastava S. K., Lacal J. C. and Blumberg P. M. (1987), Phosphorylation 
of ras oncogene product by Protein KInase C. Blochem Biophys. Res. Cown. 
145: 782-788. 
Jensen O. M. (1984). Different age and sex relationships for cancer of sub-sites of the 
large bowel. Br. J. Cancer 50: 825-829. 
An S., Hornicek F. J.. Neylan D., Zakarija M. and McKenzie J. M. (1986). Evidence 
that adenosine 3', S-monophosphate mediates stimulation of thyroid growth in FrRL5 
cells. Endocrinology 119: 802-810. 
John M. E., John M. C., Boggaram, V. and Simpson E. R. (1999). Transcriptional 
regulation of steroid hydroxylase genes. Proc. Natl. Acad. Sci, USA 85. -4715-4719. 
Johnson D. R. and Wong S. S. (1989). Conformational changes of type If regulatory 
subunit of cAMP-dependent protein kinase on cAMP binding. FEBS Lett. 247: 480- 
482. 
Johnson E. M., Hadden J. W., Inoue A. and Allfrey V. G. (1975). DNA binding by 
cyclic adenosine 3', 5'-monophosphate dependent protein kinase from calf thymus 
nuclei. Blochemlstq 14: 3873-3884. 
26S 
Johnson L. R. (1977). New aspects of the trophic action of gastrointestinal hormones. 
Gastroenterology 72: 788-792. 
Jones D. J., Zaloudik J., James R. D., et at. (1989). Predicting local recurrence of 
carcinoma of the rectum after preoperative radiotherapy and surgery. Br. J. Surg. 
76: 1172-1175. 
Jungmann R. A. and Kranias E. G. (1977). Nuclear phosphoprotein kinases and the 
regulation of gene transcription. Int. J. Biochem. 8: 819-830. 
0 
0 
Jungmann R. A. and Russell D. H. (1977). Cyclic AMP, cyclic AMP-dependent 
protein kinase, and the regulation of gene expression. Life Sci, 20: 1787-1798. 
Jungmann R. A., Kelley D. C., Miles M. F. and Milkowski D. M. (1983). Cyclic AMP 
regulation of lactate dehydrogenase J. Biol. Chem. 258: 5312-53 18. 0.0 
'01.6 6 
K 
Kacich R. L., Williams L. T., and Coughlin s. R. (1988). Arachidonic acid and cyclic 0 
adenosine monophosphate stimulation of c-fos expression by a pathway independent 
of phorbol ester-sensitive protein kinase C. Afol. Endo. 2: 73-77 
Kagawa N, and Waterman M. R. (1990). cAMP-dependent transcription of the human 
CYP21B (P-450c2l) gene requires a cis-regulatory element distinct from the 
consensus cAMP-regU, atory element. A Biol. Chem. 265: 11299-11305 
KaIderon D., Roberts B. L., Richardson W. D. and Smith A. E. (1984). A short amino 
acid sequence able to specify nuclear location. Cell 39: 499-509. 
Kallos J. (1977). Photochemical attachment of cyclic AMP binding proteins to the 
nuclear cenome. Nature 265: 705-708. 0 
Kapoor C. L. and Cho-Chung Y. S. (1983). Compartmentalization of regulatory CO 
subunits of cyclic adenosine 3', 5-monophosphate-dependent protein kinases in MCF- 
7 human breast cancer cells. Cancer Res. 43: 295-302. 
Karanjia N. D., Rees M., Schache D. and Heald R. J. (1990). Hepatic resection for 
colorectal secondaries. Br. J. Surg. 77-. 27-29. 
Karnes W. E. and Jacobs L, R. (1987). ras gene mutations in colorectal cancer. 
Gastroenterology 93: 1440-144 1. 
Karayiannis M., Yiagnisis M., Papadimitriou K. and Spandidos D. A. (1989). 
Expression of the ras oncoprotein in gastric carcinomas and adjacent mucosa. 
Anticancer Res. 9: 1505- 15 10. 
Katada T., Gilman A. G., Watanabe Y., et al. (1985). Protein kinase C 
phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and 
apparently suppresses its function in hormonal inhibition of adenylate cyclase. Eur. J. 
Blochem. 151: 431-437. 
Kataoka T., Powers S., Cameron S., el al. (1985). Functional homology of 
mammalian and yeast RAS genes. Cell 40: 19-26. 
Katsaros D., Tortora G., Tagliaferri P., et al. (1987). Site-selective cyclic AMP 
analogs provide a new approach in the control of cancer cell growth. FEBS Left. 
223: 97-103. 
Katsaros D., Ally S. and Cho-Chung Y. S. (1988). Site-selective cyclic AMP analogs 
are antagonistic to estrogen stimulation of growth and proto-oncogene xpression in 
human breast cancer cells. Int J. Cancer 41: 863-867. 
Kawata M., Kikuchi A., Hoshijima M., et al. (1989). Phosphorylation of a ras like 
protein by cAMP-dependent protein kinase in a cell-free system and in response to 
Prostaglandin El in Intact Human Platelets. J. Blol. Chem. 264: 15688-15695. 
267 
Kerlavage A. R. and Taylor S. S. (1988). Covalent modification of an adenosine 3'5' 
monophosphate binding site of the regulatory unit of cAMP-dependent protein kinase 
0 
V 11 with 8-azidoadenosine 3'5'-monophosphate: identification of a single modified 
tyrosine residue. J. Biol. Chem. 263: 5176-5182. 
Kerr I. B., Lee F. D., Quantanilla M. and Balmain A. (1985). Immunocytochernical 
demonstration of p21 ras family oncogene product in normal mucosa and pre- 
malignant and malignant turnours of the colorecturn. Br. J. Cancer 52: 695-700. 0 
Kewenter J., l3jork S., Haglind E., et al. (1988). Screening and rescreening for 
colorectal cancer. A controlled trial of faecal occult blood testing in 27,700 subjects. 
Cancer 62: 645-65 1. 
Kim K., Lopez-Casillas F., Bai D. H., et al. (1989a). Role of reversible 
phosphorylation of acetyl-CoA carboxylase in long-chain fatty acid synthesis. FASEB 
J. 3: 2250-2256. 
Kim U-H., Kim J. W. and Rhee, S. G. (1989). Phosphorylation of phospholipase C-y 
by cAMP-dependent protein kinase. J. Biol. Chem. 264: 20167-20170, 
Kingsnorth AX, King W. W., Diekema K. A. (1983). Inhibition of ornithine 
decarboxylase with d ift uoromethy I-orni thine: reduced incidence of dimethythydrazine 
induced colon turnouts in mice. Cancer Res. 43: 2545-2549. 
Kingsnorth A. N., Russell W. E., LaMuraglia G. M. (1983). Effects of 
difluoromethylornithine and 5-fluorouracil on the proliferation of a human 
adenocarcinorna cell line. Cancer Res. 43: 4035-4038, 
Kinzel V., Hotz A., Konig N., et al. (1987). Chromatographic separation of two 0 heterogeneous forms of the catalytic subunit of cyclic AMP-dependent protein kinase 
holoenzyme type I and type 11 from striated muscle of different mammalian species. 
Arch. Blochem. Blopkys. 253: 341-349. 
Kirsten W. H. and Mayer L. A. (1967): Morphologic responses to a murine 
erythroblastosis virus. JNCI 39: 311-335. 
Kleine L. P. and Whitfield J. F. (1987). Serum-aetivated T51B rat livercells transiently 
accumulate cyclic AMP-dependent protein kinases on their surfaces during the GI 
phase. J. Cell. Pkysiol- 132: 354-358. 
Kohga S., Harvey S. R., Weaver R. M. and Markus G. (1985). Localization of 
plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer 
Res. 45: 1787-1796. 
Kolonel L. N. (1987). Fat and colon cancer: how firm is the epidemiological evidence 
? Am. J. Clin. Nutr. 45: 336-34 1. 
Konishi-Imamura L., Noda M. and Nomura Y. (1987). Alteration by v-Ki-ras in 
NaF, cholera toxin and forskolin-induced adenylate cyclase activation in NIHIM 
fibroblast cells. Blochem. Blopkys. Res. Comm. 146: 47-52. 
Kom L. J., Sibel C. W., McCormick F., and Roth R. A. (1987). Ras p2l as a potential 
mediator of insulin action in Xenoptis oocytes. Science 236: 840-42. 
268 
Krebs E. G. (1985). The phosphorylation of proteins: a major mechanism for 
biological regulation. Biochent. Soc. Trans. 13: 813-820. C. 0 
Krontiris T. G. and Cooper G. M. (1981). Transforming activity of human tUMOUr 
DNAs. Proc. Natl. Acad. Sci. USA 78: 1181-1194. 
Krontifis T. G., DiMartino N. A., Colb M. and Parkinson D. R. (1985). Unique allelic 
restriction fragments of the human Ha-rus locus in leucocyte and tumour DNAs of 0 cancer patients. Nature 313: 369-374 
Kueftel M. R., Squinto S. P., Kwast-Welfeld J., et al. (1985). Localization of nuclear 
subunits of cyclic AMP-dependent protein kinase by the immunocolloidal gold 
method. J. Cell. Biol. 101: 965-975. 
Kune S., Kune G. A. and Watson L. F. (1987). Case-control study of dietary 
aetiological factors: the Melbourne colorectal cancer study. Nuir, Cancer 9: 21-42. eý 
Kuo J. F., Greengard P. (1969). Cyclic nucleotide dependent protein kinase IV. 
Widespread occurrence of adenosine 3', 5'-monophosphate- depend ent protein kinase 
in various tissues and phyla of the animal kingdom. Proc. Nati. Acad. Scl USA 
64: 1349-1355. 
Kurzrock R., Gallick G. E. and Gutterman J. U. (1986). Differential expression of p2l 
ras Gene Products among histological subtypes of fresh primary lung turnours. 
Cancer Res. 46: 1530-1534. 
Kusyk C. J., McNeil N. O. and Johnson L. R. (1986). Stimulation of growth of a 
colon cancer cell line by gastfin. Am. I Physiol. 251: G597-G601. 
Kvinnsland S., Ekanger R., Doskeland S. O. and Thorsen T. (1983). Relationship of 0 cyclic AMP binding capacity and estrogen receptor to hormone sensitivity in human 0 breast cancer. Breavt Cancer Res. Treatment 3: 67-7 1. 
Kwast-Welfeld J. and Jungmann R. A. (1988). Hon-nonal regulation of nuclear cyclic 




Laburthe M., Rousset M., Boissard C., et al. (1978). Vasoactive Intestinal Peptide: a 
potent stimulator of adenosine 3', 5'-cyclic monophosphate accumulation in out 0 carcinoma cell lines in culture. Proc. Nad. Acad. Scl. USA 75: 2772-2775, 
Laburthe M. and Dupont C. (1982). VlPergic control of intestinal epithelium in health 
and disease, Ed: Said S. I., Ln., Vasoactive Intestinal Peptide. pp4O7-423, New York, 
Raven Press. 
Lacal J. C., Anderson P. S. and Aaronson S. A. (1986). Deletion mutants of Harvey 
ras p2l, protein reveal the absolute requirement of at least two distinct regions for 
GTP-bindin(y and transforming activities. EUBO J. 5: 679-687. 0 
Lacal J. C. and Aaronson S. A. (1986). Monoclonal antibody Y 13-259 recognizes an 0 epitope of the p2l ras molecule not directly involved in the GTP-binding activity of 
the protein. Mol. Cell. Biol. 6: 1002-1009. 
Lacal J. C., Moscat J. and Aaronson S. A. (1987). Novel source of 1,2-diacylglycerol 
elevated in cells transformed by Ha-rav oncogene. Nature 330: 269-272. 
Lacal J. C., Fleming T. P., Warren B. S., el al. (, 1987a). Involvement of functional 
protein kinase C in the mitogenic response to the H-ras oncogene product. Afol. Cell. 
Biol. 7: 4146-4149. 
Lacal J. C., De La Pena P., Moscat J., et at. (1987b). Rapid stimulation of 
diacylglycerol production in Xenopus oocytes by microinjection of H-ras p2l. 
Science 238: 533-537. 
Laks M. S., Harrison J. J., Schwoch G. and Jungmann R. A. (1981). Modulation of 
nuclear protein kinase activity and phosphorylation of histone HI subspecies during 
the prereplicative phase of rat liver regeneration. J. Blol. Chem. 2S6: Tn5-8785. 
Lamb N. J. C., Fernandez A., Conti M. A., er al. (1988). Regulation of actin 
microfilament integrity in living nonmuscle cells by the cAMP-dependent protein 
kinase and myosin light chain kinase. J. Cell. Blol. 106: 1955-1971. 
Lambert R., Sobin L. H. and Waye J. D. (1984). The management of patients with 
colorectal adenomas. CA 34: 167-176. 
Lamers W. H., Hanson R. W. and Mcisner H. M. (1982). cAMP stimulates 
transcription of the gene for cytosolic phosphoenolpyruvate carboxykinase in rat liver 
nuclei. Proc. NatI. Acad. Sci. USA 79: 5137-5141. 
LaMuraglia G. M., Lacaine F. and Malt R. A. (1986), High ornithine decatboxylase 
activity and polyamine levels in human colorectal neoplasia. Ann. Surg. 204: 89-93. 
Lamy F., Roger P. P., Lecocq R. and Dumont J. E. (1986). Differential protein 
synthesis in the induction of thyroid cell proliferation by thyrotropin, epidermal 
, arowth factor or serum. 
Eur. J. Blochem. lSS: 265-275, 
270 
Landis C. A., Masters S. B., Spada A., et al. (1989). GTPase inhibitory mutations 
activate the ct chain of Gs. and stimulate adenylate cyclase in human pituitary turnours. 
Nature 340: 692-696. 
Lange-Carter C. A., Fossli T., Jahnsen T., and Malkinson A. M. (1990). Decreased 
expression of the type I isoenzyme of cAMP-dependent protein kinase in tumor cell 
lines of lung epithelial origin. J. Biol. Chem. 265: 7814-7818. 0 
Lapetina E. G., Lacal J. C., Reep B. R. and Vedia L. M. (1989). A ras related protein 
is phosphorylated and translocated by agonists that increase cAMP levels in human 
platelets. Proc. NatI. Acad. SO. USA 86: 3131-3134. 
Lasater E. M. (1987). Retinal horizontal cell gapjunction conductance is modulated by 
dopamine through a cyclic AMP-dependent protein kinase. Proc. Nall. Acad. Sci. 
USA 84: 7319-7323. 
Latner A. L., Turner G. A. and Tregoning D. (1979). Cyclic adenosine 0 3'5'monophosphate as a possible indicator of premalignant changes in the large 
bowel. Ann. Clin. Biochem. 16: 127-130. 
Lawson D. E. M., Paul A. A., Black A. E. (1979). Relative contributions of diet and 
sunlight to Vitamin D state in the elderly. Br. Afecl. J. 2: 303-305. 
Lazarides E. (1982). Intermediate Filaments. Ann. Rev Blochem. SI: 219-250. 
Lazarowski E. R., Winegar D. A., Nolan R. D., et at. (1990). Effect of protein kinase 
A on inositide metabolism and rap I G-protein in human erythroleukaemia cells. J. 
Blol. Chem. 265: 13118-13123. 
Lee C. Q., Miller H. A., Schlicter D., et al. (1988). Evidence for a cAMP-dependent 
nuclear factor capable of interacting with a specific region of a euk-aryotic gene. Proc. 
Natt. Acad. Scl. USA 85: 4223-4227. 
Lee D. C. Carmichael D. F., Krebs E. G. and McKnight G. S. (1983). Isolation of 
cDNA clone for the type I regulatory sub-unit of bovine cAMP-dependent protein 
kinase. Proc. Natt. Acad. Sci. USA 80: 3608-3612. ' 
Lee J. A. H. (1976). Recent rends of large bowel cancer in Japan compared to United 
States and England and Wales. Int. J. Epidetniol. 5: 187-194. 
Lee W., Mitchell P. and Tjian R. (1987). Purified transcription Factor AP- I Interacts 
with TPA-inducible enhancer element. Cell 40: 741-750. 
Lee Y-S. (1988). Background mucosal changes in colorectal carcinomas. Cancer 
61: 1563-1570. 
Lefkowitz R. J. and Caron M. G. (1988). Adrenergic receptors. J. Diol. Chem. 
263: 4993-4996. 
Leiser M., Rubin C. S. and Erlichman J. (1986). Differential binding of the regulatory 
subunits (RII) of cAMP-dependent protein kinase 11 from bovine brain and muscle to 
R11-binding proteins. J. Blol. Chem. 264: 1904-1908. 
271 
Leitman D. C., Fiscus R. R. and Murad F. (1986). Forskolin, phosphodicstcrase 
inhibitors, and cyclic AMP analo 'as inhibit proliferation of cultured bovine endothclial 
cells. J. Cell. Phvslol. 127: 237-243. 
Lcof E. R., Olashaw N. E., Pledger W. J. and O'Keefe E. J. (1982). Cyclic AMP 
potentiates down regulation of epidermal growth factor receptors by platelet-derived 0 
growth factor. Biochem. BiophYs. Res. Comm. 109: 83-9 1. 
Leppert M., Dobbs M. and Scambler P. (1987). The gene for familial polyposis coli 
maps to the Iona arm of chromosome 5. Science 238: 1411-1413. 0 
Lev R. and Grover R. (1981). Precursors of human colon carcinoma: a serial section 
study of colectomy specimens. Cancer 47: 2007-2015. 
Levine R. B., Lamaziere J-M. D., Broxmeyer H. E. (1985). Human megakaryocytes 
V. Changes in the phenotypic profile of differentiating megakaryocytes. J. Eq. Ated. C, 161: 457-475. 
Levitzki A., Rudick J., Pastan I., et al. (1986). Adenylate cyclase activity of NIH 
3T3 cells morphologically transformed by ras genes. FEBS Lett. 197: 135-41. 
Lewis E. J., Harrington C. A. and Chikaraishi D. M. (1987). Transcriptional regulation 0 
of the tyrosine hydroxylase gene by glucocorticoid and cyclic AMP. Proc. Nail. Acad 
Sci. USA 84: 3550-3554. 
Li F. P. (1988). Cancer Families: Human models of succeptibility to neoplasia - the 
Richard and Hinda Rosenthat Foundation Award Lecture. Cancer Res. 48: 5381- 
5386. 
Linask K. K. and Greene R. M. (1989a). Ontogenic analysis of embryonal palatal type 
I and type 11 cAMP-dependent protein kinase isoenzymes. Cell Diff. Dev. 28: 189- 
202. 
Linask K. K. and Greene R. M. (1989b). Subcellular compartmentalization of cAMP- 
dependent protein kinase regulatory subunits during palate ontogeny. Life Sci. 
45: 1863-1868. 
Lipkin M., Sherlock P. and Bell B. (1963). Cell proliferation kinetics in the human 
gastrointestinal tract of man. 11. Cell renewal in stomach, ileum, colon and recturn. 0 Gastroenterology 45: 721-729. 
Lipkin M. (1974). Phase I and phase If proliferative lesion sof colonic epithelial cells 
in diseases leading to colonic cancer. Cancer 34: 878-888. 
Lipkin M., Sherlock P. and De Cosse J. J. (1980). Risk factors and preventative 
measures in control of cancer of the large intestine. Curr. Prob. Cancer 4: 1-57. 
Lipkin M and Newmark H. (1985). Effect of added dietary calcium on colonic 
epithelial-cell proliferation in sub eels at high risk for familial colonic cancer. N. Eng. 
J. Aled. 313,1381-1384. 
272 
Lipkin M., Blattner W. E., Fraumeni J. F., Lynch H. T., et at. (1983). Tritiated 
thymidine distribution as a marker for hereditary predisposition to colon cancer. 
Cancer Res. 41: 1899-1904. 
Lipkin M., Blattner W. A., Gardner E. J., et al. (1994). Classification and risk 
assessment of individuals with familial polyposis, Gardner's Syndrome, and Familial 
Non-Polyposis Colon Cancer from [3HI-thymidine labelling patterns in colonic 
epithelial cells, Cancer Res. 44: 4201-4207. 
Lipkin M. (1985). Growth and development of gastrointestinal cells. Ann. Rev. 
Physiol 47: 173-197. C% 
Lipkin M., Uehara K., Winawer S., et al. (1985). Seventh Day Adventist vegetarians 
have a quiescent proliferative activity in colonic mucosa. Cancer Lett. 26: 139-144. 
Lipkin M., Enker W. F. and Winawer S. J. (1987). Tritiated thymidine labelling of 
rectal epithelial cells in 'non-prep' biopsies of individuals at increased risk for colonic 
neoplasia. Cancer Lett. 37: 153-16 1. 
Lipkin M. (1988). Biomarkers of Increased Succeptibility to Gastrointestinal Cancer: 
New Application to Studies of Cancer Prevention in Human Subjects. Cancer Res. 
48: 235-245. 
Lipkin M., Friedman E., Winawer S. J. and Newmark H. (1989). Colonic epithelial 
cell proliferation in responders and nonresponders to supplemental dietary calcium. 
Cancer Res. 49: 248-254. 
Liu A. Y-C., Fiske W. W. and Chen K. Y. (1980). Regulation of Cyclic Adenosine 
3', 5'-Monophosphate-binding Protein in N-18 Mouse Neuroblastoma Cells. Cancer 
Res. 40: 4100-4108. 
Liu A. Y-C. (1982). Differentiation specific increase of cAMP-dependent protein 
kinase in the 3T3-LI cells. J. Biol. Chem. 2ý7.298-306. 
Liu A. Y-C., Chang Z-F. and Chen K. Y. (1986). Increased level of cAMP-dependent 
protein kinase in ageing human fibroblasts. J. Cell. Pkyviol. 128: 149-154. 
Livesey S. A., Kemp B. E., Re C. A., el al. (1982). Selective hormonal activation of 
cyclic AMP-dependent protein kinase isoenzyme in nonnal and malignant ostcoblasts 
J. Blol. Chem. 257-. 14983-14987. 
Locke F. B. and King H. (1980). Cancer mortality risk among Japanese in the United 
States. JNCI 65: 1149-1156. 
Lohmann S. M., Schwoch G., Reiser G., el al. (1983). Dibutryl cAMP treatment of 
neuroblastoma-glioma hybrid cells results in selective increase in cAMP-receptor 
protein (R-1) as measured by mono-specific antibodies. EAIBO J. 2: 153-1.59. 
Lohmann S. M., DeCammilli P., Einig 1. and Walter U. (1984). High-affinity binding 
of the regulatory subunit (1111) of cAMP-dependent protein kinase to microtubule- 
associated and other cellular proteins. Proc, Nail. Acad. Sa USA 81: 6723-6727. 
273 
Lomfi A. and Marie P. J. (1990). Distinct effects of calcium- and cAMP-enhancing 
factors on cytoskeletal synthesis and assembly in mouse osteoblastic cells. Biochint. 
Biophys. Acta 1052: 179-186. 
Longo W. E., Ballantyne G. H. and Modlin I. R. (1988). Colonoscopic detection of 
early colorectal cancers. Impact of a surgical endoscopy service. Ann. Surg. 
207: 174-178 
Lorimer A. J., Mason M. E. and Sanwal B. D. (1987). Levels of yype I cAMP- 
dependent protein kinase regulatory subunit are regulated by changes in turnover rate 
during skeletal myogenesis. J. BIN. Chem. 262: 17200-17205. 1-15 b 
Lotan R., Giotta G., Nork E. and Nicolson G. L. (1978), Characterization of the 
inhibitory effects of retinoids on the in vitro growth of two malignant murine 
melanomas. JNCI 60: 1035-104t. 
Lowe D. G., Capon D. J., Delwart E., et al. (1987). Structure of the human and 
murine R-ras genes, novel genes closely related to ras proto-oncogenes. Cell 
48: 137-146. 
Lowe G., Nakamura T. anf Gold G. H. (1989). Adenylate cyclase mediates olfactory 
transduction for a wide variety of odorants. Proc. Nail. Acad. Scl. USA 86: 5641- 
5645. 
Ludwig K. W., Lowey B. and Niles R. M. (1980). Retinoic: acid increase cyclic AMP- 
dependent protein kinase, activity in murine melanoma cells. J. Biol. Chem. 
255: 5999-6002. 
Luis J., Martin J-M., El Battari A., et al. (1987). Cycloheximide induces 
accumulation of vasoactive intestinal peptide (VIP) binding sites at the cell surface of a 
human colonic adenocarcinoma cell line (HT29-134). Eur. J. Blochein. 167: 391-396. 
Luk G. D. and Baylin S. B. (1983) Polyamines and intestinal growth - increased 
polyamine biosynthesis after jejunectomy. Am. J. Pkyslol. 124: G656-G660. 
Lund J., AhIgren R., Wu D., et al. (1990). Transcriptional regulation of the bovine 
CYP17 (P-450-17-ct) gene. J. Blol. Chem. 265-. 3304-3312. 
Lynch H. T., Kimberling W., Albano W. A., et al. (1985). Hereditry non-polyposis 
colorectal cancer (Lynch Syndromes I and 11). 1. Clinical description of resource. 
Cancer 56: 934-938. 
Lynch H. T., Kriegler M., Christiansen T. A., et al. (1988). Laryngeal carcinoma in 
Lynch Syndrome 11 kindred. Cancer 62.1007-1013. 
274 
M 
McAtee P. and Dawson G. (1990). Phospholipase C activity in NCB-20 cells is 
inhibited by protein kinase A-mediated phosphorylation of low molecular mass GTP- 
proteins. J. Biol. Chem. 265: 6788-6793. 
McCachren S. S., Nichols J., Kaufman R. E. and Niedel J. E. (1986). Dibutryl cyclic 
adenosine monophosphate, r duces expression of c-mYC during HL-60 differentiation. 
Blood 68: 412-416. 
McGrath J. P., Capon D. J., Goeddel D. V. and Levinson A. D. (1984). Comparative 
biochemical properties of normal and activated human ras p2l protein. Nature 
310: 644-649. 
McGregor D. B., Jones R. D., Karlin D. A. and Romsdahl M. M. (1982). Trophic 
effects of gastrin on colorcctal neoplams in the rat. Ann. Surg. 195: 219-223. 
MacKenzie C. W. and Stellwagen R. H. (1974). Heterogeneity and unusually high 0a 
affinity in the interactions of adenosine 3: 5'-monophosp hate with specific binding 
proteins from liver and hepatoma cells. J. Biol. Chem. 249: 5763-5771. 
MacKenzie C. W. and Stellwagen R. H. (1974). Differences between liver and 
hepatoma cells in their complements of adenosine 3': 5'-monophosphate-binding 
proteins and protein kinases. J. Biol. Chem. 249: 5755-5762. 
MacManus J. P. and Whitfield J. F. (1969). Stimulation of DNA synthesis and rnitotic 
activity of thymic lymphocytes by cyclic adenosine 3'. 5-monophosphate. Erp. Cell 
Res. 58: 188-194. 
McManus J. P., Franks D. J., Youdale T. and Braceland B. M. (1972). Increases in rat 
liver cyclic AMP concentrations prior to the initiation of DNA synthesis following 
partial hepatectomy or hormone infusion. Blochem. Blopkys. Res. Comm. 49: 1201- 
1207. 
MacManus J. P., Braceland B. M., Youdale T. and Whitfield (1974). Adrenergic 
antagonists, and a possible link between the increase in cyclic adenosine 3': 5'- 
monophosphate and DNA synthesis during liver regeneration. J. Cell. Pkystol- 
82: 157-164. 
McMullin E. L., Hogan camp W. E., Abramson R. D., Merrick W. C. and Hagendorn 
C. H. (1988) Phosphorylation of the p220 subunit of e[F-4F by cAMP dependnet 
protein kinase and protein kinase C in vitro. Blochein, Biophys. Res. Comin. 
153: 925-932. 
Magnusson I., Rosen A. V., Nilsson R., el al. (1989). Receptors for epidermal 
growth factor and sex steroid hormones in human colorectal carcinomas. Anticancer 
Res. 9: 299-302. 
Magoffin D. A. (1989). Evidence that luteinizing hornione-stimulated differentiation of 
purified ovarian thecal-interstitial cells is mediated by both type I and type 11 adenosine 
3', 5'-monophosphate-dependent protein kinases. Endocrinology 125: 1464-1473. 
275 
